var title_f7_59_8112="Pancoast tumor on CT";
var content_f7_59_8112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancoast tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image of a 60-year-old woman presenting with a four month history of right shoulder pain and numbness and tingling in the right arm. The cavitary mass involved the rib and was squamous histology on biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8112=[""].join("\n");
var outline_f7_59_8112=null;
var title_f7_59_8113="Angiogram with CAV";
var content_f7_59_8113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65796/angiocav_conv.mp4?title=Angiogram+with+CAV\" style=\"width:400px;height:416px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left coronary artery angiogram with cardiac allograft vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An almost normal angiogram of the left coronary artery of a patient eight years after transplantation. Green lines indicate the position of the IVUS image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Finn Gustafsson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8113=[""].join("\n");
var outline_f7_59_8113=null;
var title_f7_59_8114="Port placement for TAPP hernia repair";
var content_f7_59_8114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Port placement for TAPP hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8114=[""].join("\n");
var outline_f7_59_8114=null;
var title_f7_59_8115="Docusate and senna: Drug information";
var content_f7_59_8115=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Docusate and senna: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/0/31747?source=see_link\">",
"    see \"Docusate and senna: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/52/5955?source=see_link\">",
"    see \"Docusate and senna: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doc-Q-Lax [OTC];",
"     </li>",
"     <li>",
"      Dok&trade; Plus [OTC];",
"     </li>",
"     <li>",
"      Geri-Stool [OTC];",
"     </li>",
"     <li>",
"      Peri-Colace&reg;  [OTC];",
"     </li>",
"     <li>",
"      Senexon&reg;-S [OTC];",
"     </li>",
"     <li>",
"      Senna Plus [OTC];",
"     </li>",
"     <li>",
"      SennaLax-S [OTC];",
"     </li>",
"     <li>",
"      Senokot-S&reg; [OTC];",
"     </li>",
"     <li>",
"      SenoSol&trade;-SS [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Stimulant;",
"     </li>",
"     <li>",
"      Stool Softener",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Constipation: OTC ranges: Oral: Initial: 2 tablets (17.2 mg sennosides plus 100 mg docusate) once daily (maximum: 4 tablets twice daily)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/52/5955?source=see_link\">",
"      see \"Docusate and senna: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Constipation: OTC ranges: Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2-6 years: Initial: 4.3 mg sennosides plus 25 mg docusate (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet) once daily (maximum: 1 tablet twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-12 years: Initial: 8.6 sennosides plus 50 mg docusate (1 tablet) once daily (maximum: 2 tablets twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Constipation: OTC ranges: Oral: Consider half the initial dose in older, debilitated patients",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doc-Q-Lax: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dok&trade; Plus: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Stool: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peri-Colace&reg;: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senexon&reg;-S:  Docusate sodium 50 mg and sennosides 8.6 mg [contains calcium 20 mg/tablet, sodium 6 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SennaLax-S:  Docusate sodium 50 mg and sennosides 8.6 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senna Plus: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senokot-S&reg;: Docusate sodium 50 mg and sennosides 8.6 mg [sugar free; contains sodium 4 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SenoSol&trade;-SS: Docusate sodium 50 mg and sennosides 8.6 mg [contains sodium 3 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Once-daily doses should be taken at bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of constipation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F220518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evacuate the colon for bowel or rectal examinations; management/prevention of opiate-induced constipation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Senokot&reg; may be confused with Depakote&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, diarrhea, abdominal cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine discoloration (red/brown)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component; intestinal obstruction; acute intestinal inflammation (eg, Crohn's disease); ulcerative colitis; appendicitis; abdominal pain of unknown origin; concurrent use of mineral oil; pregnancy (per Commission E for senna)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: Not recommended for over-the-counter (OTC) use in patients experiencing stomach pain, nausea, vomiting, or a sudden change in bowel movements which lasts &gt;2 weeks. Not recommended for use longer than 1 week. Not recommended for use in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F220507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6256183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Doc-Q-Lax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6-50 mg (100): $23.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DOK Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6-50 mg (100): $18.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Peri-Colace Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6-50 mg (30): $11.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Senexon-S Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6-50 mg (100): $4.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sennalax-S Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6-50 mg (1000): $284.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sennosides-Docusate Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6-50 mg (100): $4.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Senokot S Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6-50 mg (30): $15.17",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Docusate is a stool softener; sennosides are laxatives",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9432 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.211.0.116-3CD79DF107-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8115=[""].join("\n");
var outline_f7_59_8115=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220521\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220511\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220517\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220512\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220500\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220492\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220503\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220501\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220518\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220527\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220519\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220505\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220495\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287238\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287239\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220507\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6256183\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220494\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9432|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/0/31747?source=related_link\">",
"      Docusate and senna: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/52/5955?source=related_link\">",
"      Docusate and senna: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_59_8116="Budesonide (nasal): Patient drug information";
var content_f7_59_8116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Budesonide (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/55/19317?source=see_link\">",
"     see \"Budesonide (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/35/42547?source=see_link\">",
"     see \"Budesonide (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7998588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rhinocort Aqua&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7998589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mylan-Budesonide AQ;",
"     </li>",
"     <li>",
"      Rhinocort&reg; Aqua&reg;;",
"     </li>",
"     <li>",
"      Rhinocort&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness. It may take 2 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to budesonide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your spray use with your doctor at each visit. Read and follow the facts on how to use the spray. Make sure you use the spray the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store spray at room temperature with valve up. Throw away any part not used after 6 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11453 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8116=[""].join("\n");
var outline_f7_59_8116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030240\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030239\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030244\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030245\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030247\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030242\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030243\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030248\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030249\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/55/19317?source=related_link\">",
"      Budesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/35/42547?source=related_link\">",
"      Budesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10873?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25303?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21064?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_59_8117="Phenobarbital: Patient drug information";
var content_f7_59_8117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenobarbital: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     see \"Phenobarbital: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     see \"Phenobarbital: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Phenobarbital",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat high bilirubin levels in newborns.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenobarbital or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the airway, liver disease, porphyria, or shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 to 60 minutes before bedtime if using for sleep. Do not take for more than 2 weeks in a row.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (elixir) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take elixir with water, milk, or juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695140",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug long-term, take calcium and vitamin D as you were told to do by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11826 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-2E1E3D353B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8117=[""].join("\n");
var outline_f7_59_8117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208959\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030652\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030654\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030653\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030658\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030659\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030661\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030656\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030657\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030662\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030663\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=related_link\">",
"      Phenobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=related_link\">",
"      Phenobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_59_8118="Tracheal hamartoma";
var content_f7_59_8118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Tracheal hamartoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 420px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGkAfoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACporaeb/VQyP/ALqk0/T7drm5SJe5r374f6YtrBAiqN3BJxQB4Mmkak/3NPvG+kDH+lSDQtXPTS78/wDbu/8AhX3j4bjEcKfKucf3RXX2mMD5V/75FAH5wDQNYPTSdQ/8Bn/wo/4R/Wf+gRqH/gM/+FfpnEAQMon/AHyKtLFGR/q0/wC+RQB+Yf8Awj+s/wDQI1H/AMBn/wAKP+Ef1n/oEaj/AOAz/wCFfp75MX/PNP8AvkUeTF/zzT/vkUAfmF/wj+s/9AjUf/AZ/wDCj/hH9Z/6BGo/+Az/AOFfp75MX/PNP++RR5MX/PNP++RQB+YX/CP6z/0CNR/8Bn/wpP8AhH9Z/wCgRqH/AIDP/hX6feTF/wA80/75FHkxf880/wC+RQB+YX/CP6z/ANAjUf8AwGf/AAo/4R/Wf+gRqP8A4DP/AIV+nvkxf880/wC+RR5MX/PNP++RQB+YP/CP6z/0CNQ/8Bn/AMKX/hH9Z/6BGo/+Az/4V+nvkxf880/75FHkxf8APNP++RQB+YX/AAj+s/8AQI1H/wABn/wpP+Ef1n/oEah/4DP/AIV+n3kxf880/wC+RR5MX/PNP++RQB+YX/CP6z/0CNR/8Bn/AMKP+Ef1n/oEaj/4DP8A4V+nvkxf880/75FHkxf880/75FAH5g/8I/rP/QI1D/wGf/Cj/hH9Z/6BGof+Az/4V+n3kxf880/75FI0MeOI0/75FAH5gvoerIjM+l3yqoJLG3cAD16Vm1+mHjNAPCeu/Kv/AB4XH8I/55NX5oN94/WgBKKWloAbRTsUooAZRUoFPRc9qAK9FdT4a8LahrspNpDi3X788nCJ+Pc+1eiaH4W0bRv3jquoXa/xSLiNfcDvQB4lRX0ULM6oUEMULueiLCBj9K3dL+HtxcbTNDCi98oOaAPliivtfS/h9plsAZ4IpW/65jFdJbeHNJg+5p9p/wB+V/woA+BKK/QYaZYA/wDHhaf9+V/wpDpVgwINhaY/64L/AIUAfn1RX37L4c0m4ADWNtn2iX/Col+HukTuX/s9GB7BBj+VAHwPRX3ofhdZtOhhsUEYPzK6Dmukt/CNtaRiOPS7cgDr5KH+lAH5z0V+jM2hW0BBk0y1UHubdP8ACq0uj2Q5bT7QA+tuv+FAH530V+hTaXYYx/Z9n/34T/CoJNLsB/zDrP8A78J/hQB+flFfoBLommup3adZEf8AXBf8KxNR8DaDeqxGnwRSeqRgfpigD4aor601P4byW7PLp6W8o7Axrn+VcTqmkXOnyFLywjAHcxL/AIUAeA0V7xp92LRTtsrSaI/KyvCpB9ulUNX8EaN4gjefQmTTNQ6m1kP7mQ+in+E0AeLUVs61o17o97JaalavbzqfuuOvuD3FZrJj+GgCCipCtNIxQA2ilooASiiigAooooA6fwPYLNcXl/LYm+is4twtxHv8x24Ubcc9z+FUfFunDTNfuoEQpCzeZECMYRuQMe3T8KoLfXC6e9ismLV5BKyBRywGAc4z+GcU+a9ub42sdw4kECCKL5QCqDoMgc/jWShJVOa+h6E8RQeFVBRfMtb6b63Xe1rfNbI6HwZYhruNmGTnNe9+EIf3qccV5F4IhHmBjXtnhRVXb0rU889R0X7i/SupszlRXK6MflWukt5QooA2oCMVbRsisuCYEAg1aWYDqRQBdoqmbkevFN+08GgC6zBRk1GZlFZ8lzk4z+FRGYn+KgDUE6mpEcMuayBMPXmrKTYj5NAF0uMmlRtwrNM/YGpLec560AaFFIpDDIpaACiiigAooooAKKKKAMHxqv8AxSWun/pwuP8A0W1fmU33j9a/TjxqP+KP17/rwuP/AEW1fmO33j9aACpIBmaMEZG4A/nTAPWnoSpBU8g5FA07M9C1qytJLvxDaounOILcyQ28FsI5YSu0li+wZGM8bjnNefAZ7Vr3Gvald+f5sse6ddsrpBGjuPQsqgkcetJo2jXeq3AhsoTI56noFHqT2rGjTlBWkejmWKpYqopUlbf8W2ur29bdkjNjjZiAqkknAAr0Xw34FWKGO98Q5SNl3x2qnDv6bvQVraJoNloCLMNt3qPeRh8sf+6P61pW1rfardHyhI8rHAGMk1seaWllGxUgijtrUKEWOPgYHtXS+FPCVzrBWadTBZ57jlh7VteE/AZhaO51Zt5X7sfYfWvQ0RY0CxjaoGBjpigClpmj2WmRLHawqPUnqa1U2gDAAFZeo38Fjbtc3U0cMCDLO7BQPxryfxT8dNOsd8OiQG+mBxvb5Yx+PU0Ae3hgo5IzUFxe29ujPLIFUe9fK918b/E07HatrGmc4VSTVW2+LOpfbUnvLdJ1By0e84NAH1Euv29xbPLatvVcgnHQ+lZ+neIbzUrw2cVtskYgLJ1GPWvB0+N93DDcwW2k20UcpLLznBq94A+NElhrsE2u2wezGQxi+8Ce+KAPqrQdJkixJduJyPQYB/Ct6S6kjGBGAMcY7Vy/w88d6J4qtJ5dLvA6o3KsNrLn1Fdp8jrn5WU96AMmXVJFIVQN2fSr1pcSTKDtP0NDizDEt5WT+NRHVtPhO17iKI+jHbQBbnRXiIkUMOuKp3s3mW5UIuOnPNPk1G0eB3W4i8sDJYsAAPrXmmsfGLwXp0Fzbvqay3EUhQqik/jnoaAOneFItxK7h6ZqrO9vtyr7H7K/+NcIfi54WudPa4j1EKUbBRhhvyrK8RfFLw3Z7RBfLI0i7gFH9aAO+GoQh9jHYc4O7gH6VaBVwMHPGcivnLVPitpRk3RrJK27qckD8K19D+MVi7qplCAEAh+DQB7m6j8aq3dlb3kTRXUKSq3XcKwtE8YafqiLsnTJGQN3Wt5bhJMEMMdiKAOC8SfDyGWKRtJPl7uTETwfpXmd9p15pM7RXkbIynow/rX0UJOcnqOtUNZ0uz1a1Md1EGB4zjkfQ0AeEm/tNYshYeIIFu7YcI/SSH3Vv6VwXi7wFc6XFJfaS51HSRz5yD54/Z17fWvWPFfgi50qTzrPMtsT17r9a5iy1S70y6zAxUA4ZCMhx6Ed6APFGTB96iIr1nxR4Xs9ehl1Hw9GsN8mWnsl4D+rJ7+1eXSxFGIYYI4IoAqkYpKkYU0igBlFLSUAFFFFABV/TId8gY/hVFRlgK6nw5aCSVFxz15oA7nwnZ+VErMPmPavUvDkbbkK9K4fRLcIijFdY2qJpVgWOA5HHtQB6A2sxadCu6QA+9U5PiLa2o5HmY7g4rwvXvGDGVnmlJPZRXFaj4lurtypfZH6CgD6ptPitZySKkYG48EZ6V1Fn4pW5VWD5De9fFNnqs0TBkkP516J4U8VTgrGZenOCeDQB9VQ6opx84INWVvv4d1eOaN4hMxXexGPfpXUWGtoWIJzn7pJoA7a4uwkgJao1vNxPOK5KfVldwCw3H3rU08yTrlRx6mgDeM5ONp/GrsE7MhX2rKCmKIZOeantJwWPv0oAc1yVYjdg1btrobvvdqw9UuILZWluJY4U7u7BRS6fMJdjRndG6hlfGMg+1K62K5XbmtodxZSF4+TmrBIFZenS4XA9KtPJzTJLdFQRsT1qYHpQAtFFFABRRRQBjeNf+RN17/rwn/9FtX5it94/Wv068af8idr3/XhP/6LavzFb7x+tAEgFSonI4pijPaul8IaE2s6qluTsgUb5pP7ij+vYUAP8L+Gp9WYytmKzQ/PKR1PoPU16PshsLZNP0uLy4AAWI+859Se9aNlp0t1PFYaZDi2jGxIwP1P+Nej+GfAsFmVnv8ADyf3ewoA4vwx4OvdUUTzAxw54yPvfSvVtH0Wy0iALbRDeBy5HJNasEarGgjAVR0A4p4TIO7igCu1yiuA2Bxz6CuS8a+O9O8N6XLdXL5IO2ONfvSN6VY+IninTPCGiS3V8A87/LFCOsjV8ieKfEV94j1J7u/k9o4l+7GPQUAafjbxzq/iy5Y307JaBsx2yHCL6Z9TXKFsimUooAcDS5poFO7ZoAM9alicgiogM9qctAG7o2t3+lTedp15PayEYLROVJHvXTj4keKSEH9t3mE6APj8/WuDiz+AqxGD36UAe2aT8X/Ej6RcztcIZ7VPveWPm9Ca8x1bxPq2pX0l5fahcS3Eh3M5c/p6Cu28CeE5rvwnf3Mq7UuEP3uMr0BH4815ZfRPBNJFICHRipHuKAL8+v6jJEYnv7pozwUMrYP4ZrIluCxNQuT1zUTHmgCRpCetRlyaaaQ0AKSSaTNJRQBq6Rr1/pUqPazthTkKeRX0N8L/AIm2muolhfsLfUSMKWPyvXzJninwyvDIskTskinKspwQaAPt231lPNeKdHjlQ4b3HrWtbSmTk8Z6Y714T8H/AImR3s8ek+JHT7Qw2RXD9H9FPvXvkcCCMGIjafSgAdBIhWQBlxgj1rhvFvgO3vy8+nqsU2M7B0J9q7zcEUhh0HU1Erb+RQB853NleaJfAvvilRgc4wc1znjzQlurYa7p8Xysdt5Go/1b/wB76GvpzxDoFprVs0dxGBIPuvjkV45qem6h4W1ZkdQ1rJxhhlJF9CKAPAZUxULCvQPHnhuKz26lpkZGmzttKdfIf+79PSuEkUg0AVj1pKc/3jTaACiilAycCgCxZRF5RxxmvQfDVouFLKPrXJ6NbZcMQTgZNd5pAWGIM/QD86AOqt5ltYwxPSuJ8feKv34trZ8so+bnpTfFviA2dsYomHnMOPavNpZHlkZ5GLOxySe9AE093JO5aRiSaYJT61DSg80AXoJ2DgZyK6DSLkxTKwYjmuVTr1rasJAm09RQB61ol6xjBUkn2NdjpN8Cqgvtk/SvKNF1AbVwcGussrrJTk880Ad3LqKCRTjDZwa7XQtURogokBIHX1ry6FjNaM4xvTn61a0fW2tJh8qtnjBNAHsUV+siHceMVm3CXWoPssdUks2Ax8kasP15/WvPrrxPNcFEQhEHUL3rofDOqGTUEQv+FJrmVmXTqOnLmjv5pP8AMy9f8N61DfJPczPqaKwJZSXYDP8AdP8AIV3dlZ6lcRrPHrZ2MoYE2idPpVqZnWTcT8zdKuwSfIR1x1rGGHjBtpvXzPRxGa1cRCMZpXj5L8mn+Fi74de4QMt3cm4cZAfywn6Ct3zMqCBiuctJM3ahCAgBrUhnABBbNbpWPMlLmd2aUUhJBJNXEbcBzzWPDKSc1ehcdc80CL9FMibctPoAKKKKAMbxp/yJ2u/9eE//AKLavzFb7x+tfp140/5E7Xf+vCf/ANFtX5it94/WgC3bplv516/4IshZeFllxia9k3sfSNeFH55NeTWaFmAXJYnAFe+29iY0stNiUfIkcP0OBn9TQB6X4A0lLTSku3T9/ONxPoK62Iloxu5PPNR2dt5FpFAOkaBRirHCKAO1ACAbYwR1zWL4p8RWXhzSLjUdSlEcEQOBnlz2UepNSazq8dnDJKzBI4uXdjgKO5r5R+L3jp/F+uFLZmXSrYlYF/vnu5+vagDE8e+Lb3xfrst/esVQErDDniNPT61zJoNB+tAAKUUlKKAHgfnTgOx6Ui1IB6UANC1Ii809Fx2qxCmTQAQxEn0rsPBvhC61+WSVYytjb4M8vb2Ue5pngnwrfeKNZg07TYt0jnLOfuxr3Y+1fWfh3wXYeHNBj0+0HmIoHmFh99u7GgDjZNQSbw7baZYWYTy1EbAYBUAdK8L+Jvhy7sL8X0tjLbw3BwWYcF/8cV9H3vhm8e/ea1VIw2CD6Vm+LbTVbvw/JpOp2MdxBLw0qrkgdiPQ0AfIEsRB6VWZefeu+8Y+EbvQJwZI2NpIT5UuOvsfQ1x89vigDOPFJUjptqMigBKSlooASij8aKAHKxVgwOD2I619HfAf4jy6jjQdZm3XSj9xK55kA7H3FfN9WbC8msLyC6tZDHPC4dGHYigD74LBicjPYimCMQxkIQAT0NcP8NPGsHi3w/HdbgLyIBbiMHkN6/Q13UT+ZDkcgjigCG5kEcOSQvbJ7Vla1ptvq9jJb3AUkr8rDsa17q1SeFo5OUaqiRGH5QAQo49xQB4ld2S2lze6VqalrOZfLlB7ejD3HWvGvE+kTaLqtxZXI+eM5DdmU9GHsRX0N8VbZUmguU+UyDBPriuB8V6VH4l0WI2XzarZqfLXvNF3UH1HagDxeXhzTKluFKTMrAhhwQRgioqACprZN8g9Khra0S0MzqAeSaAN7Q7bbEMj7/8AKuguZVggy3CxrvNJplnjYMcCs3xpMLbTJFz80jbRQBwup3TXl5JKxzk8VUoooAKKKKAJEq7ay4bFUFODU8bZYc85oA67SrmFARIDuPQjoK6PTdUijJVjk44rg4H2gAnBrY0yfy3G9Qyng0AehLfyLZ743wSOntUC3+ZI2HU9axInlukkFu2IwMAmsy2uGgnLSyhsHG0Hv60Ad3HfxRzqGYEDkjNdf4IuhcavE4P7sHk5rx1bl3uMlsgnB9q73wRqCpfQQx84YFqAPfJZd8gA7DGSKVroQLtU57lvSuVfWJZp3VCGXGABTru6220QY8v97BoA6bSrzzb9BkliTn6Vuhtp5JzXF+HbtRfbTjAHJHaukmvAJR5YznuaANmKUqePwrQt2ZsE9KwY7hhtLkLkdK1rR2dQScCgDat24I61ZHSqlmc/l1q3QAUUUUAY3jT/AJE7Xf8Arwn/APRbV+YrfeP1r9O/Gn/Ina7/ANeE/wD6LavzEb7x+tAHZeAtNOpeIbSPaTFE3nSnsFXmvoDwRAL/AF4yyDgP5gzXn/h/SoPDlnJbxMJr644lkHRV7KP5133gO8jttZjWV1RdpByepoA9dUYXHNSx25KF24XsPWnafGLuZVTlepPtXN/HHxVH4K8DTXMDKL65P2e1X3xy30AoA8E+Pnjcyzy6Bp8vy7s3TKevoteHmpbu4lurmWedy8sjF2Y9yahoAQ0A+lHaigBaKKWgBy9anX7tQLUiGgC1EM1qWMDSOqKpZicAAc59qzIOWH86+hf2dvAVvqhPiPVE3wW0uy2iPRnHVj7DjHvQB6f8FvBv/CKeFVlvIgup3pEkvqi/wp+H8675+RTiccdqhLgS7CeeuM0AOKj06VG8auMMMg+tTHFMPQUAYuteFdK1uyktb+2SSJ+Pp7ivmj4p/Cu98KtJeWRa50snO/HzReze3vX1kTg571De20N7bSW9zGskMikMrDOQaAPz3u7cjoKz3GK9q+NXw/HhXU1ubBW/su6J2d/Lfuv09K8fu4tp6UAUjSU5utNNACHrR+tFJQAtAo9qOlAHXfDXxbN4S8RxXWd1pJiO4T1X1+or670/U4ZbOO+tn8y0kQPuByAD3r4XFe4/ATxkrRv4X1SQ+VICbYk/mtAH0bFKs0YeM5UjioyAfcjjJrh9Tvb7w+qmDLW6naoY549Kgm+I1vHaHNs5nwflzxmgDJ+KN3HcAWgDedAxyDwCDXmsVw1uw2lowhypB6Vtavqk+uSG6uJB524/KOMDtWJIquzGYEMO9AHC/ECVZ/EbyqgVniRnwMbmx1rmq3/Gxzrhx/zyT+VYFADkGWArtfCsGVZsdMCuMtxmdB716N4YAS1G8DDNwaAOpsYwkOSo6da87+IV0Hvo7dSPkGTXoUsywWbyMQAq5P0rxrVro3uoTTsc7mOPpQBTooooAKKKUdaAFFPVsEetKqAjg81IsZBGeKALcJLYrTs3aJHbrkY5rLgRscdPWti0C+V+8GaANvQZm2kjmPgEVQ1C1+yahMWGY2+ZfxrY0eBmtyEBOT6Vp6logm8ppHOFUEigDlVuHSBygJ4HPvXRfD2ZhqB5JJIpmu2tulg0duuJFxnFbPwv0cTXfmSEqN2QaAPRIpihDKCoHXB71auZdxSRTlGGM9h7VlXV2FlMKgeUGPPc1It07RrDEAUJ3DPY+tAGnYaitq5RCWduSx7VvQahPIoKMd5HQdq4q1LRzu8z8Z4GMk10ul3LTTqqpwF7CgDq7Gdjt8xi+OpJrp9OuCVDdBXHWs6KyhuMdSa3LO9XbheR70AdjZzfhV+KbJ5rntPm3A49K0UY5FAGxRUcGdgJ71JQBjeNP+RO13/rwn/9FtX5it94/Wv068af8idrv/XhP/6LavzFb7x+tAHv8KAxrtwX7mtvTNLup7yGF4mRpMH8PWo7CHTGtoVErveSYwoHCV674T8LmJre8kkZw2F+btQB1WhWo0zR4Y3cmVwBknnFfI37S/jJPE3jtrKyk3afpS/ZoyDwz5+dvz4/Cvo340eKV8LeFdSvkYCUx/Z7VfWRhgfl1r4VldpJHd2LMxJJPUk96AGGm0p6Un1oAWlpO9KKADvSiilFACgflTwO9Sw200sM00UTvFCAZGVchATgE+nNR9KALFs5BGa+w/2bdTtrr4dR2kcifabWeRZEyN3JyDj0wa+Nlbb/AIVraPq13ptylzYXMttOhBWSJypH5UAfoLJ064rCu7J5NWi1A3TQxxKY1CtkP3ORXzj4Z+NHiOZ4bDVrpJo5GCCfywrjPqR2969K8V/EmPwPoVqj2kF7q92DLFDITsijzjc/qc9BQB6To2uQauZVhOHiYowIxn3rVwec188+EfjtMdXjTX9KsVs5G2tJZxmN4wf4sZOQK+iMoyRzQSLLBKoeN1PDKRkGgBDj8qD1pFzjmlX0AoAxPGfh628T+HbvTLpFKyodj45R/wCFh+NfEHiHTZtPvri0ukKTwOY3U9iDg19+gdjXzb+0p4Taz1iLXraP/Rr0bJiBwsoHX8R/KgD51WHzbhYt6JubG5zgD61XIwau3ke1j1/OqRoAluLO4t4beWeF44rhS8TMOHUHGR+INQZPFPeR3RFd2ZUGFBOQo68elMoAKSlFBoABU9nczWd1Fc20hjniYOjDqCKg9qKAPrfwF4jtPHHhWN59v2lcRzRk/dcDt9etcz4n0ySxkuohENmQd2Ocdq8m+EnilvDXimEyPizuSIpR2BJ4b8K+m9T0iPW7aRkO52TIYHH0oA8h8P2VjNJMuo3ZtmUZQ4zk1WvUh+0Swq3mRryk2MbhUusWb2U8kcu5XRirDH61RaMS7QGfK9fQ0AeceN1RdcYRkFfLXpXP10fjyFoddw67S0SsB+dc5QBPYjddxD/ar07TYfLtYFxjI3V5zocfnatax/3nr1uCD5gMDA4oAxPGlybTQWUHmX5BXmFdz8TZz51nbYK7VLdetcNQAUUUUAFLSU5Bk0APjJBGK0bXa45HP0qokfAPGK1bFN5U4AHTJ6UAW7G13yBSOT05xmuistFZlJTDf0qnaWqo6CZgyHoy9q6nRCxbGcIOAccmgC14X0mZ71EPCs2AAOTXd+KvDf8AZ2nw3EzqBjDCqHhsm1vopVjLc9a73xNZS63oxZRlQQ2KAPCLySB79IFXKPwWHevU/h/HbW9n5TRZZjtz7V5zqNh9m1BCYyPmwcdq9I8GCC2TzpZCX25CD+dAFG+t0S6nTY4CkncRxismVnVN8EhI6fSn63qE9zcTNu8uPceB3HvWfBeIYnjcjHXdQBpQyvGy7iW9O+TXS6fqnljBibBHQcD8a4WLUFQlUYEMOvpVy21CQyAhwSeDzQB6baajbPGpnizj0rZ0++tHYBMrz/EK80ttSn2hVYgg9K6/w1NNIA0uPTkUAek6XIjx5Rcj1Fa1su7BPSsTTJcIgOAB6VsQzDAwaANmP7oAp1U4pse5qwG3LuH5UAZXjX/kTtd/68J//RbV+YrfeP1r9OPGbBvBuu/9eFx/6LavzHb7x+tAH0t4MltV1mJ7uRQmecivotHQaTGLEiRYU8zC+vavC9P8EXlpqEUlwqlNwLFTxXsnh+4S0imjBHKLke2aAPnT9q3XJZdR0XRS2DDCbmdR/fbgZ/AGvn016F8edXGsfFHW5o2JiikECfRQB/PNee96AEPSkNLxzR3oABSik7UooAUDmnqM9wMetMXg04UAammatLYWGp2kSgpfxLC+T0AYNn9KisRZGC7+2tcCYRZtvKAKmTI4fPQYz0qiKfQA7IxShyvfimmkI5oAtQSlSGzyDkV3PxZ1WTUfGlxvGFtoYbZRnssYP8ya4CMcnJx6123xVsTp3jm8AbdHPFDcRP2ZWjXBH5GgDrvBHw7WezF7r5mgRwCkYGDj1r6N8DXdpZeFIbQXAEdjmHMrYIHbrXi3hb4m+Hr3Q7ZvE0s0Wp2wCFFQlJABgEY+nSuk8Eat4Y8Y65fW1vZyunkl18wlShHQjFTK9vdNKSpuX71tLyV/1R6Rd+MdMju0s7Fmv7uRgiR2/IyfVumPzrplzxxz3xXmi+AhFLbX2nOJQuGktLgkbh3AYfj1rr18MaMRkWWPYSOP61jTlVbfMj0cVSwMYw9jNvvpd3+9W/rU3qwvHulQ654M1XT5oxIXgZkGOQ4GVI981r2sEVrbrDApSNBhVyTj8TTpRujcdcqRj8K6Dy3a+h+e2rRFHYHgg4IrIaun8WR+Xq18oGNs8gx6fMaw9NuYbPU7a4ubVLuCKQM9u5wsg/unFAijRV69a1uZr25gVbVDJuhthlsAk8A+gqh2oAKKDRQAUdaPpS0AKK+uf2ddXk8Q+F5hcNultNkTE9TXyKK+lf2OrlWl8U2jH5jBHMo9cMQf6UAaPxQ0Se38SymNSUmAK4HX2rQ8MeB4hbrLqZO9/wDlmvGPxr07xlpUMt/pl5KudgOM9M4qi2Nw9f5UAfJvx+0+30zx79ntFKxfZImwTnnmvNq9V/aU/wCSjj3sof8A2avKqANnwegk8S2CnoZP6GvZ4Lfaeh61434K/wCRp0//AHz/ACNe8WagDjHrQB478UD/AMT9F/uxgVxtdP8AEWbzfFFxg52gCuYoAKKKKAFAyasQxZNQoOeelWYwSeOPpQBbt0j7DJFWzONu0AADuBVSCMqfmPHerkQQdt1AGhpvmSDZ8wVv4vSuq8POIJys0hcY4JPNcmJXiAjUjYOwrpPDEf2qZdoOO9AHpFpKWMTRr8pHWvS/CU0kenSrOBtI3HPJrzzSrd1kjROR0JI4Fd/aWvlWDmJm3lOCaAPNPFjWx1SXb8hZzgetWfCU4F0BzjBBzVLXlElzIZUxJnkEcg1i6NqUsDzWrKVLSAqR1AoAm8QTESyorjkngVzn2mRbcRMVyGyMdxV3WcSXrmRsDOWGetZzRiQysFypxtPpQBMjs0ijOPWtixUhupOefpWHZ2s886lh8oPUeldpptkqKDuTAHQmgDb8N26lt87AKK7jTWjEq7cH/drjtMgHzPJNGvYLmuh0x0hwxmTPbnmgDvLG5CjntWgl6ByOK5LTC80hbzd3sDWjv3uI4ySwPQUAdZY3RkPU1rQO2M54rF0mErEpf71a6sAhz2oApeMG/wCKO10f9OFx/wCi2r8y2+8frX6W+LWz4S1wZ/5h9x/6KavzSb7x+tAH3pNMtpbES5ZVxyeuM1jav4gtPD2swJqVwsUd3GVQk8HBH+NdFcxJNHtkTcDXB/FDwInjG1swLhopLUkR49x/9agD5d8aSrceLNYlRt6vdSENnqN1Yhra8X6Dc+G9fudNvDukjwQ394EZBrEoADRRRQAUopBS0AKKd600VLEIzHIXZg4A2ADIJzzk9uKAEHSne/pTR7dK2PDGiSa9qX2OO6tbQLG0rz3L7I0VRnk+vbFAGVjmg+tK3ysQMHBxn1o68GgBFbBrrB4gi1vTdP03xCWU2SeTa38abnij/uSL/Go7Y5Fclgg9KlRTwTQB00fhi+lu1h0qW11VXOEazlDFv+AnBH0Ir3v4A+AdV0O/utW1yM2gktzDHCTlzkgljjoBivmqzMkUySRlkkUhldTgg+ua+j4/E3ifxL8JYp9KijuZIla0v9mfOGBxIuPagD3a0kieLMLb4yeGzkGp1A61x/wvMlr4E0SG/BSfyMFW4OMkjP4V1/TjvQA49OKq6hOtrYz3DkKsaFzn2FWScDmvLfjd45ttA8O3GnQlJdRvYzGq/wBxTwWNAHyl4luBc6hdzY4kld8fUk1zrdetaGoSbyen+NZzdaAENJRRQAhqWFI3WUySiMquUBUnefTjpUVFABRRS0AAr2T9lnVhp/xJNu5wl7aSwn3Iww/lXjYr0r9neCSf4uaEsYJO9yfpsNAH2rrirN4etZWwdrYzXLHIJLEdenpXU6wm3w1HG+RiUiuVcY+UkHt1oA+Wv2kzn4jj/ryh/wDZq8qr1X9pP/koy/8AXjD/AOzV5VQBveBhnxZpw/6aH+Rr3hVMdu7YI4NeDeByR4r04j/np/Q17jq18ItNkYjGEJOKAPBvFE/2jX7x/wDbI/KsqpruUzXU0h6u5P61DQAUoop6L0oAVR0q2inaCT17UyCEkkt0HSr6Q5IO3mgCNFbAz1q1Epxx3q5Z6dLcOqqhPviuktNChWJmuDh4x8qDoTQBhaXYSXUuDkKOSe1eh+Hra1hGEbbgYLAViJFtAUJhfQVv6GrRzGORR8w4FAHZ+H3P2pU6jOAfWvT7eHfZqANoHfFeYWEL27ox4Y8gCu50TXJLmaOJSMJwc96AMrxX4aMnmXyLtUA5yPvV5FeF7Te2zBL4LHqK+pbyASWDo+DuX8K+f/FempDrU0IH7vOeaAOF1AiZtw4JOetJFER8rN1rb/siITE4IwfWnSaWjKxTmTtigCrpdwoYxDLFeCQOlbvnRiHDxjI/i6VlSWUtm0aLFgMMsx/rUdxNu+TzDkH+GgDeS6t2CrGzA96vQGFnBeRx0Iya5K1bsNzEnqa39L8xmHyAoOu6gD0fQDaxnaszyORgDpXY6XBDF8wcux9a4LRPs0Lb2ciVuvtXV2d1HG3L+/PFAHaWb4wOgq4ZCHwOlc1bajFIvyPkDg4rWjmWWPgneB+YoAj8VH/ilddwf+Yfcf8Aopq/NhvvH61+j3iNy3hXW+c/8S+4/wDRTV+cLfeP1oA/QCM7h+NLKgMbAEDvT0I2jpx/OpHQvwBz6UAfMn7TGk+Rrumaqq8XUJidh/eQ/wCBrxY19W/tC6FJdeBZ5TE3mWUqzqcZwOjfpXymwwcd6AGEYNHc06koAOaUUgFLQAU4e1NpRQBIK27Sz0qXwvf3c9+YtXhnjWG0K8SxEfM2fUGsJTTwfSgB2TS0g605f0oAApJzg1YgXdgUyNa1tGsZbu7hghQtLK4RVHck4AoA9K+Cfw3h8a3d7LqMssNhaKuTH953boM+wGa+jvh74HfwjazWWnI8tpJKZGllOGbjHQcYxWx8LfBVv4T8OW1mo3PjfM39+Q9T9B0Fdyw6YJFAHl3jKHUNPkglhs8wqxLSBsbPqPSq+n+MrF4mM86RpGuZHc7QuOvWvULqFJoWhukEkTgqwIr5e+P3gi40BIriyMr6aznv93PTP0oA0vG3xy0+3jkg8ORyXMvIEzjag+nc185+IdavNXvZbu/maWeQ5JJ/Qe1QXZZSc1lTSEk5/OgCGd9x70yQR+diNm8vIG5hyPfApHNM70AWdVtobO/kgtrqO7iXG2ZBgNxVWiigBKBQelLQAUlLRQAD3r2f9lKy+0/FGOcj5bW2kk/E4H9a8YFfQ37JVqYtS1jUGACbVhDH8zj9KAPpnxXP5dpbw/xMxcjPTmuVmGCWB5xzmtXWblb66MmMqPlXNUWQk/LgUAfKf7SX/JRVz/z4w/8As1eVV6v+0shj+I6A/wDPjD/Nq8ooA3fA/wDyNenf9dP6GvVPHs/2bQbkLwzKQK8w+Hyb/GWlr6yH/wBBNek/FOJl0WTb/Cec9qAPFKKKeiljQAqLnk1etLcswOKLWDJBx+ddBpWnPM67RkUAQ2umPKFCA811WmeH1i2yTgEAchulXbKwW3VMfNJ39q2orYuoV2LfWgCgdigJaRBQOMgcUhjlCnJJBPIx0raitAAFC5q9Z6Q00oCIdx/KgDFjsFkVWUFTjpXTaVpkhhjmeJtg4z60wWhSZVCncGwwxXcR3MSabHDGpjYDBUjke9AGLKUSMmWN0AXCgml0298qRPJQABt231+tajaLfXRBuGzCv3ST2qnLaR6YWdz5gB4XFAHp2kXxv9PBkX58crXkvjKyebWpynP1rt/D+pqbSRwdnlrn/wCtXNeKXhubR7tWPmbuQKAOBmk+zBhK4x0qidYtkbEJw543HpTdXmDoRtDHsO341zNqJz50kgVFUYzjg0AdFdXbalEES5BUfebpVG3tLiHghgf73XIqnp9u0ud8vlkdFX+ddhpFm0sZL3SlkXI38UALp1llFaWPDEfLkY3VpPDJbqpliAB6AHpWfLe3MbgKQ23v6U861MUzLCrEDqR1oA6LTb2KNiXTHHJzS3+vMyhEBCng881gw6istuzGAhuxHSrOl2cl1MhkwFBzz3oA7jwpJMSHkyI3X5VPSvQLZyiox7jFcvo0USW8ZOCV4zXUxqGiDHoPSgCDxG5HhjW8HGbC4/8ARTV+dbfeP1r9D/EeT4X1onBxYXH/AKKavzwb7x+tAH6DqmTubrViIBZkY9jVzXbdbG/dVGI3+ZaqRxtKMqMkDNAHQ+I9E0/X9ElsbpQIb2Mx7h2JFfnz8QfCt54Q8UX2kX6ESW8hAbHDr/Cw9iMV+guly/bdJkgziWHlfWvIf2nfBI8S+DYvEllDu1LTV23AUcvD3P8AwE8/QmgD4ypKcwwcU2gBO9LSUdaAFpab2paAFBp4NMpQaAJAakXr7Col9qniGT0oAngTJAAr2L9n/wAJS674ytpyhFrZETu2ONwPyj8/5V5fpFqZp40C5JOAAK++Phj4QsvCfhKxtreELdvGstxJj5mkI5z9OlAHYooVQo6AYpaZE2+ME9e9PoAQgEYNZPinSYta0G8sJ1DJLGVORngiteigD89viB4cuPDmt3NjcKSIyTHJ2dexFcJcLhuOK+yP2mfBltL4aGt26H7RBL83PRG6j8+a+Qb+La5oAzWpppzDH1ppoAQ0UUUAFFFFABRRS4oAFGeBX1t8KNGOg+CbK32lJ5F86U9yzc4r59+FXhl/EPiaAuhNnakSzHGQeeF/E19Y2sTlEG0gD9KALMcxVFQqeeKe8kijPA+tR7QGZyScd/SmvGjOAT1oA+Zf2lNx+IUJbGTp8J4+rV5RXs37Vtulr8SrSJBgDSrcn65evGaAOp+F6eZ490ZemZT/AOgmvYvijYI+jXhZ8MUJ6eleQ/CkZ+IWij/psf8A0E17d8Q1DWN0jdPLYUAfM209qu20JOOOtPFr8/GQAa0rK2d3wo/KgCxplk0zqirmu80eyit4sAZOO9ZOiWxjACLlz94119hakgBsHigBllANwwuTnr61u2Ng8pIK7fep9P05pGHRF9RW5Bb4KiPgDqaAIFt4LeLCx/vB1J5qxZCbziygE44GOK07PSjdfLDxnqTXTWGjwWKCW4bLKOFoAw9H09+bm6VVB/hI61oNFaqTNKF+UZA96s6pcpLCiwgrz8x/wrDZDJIUJO3BOaAJrjWA2CRhR2HQ1j6tdpOm4L8q9z3qC5yjkYG3+EevvVfUJI5rVBDKFbOGTHWgDW0K732N3tBIKdQOlZ93C32SUIDIJhu/Gtu3tYtL8Ph52CiTg496uadHHcWE8kKbkKYQDqRQB4teo6NNB5YZ2z83YVShRHsIreWNkdWyzH+Ku7fS431EmVQFycrnvWVqVkVcFYwMHAHoKAOYjgjQllDDB60XOomGRVQk/rWjO0cETZwW7+1c3fHczNBIeDkgUAXrq+nQCQbiT2UcVLZ6k0mFYHPcg1jrI7Qshd8k84q9b6ekBVt5wwyKAOmsmZwdknGfuk10+ihhMgRowehB6muTsoi4VY3HuTWxZS28EoSW4+bPLjoKAPY9CSFoDFuG4jOR2rStt0bMm4FeorgdJ1Ga1ZDG4YKuQR0NdBHqrTrBdouFfiRf7p9aANnxE+fDGtAcH7BcZ/79NX55t94/Wv0E1iUP4U1plO7Nhcf+imr8+z1NAH6O6pex6rp0TyAJdxNgjpkVm6fO1vOjcnaeh6UWJj1PUig/dK5wDnjNSahbtYXJhl6jkHHWgDoDF9knTULP5oHGWX+YqXWJozpskqKstrKjK6Y4II5BFYdjqrwQSQffjcYwe3uKpC8mjR0X5o2+8hoA+Kfif4abw54nuooY2GnzOZLZjyNp7Z9q4819iePPB2n+INKlt5k+VSXjx95G9Qf6V8u+L/CeoeGbsJeRk2z/AOqnXlXH9D7UAc4aSnYowaAExS0UUAApwFAUn1qxDAXPTmgBkaFugrSsrVpCABmug8F+CtW8Uailpo9lLcyt1IHyqPUnoBX1L8NfgZpOgPDc+ISmpaiuGFuo/cxn3/vfjx7UAcJ8APhRcaje22va5C0WmwMHhjcYM7Dpx/dB796+obq8it42aU7QOBnufSkuLhLVFjjj3MBhUQYAH9BWYmmSajeR3WoybhE2+OJeAD7+tAE+pzPYwq6Odznp6VlSXU8nzNKx+hrd1m0+12ZCjLp8y1xs9wYCUY7W6YPFAGumq3ESFRIAR03c0x9WvNMkhlv9oinON56D0pukad/aQ3Shhb9Sf73tXRatplpqunvZ3sQeFh07qexHoaAM3xVp8HiHw5dWMg3RXEXHua+D/H/hq50DV57WeNwisQjEYyP8a+vvCPjGLSdTn8Pa5J+7glMUF0/TrwG9PrWt8RvAekeMtOdLhUS4K5jnUZH40AfnpNGQTxUBFer/ABH+Fet+Erh2ltzPZE/JPF8yke9eZTW5U5xQBUpKey4NNIoASiloFAABWlomj3es6jDZWMTSTSnAAHT3rX8A+C9X8aaymn6LbGVzy7nhUX1Jr7L+Gvwx0X4cadG8qR32tyDmVl4B9F9qAM34UfDf/hGPC0MUkO2eQ+ZIW+87evsK3rvZFI8SjlDjiu2u7prHT2nucG5kHyr6VwVwzmRm3fMTmgCvGCoO4YB9alsLd7q9iiT7zsB+tQspeQKNzc9M9TXUWFoNB0x9QugPtTKREnpmgD5I/azcN8W5FByI7GGMfhurxivUf2jpXm+Ixkk+81pEf1avLqAOv+Ehx8RtDP8A02P/AKCa9u+IE0UyzrGeQjZFeGfC5tnj3SG6YkY/+OtXqutzm4uLjd0ORQB5TDAGdhgs2e3atvR4AGODkkYwRVm2shEroB3znHWtfTbNYnDKM+lAF3TbTygOPmPJ9q6nSrTewJ5HaqWn229Q2MHvXUaRacBmBz2AoAv2lviMBVw1dDpWleY6eZkDvijT7QBR8nNb9ooVhjoOTQBKIoLSImJQMcAVQupmmRyTz6VNcyiWQgNhKo3MqxqTnLngUAV5xhPQCsO+vVGI4QfTcO9at5vkTykPUfMfSse82RRkAjeBQBRnCvGWJIkHG41BaxpICVUuw4GeB9agmdmbDNlSenpV/UIF0iAXDupDplFzz75oAr+IfEH2q1+xKMouAp9TWpoHiK3sNMNs5/eqteWyambzVHeI4jXhQO9RX+pNb3KK/Gfu570AdRf6sytPMccksM1m3erNeW6kcKR24rOivI76Vo24dOQM9RWVLdytqMlrERGo6A0AXvttoYmRlJccYBrLlu7S3kzLBKgYYDVZmtJobZ5CNxB6VBNcQvAPtFuDQBYs7vTy3+twT2Za2LZLScr5V0nXoT1rm4LezZQwRk75U1dtLC0ds+ZJjvxzQBsag7WwCxLls4AFJpkM0pYzAetJ5ccciiN2IHTJrS065+dU8tGY8ZoA6Tw+QTHiQrlSMHvW7Y6gXfyAEMR4+X1rB0uUxX0UNxEi7WB+bg4NdbZaTB9oZ4MoSeRQBr6luTwjrBbjNjOMf9smr4JPU19+eIYynhLVc8/6DP8A+i2r4DPU0AfeFlOLfBGQc5zXbwvb+IbFFaQLexjAJONwrz+Fh24z0z6VdgneEh4pAGHPHFAGxeabc2LETIwHZsZB/Gqu8nueR3q9aeKLsKEnRJ48ciSrEZ0rVH8sf6DdN90E5Rj7UAYVypODjk8Y9axNd0Gw1fT5La9tkmt3HKN/PPY+9dNqml3Fk+yYMoPRlOQfpWbIj45nC+uRQB8zePPhJf6TO9xoYa8sjz5ecyJ7f7VeYzWs0EpjmieN14KuCCK++7KzguoArNHI3fjtXGeP/BeimyknfSJb+fHyxwx5Yn60AfGZjwOadFC0hIUZr2XQPg3ruv63m70m50nTN2SZBzt9s17x4c+CfgjTYFVtHn1CcAbmnmOM/QUAfHWlaLdX9xHBaW8s8zHCpGpYn8BXvvw8+AM7xRaj4zmOn2hO4Wq8zP7H+7/P6V9G6B4Y0/RoNmjaVY6YT/HDEN+PqeavXS2Nmu/Ubje3+2eT+FAGd4X0mz0ywjsvDtjHYacvVlGGf3J6k10kmIoWO7HHLdzXHav4plfyLfRbdjE3LzHgKo7Ae9btprdtc26G4QxyEcowzzQAtujXMgLDgHrVq/vYNOti0jjcBkLnk1kahrkgxFaRGNT1c4yPoK528LT7jNMZWYH7wyaAO50nU4dTtllgzkjlSMEVieIvDc+q3iT2141qRw6qoO4fj3rkfB95JouvPazSTGGQb03njb3A+legXN9JZ3Gwr5gc5U+1AFzToFs7aO1QErGv3ic5rP1/WYLFDCJ0Sdh0J5FJqeoPY2zzybRcSDESf3R6mvOtR0uC7knbL/aZWzJM5yzf0oAvx6JYajHcSTwiWSRtzP8AxE0lqmr6B+7Dvcaa44QnLRf/AFqSxiuNMRFti8oUbdrtyfxrdh1CPy8TqWbHzYGefSgBun3Yv4TDcwiSI8NHIAQR9K83+JvwN0rXLWS/8MqthqABYw/8s5f8DXa6bLd2msTXbrvtJeBGBygrpo7+CZSIpV9x3U0Afn/4m8LanoN49tqdlLBKpx8y8H6GuceJlOCMV+g/inSLHWbX/S7eKQqOrAZP0ry3U/h1o0+8vCjDOUOASvtQB8q6bo99qThLK2klJ7gcV6b4H+ErXtxFL4iuhbwZyYouWPsT2r22y8I6RCm2OGOMjGNq4Na1rYaPpxUuoKqwY85OaAOu+HHhzTfDFglvolmkEZHPy/M3uT3rrL+WCzzdXhDOB8id65yw8TReTtsoMKON7f0rK1S4kvJC8zlifXtQAmo6rLqFw8jbto4ABxj6U3TbC61CQC3i47sTx+NM0ywlvZ1hj55yW7AdzWnqOtrYoLLTGEcacM/8TnuaALy2+n+HIvOumWa7PIQdjXKazrFxql2XkO1B0UdhVW6uJZW3SSZJ7nk1SkLNnue5xgUAfNX7QgI+IAz/AM+cX/s1eZ16T8f2LePyT/z6Rf1rzagDo/h42zxlpjDs7f8AoJr1l08yV89ya8g8Dkr4q08j++f/AEE17lptssxKE7T2PoaAMVbEIx7g9OOtaNpZ7QBjgc1txaZg/vOtTpaFTjC5J7GgBmnQDIOOOwFdZpahSGHXpismBFihUsRjtitexnRAGOMDnmgDfRmWNcsNzdvSrXniNWA5OOaw0uyGzjJbpmpIWLPktxjpQBZkudsbEH5j0qKFDJguc470xhmTk8UrTY+UCgBt1OscbrGPmPU1zWplm4A5Pat6ZcNvU5/Csy5mW1KznmUn5Ex09zQBn2luluhnvBluy+lcf4t1mSbfIGwiKdue9a3ibVZEj8ksCz85zXnXjHVFtbPycgyMOnpQBk6VqotZA9w3zM2ah1PVnv74sgOI/uc1yZu2dzn6VJa3JZmAOKAOotdSkuLtWRisnTA9a0LZz/aqzSoWdTg+5rndMUJdRS9ga6C31FrPVEXyhICc56kUAdI8syw7xjaOXBHNUJ3jjVTKR5hHQjFW9Rn8+2XYGVmxWJexhiiTZLep7UAWHaF9snzI4H3QeDVqxnRQWySG7GsGN3iuGiZen3WJ7Vbt4XZ98Db424x6UAdFEfM+6SPb1rV0/bHJ+8Ry3tXN+abWIbCd3cZroPDmoLcttuAA4HDUAemaf9mv9LjmcB5Yl+dT94D1ro9KMc2wxt8wAAGa4TTUktrmOaBxtK4z/e9q6jwvFIL7zIyfLc5YHtQB1niZf+KU1jd1FhP/AOimr89T1NfoN4nmDeFtZK9PsVwP/IbV+fJ6mgD7VF9aQymFru1JHIYTKQQeQRzVqO+tN3Fza+/75en518P0UAfcq39r0F3bDjj98v8AjUpu7SVArXVowzn5p14P518K0UAfoZp3iSx+zfZdVvbSa1P3W85dyfrVPUFsIyJbbUrKa2b7rCZenoea/P8Ap+w+1AH39oX2JrsmPU7KMe86j+tdDe6zpunspkv7WU+iTpn+dfnBsPtRsPtQB+kA8deHFhD3F7FGB/ekU/1pqfEHQpSV06aKY+vmKq/mTX5w7D7UbD7UAfopfeKnn8vy76ziUn5lWZOn1zWdPf2kzZe+tD7tMuf51+fnln2pfLb2oA+9NP1ixknuIYru3VIm25aZefpzV6PUrFjg3lqSPSZf8a/P0RMfSpBauehWgD78m1K0BZkurbeoyo89cZ/Oqq6nZXVsJBd20cvfMyggjt1r4RFhMe6fmaa1lKvUrQB9u6/c2F/p8ga6t47qJCyOJlODj1B712HgHXrHV/Dll/aN7areWmI3zMvzAdD17ivzv+zP6rVzSND1DWL6Oy0u3e6upPuxoOTjk9en40Afd3inW7DUL2ZI76387lFZZ0+RfXrVe0vrK0t0EupW8gUcyPMhJP518fx/CfxtIm9NBuSvTOVH9ar3fw18XWis1xotygXgnjjigD7P/tW0Yblv7TBGAPOX/Gnw6hZRphb20P8A23X/ABr4Ov8ARr3T55Ib2IwypwyuCCKoGMg44oA+/wCfVLKFWle9ttirlgJ1/wAaxNNvtPuZp777ZEPOICp5qgBexxnrXw3sPtQIzQB9xXeqT2yyrDe2ssWPkH2hdw/WvPbrxVdoJIvtkAl37iQ4BA9M5r5gETH0pfJb2oA+sdN8VTT2zA3tkJQpPzuCW9utbOh+RPH5+oXVpvf5gPNQAfrXxoYmHXFJ5Z9qAPu6K7sIQMXlpjsonX/GtLT2tb+VUF5aIo6s0yYA/Ovz/wBh9qTYaAP0F1PxDp1lG9lp15bhPuvKsqZc/n0rmnvLNmJN5blj6yr/AI18PlT6igKT0xQB9rSXtoCR9rtPXiVf8ax9X1/T9OtjJNewZAJ2q6kn8jXyDtNIRigDr/inq6614re6TAXyUQfQZ/xrj6KKAOg8AsF8X6YW6eYf/QTX0Lp4iM+NhxnrXzz4DUv4u01V6mQ/+gmvorTkdJl3KB9KAN1rVWCkfdrPktisvAwvWt2KDbEHY4HUk9q5/U9QCyPHBznq1ABJKgAAyVHGB3q5bs0ke5unRVFZFsVUGVskngCtW1kHlgA98k46UAaNuWVfn4x0Bq7CQ3cjHU+lZZug0igtzT4bvywzryo9aANCaZVXA4/nUccgHL5A9Kxpb5mmLd29KebpgvzN82OBnpQBp6pciFFOSGI4ArldX1HbC7y/K4HAHpU15etIQnmbhnqe1efeOdXNumyJsEnAOetAGdrmugXReTJZRlQema891++lu5TJMxLMf0qe6ujJI0jscdeaw7mUyyE547UAImScDqasQMsb5PX0NVFOGBHGKmaTc2ehoA6GynCwM7EYUY4rQ0N5Lu8iy+HDcnPJrlTKwRVU/KefrWxpTSWwS43FR2I6g0Adrfm9W2ePcCyNkYFYsetXSzhJo1lA+8CtWl1n90rJKN45YEdaoXl6ftHnIiru52+9AGzFPHcbvMtQ0ZHDZxitjT4YI4SMGMgZAHOa5fT9ZdnEUyDB7+lblvqfkkjamAOc0AQtBLeXjPE2FB5Rh/Kt3T7YwNEQOejH0qlbTBnEuwbT12112nxQz2RMY3eVyV749aANTTnb7DGQxdVYqwxXe+GCm0FBxtx9K4XR8G2liGWDNuGB0rvPDarHD8vJx1NAFzxM23wxrCjp9in5/wC2bV8Dnqa+8/Ez58N6xn/nyn/9FtXwYepoASiiigAooooAKmHSoasom51XpuOM0BuNGM8mg8V0eoeHIYLnUbW2vXmurGMyyI8GxWQYJKsGPIyOCBXPdfpUwmpq6N6+GqYeXLUVt+qe2j2G0oFKAfWrCR5XrkVRgRCPNSLF+VTpFk1csrGW7uo7e1jaa4k+7GgyT/8AWoAz1ix2NXLO2ea5hijBMsrqigDPJOBxXpdj8LS5givtVjhuJEDMEKsgP93OeorttD8CaXp24WYZ7m3YyPNLGSVUnGc/3R6igDf0j4KeEE0a1OpR31xd7AZJReFNzHngDgCuW+JPwu8M6No00ukxXy3qI0qhrgyDYuMkgjtmvUtHsZ18PXFhBNLHI7iVbqIB+GxkqD3I4HpVTXtLuo7xJVvZrvT5rR7W4e5GTCjuqsVAAJOO3tQB8h3lqkN1JGjFlU4BPU10fwwdbbx/oEkpHlm7VX3HgggjB9s4r6I134ceG9Wv5ftVq6OJ4oohFIVCxkckgEE8H8K8O1Tw4PDPxItNMinS4EN7AykHJGZAVB9+nHNAH19BZWzxqHt4pIwOFZAVz9Kim0+2LKrWcSQRDcAEAVfoK1dNINshHVlBNT3aoYmyB0waAPlT4x6WXmlVAqzS7h83fJz/ACrwaRQCRmvpL41uP7RQAbwQ5zn7p6fyr5ukUZPXNAER6VJHGWxxxTkQcZrV0jTLi/vbezsoGnup3EcUSdXY9AKAKSQEjgGlEJNeqJ8HfFcc1tG9pCsU7lTMsmRGB3I6/TFaMPwa1GbUWsZdUt4JzzEGiP74dwOeD7UAeMNDyQRUbRcnNeneGfhrfa9e6vFFdwx2+mS+TJNtOJG6kKO2Bk8+lV9d+Geu2N+8OnWz6nbYJiuIgqGQZ4wpbOcYOB60AeatGRURXBIrsLnwZ4ghneKTR71mDBC0ab1z6b1yM1zs0BSQq6sGUkEHsR1oAzzSEVZePrjtURUgDg/lQBHimuKftJIHrTX6e9AEdFFFAHTfDVDJ440lF5JkP/oJr6SiaKORGudyAHB2183/AAzUt460gDOTKf8A0E19LyWkjRtGqkg9aAEkvpL7zFyEiHCAdxWS1rmTLHr2rVisHC42ncvSludNusZCFiRnA60AYz4DBBnAqaOVkjPUDoDVuz0LUbmQ5t3X6jrW5D4OvZIwsjqg+nSgDmlYkcYHp6mpTLI0exCAg6k11kPgWQLmS5B9ABVe78FXQRxDMp9ARQBxktzGj4AOO5qvNdu77YvlB71e1TQLyxY+cjFR1KjOawbjzATtRxj1FAC6herBC4XJevKvGd95uofMeFUDGa7PVZZxkLFIygZPFeTa1O8t9IT60AV7qcyHAPy1WpaSgAqQfdzUdKDjPvQBIp6ZPFaNjduWVP4B2JrLB4q3aIQdxoA0mlwzBeqnIqyLgTABjhh3qiUZiNo47URIyy/KPwoA0vMJUsMfL1z1rTtkc2/mI25e/c5rNWEyjI+VhzjHUVch2iB3i4KjnJoA29EvQjeTLxuPHpXe+HZ1S8RQw8uQYY+1eUQ6k6TIECMBxjFemeGriG5s2fZsmQYxQB6FaQfYLgBow0UnKuOjCus0qNFikeLlPT0rzrRNVZPKtp5N8W7qe1elaYqx2vyD5W5AoAzvFEufD2rD/pyn/wDRbV8MHqa+4/FaAaBqhB/5c5+PX921fDh6mgBKKKKACiiigAq3GdsiMQcAg1Uq6qt36UDTtqdNqOuWB1HVb+zF09xfRNCEljVVjDAAnIY5OB6DrXLqpzwPpUwjGelSxxkjgVEIKCsjoxOKniZc0/N6d27v7yOJT25qzGvyktgAdadFHjriuk8H6PdX+v6aqW7CEzo0kkkBeNEDDLN6j2zVnMbWkfD2ZvD1rrGt3Ladb3csa2yBVdpo3Aw64J6kjAxXtfhjwVbmKxGmWS2VtbFvOkKhZJnGAWJHrjpU+laPaW09obCdb5LQFYy43Kz5+VY19BkDIPFbWsQ31tbJFp8hknunMd0YDu8t8BgF7Zz396AI9Q023sLi0gnS3jubq5EaoI8LcA++OMZqTTIbPTpby1eaCO4iImTzgcsh4bOB90dOM1o65q+yPyWScsu0s0cZcJIBnOemA2AaqQxPqUGlwzuWvrExSyTIB83Quh9VOTxx0oAqWs0elalMDIGWWImVoIiUEK52vGc/3nUVe0INeabGkT3UZkkeZ/NOW2LIQuBn5c4B/GktYZLTUdae7QW6XKt5BJzHDGw4U/iOeO+KXR4JdK09rdmtTeWsMjSbX3Bo8DbnvigC3caMyxm6aSO/VFzC85G5NxGfnHUe1eZfGHwwi3VnqWg2jnVYJ4iXC/McdTycEDAPrxXpy6lJb3KWl2NP/sqWNpYPmJLKu3HXjuDVvxBF57iBrVm82MsJzjYHHIHqKAOn0qNfsUO0nGwY/Kq+vTC1sJpSThVJ46mtGxjEdsiDoFArmvGtwy2bqoBJHHtQB89fElpHeOaYksWLbewGK8EdSc56Zr3T4kvtk8rdlkXee/UV4d1oAdBH3JIA/Gvp74G/CUWX9leJ9d81b4AzwWjBdkakEIzd92DnHavOf2cvDC6540GoXGPsulbZQuBh5TkKCD2Ayfrivr+HCQl2PvQBDcCJSoYqApySe1cf4nsJ7vU7eawQG7RDJBjruU4Jx6YJFXfEape3AgknCQkNNKucHaq8Hj3I6elP8MPdLFBJexM121iEtxISN2AWfPGVz8vXmgDl/wCwLnw7YJHK5v5tUuZHuZWfYVkc5DnA6KMDHesW68O3drIVe6SeOK4VRcB9rscEnHpgjn8K9H/tAXM+lCRIxdqodi24RgNHlue5wRx61HfT2M0U1nfHDMJpkZ+B5e7jB9cY460AeWSWWo3OktYBYVeaberSZbAX592B1U/zJrk/Fvw/0eZILW2aOx1rY0kpgixFO393GeMHA7fer1SXQHmv7HfcfYprkMYA65yxUsqEds4PA9KzdP0vU28TXF5LbJ9pa28yK1dBtQ7trOMnPAHGf7woA+Xtc0W60i+ktb6PZJGRz2IPQisqWHP3eRX1Xr/gewvfGkdxf2VqbDyfIMAYHaXOc4P8WcYx/erzvxz8NpBBd3unpHHc20YWTTraME5UD7oXnJBHY5oA8QeIiq0oIHNb+p6dcWF3Ja3kL29xHjfE4+ZcjIzWNeIFHA79aAKlFFFAHZfB6ITfErQoyMhpj/6A1fYcdgqtwOM18h/BAZ+Knh4f9Nm/9Aavt2GEZOBnmgChBp0RALRDP0q/Dp0WQfLUCr8EQ6dKtrGO3SgCmsCgAbRipPJA7VdCDHSjYKAKSxBlBGOaGtyRwOa0FQEdKmSMCgDnjoySEmZd3fFUdQ0WzaIiS0jPttrsGAUc1n3c6btuMn3oA8j8Q+Bobm3mlidoDgkRgcV8u+N9Cn0jVJ1uIiULfIw71923USTQuGXGRXhXxS8NpdXX3BtIPOOn0oA+XRhnwB07Uo8rByDur0y08EebfgON0ZyDgcmsbWvAN3azv9lO5RyFPXFAHFpCJHwhPPSpTp9x2QmtIaVd2k6NJA4CtkkDINetaRpdrd2UcsMSbXUZyOR7UAeM22i6hcE+TbSMB1IHAp8ul6hAN720ypnGduRX0do2hRMJEVFxtyMDvT5dAABTYMH1HegD5mV5ldclhtPcYq4lxMjLIeTnkEV71f8AhK2dT5ttGT1+7WaPCNlMjIbdVwOOOtAHlsWs7VTzbZGUdSODSaleQykfZQyqR8w6ZNd+fA6+VL5CFSh7jIFchq+jTWlyPNQYBwWAxkUAUtCtBdXqNnZtI616RoMgt7q7RgdpPX8K4GIeRKnlfKpOTXWQXUcN62SdzgEj1oA62wIMwGAFznmvW9KnP9nxEEYAArx3R5RKwGcseles6aBFp8UfqBnNADvFDKfDuqkEH/Q5/wD0W1fDB6mvtfxJMP7D1Ze32OYD/v21fFB6mgBKKKKACiiigArXRM9qyK6aKHK5oArpD610vhHwreeIJ3aBCLO3ZTcSdwvfb6kD+da3hPwVc6rcMb9JrO1iYB98bK8nGSF444wcn14r1rw9pdppgtbCwLx2vmFmVQW3N1+buTwPyoAy9J8DaYul6ha22lS2xGblb+4cSPIoXAhXPbOSenUV22nxsZbie9k06KzFqSkUXyOzKpP48VzupWl5NtuZ76OU+WUMPneX5bkkksR1AHOPWuzvLC0t47IxW321I2V55ZUO2NMqRj169u2aALCQ293wURYreVZbKe3ZQs0L43BMdCMkE9uvWrirc6XdzMLdZLfz9wYsPm5wMf8AAcc+1ZpvhdT3un3ZhtVkZJYSpxH5AOWXjG1m9B6VDNe/bhDAqywT3KeUA+djqPmUc9Mgdce1AHTXcepy6WWtpPswZHQQugdWySSfxzwa5rUHGmWVjd6PtWPUiEb7V8yq4IwW7nnsPetfWYoLnw5BdJJMl9NGgtnXLBZWx8qr9cjkY4pv9nyya095bSBrYEKIWB2xTKMEqB9DnHpQBa1Cdkt0vLgwtNFHJHeW/GJQqFsD246ehrL8O6QmqLaa3EYmuZrUxwsxyqhzuIb/AHPujHFal9psF9Koi1cqzSRuVCLtYuMAdOcgEZJz1zV+PQ10yxjRZCyW67Yh0CqeCMd6AOX1Sx0nWootM0iKdRHbNDHOW+TyYyAVAJzliPvDnit+2ia4ms3DMYnbaQ2RnaARx3HXJrlfHt6NLlt76KdvMtozsAOP9k/XGeh9a7Tw/oynWY9UlULNJaRgxpwqA8hcd8etAHVqNsX0FcL4ulIjyMk7WBru7g4iJ9K808ZXSBZUAIboKAPBfiPelrjUXCfw9PwFeNkA9Bx1r0vx3JIg1GXap35T5ueCdpx74715yoDEg/h70Ae7/suX0FtNr1vNMiSyGKQKTyVAIz+dfTOoFxpTvbqXYLlVXkmvj74EaJeX/i2LUYSqWNiwS5LH/W7x8sfv0DE+gHrX1joMFxBCIrtpLiODlCQMrk8D3wOAaAMTU1k0+70m6Zmlvmb95FGmWcEYwB2A7+1WJjcwLZvqEjwxN5kcjQ7jjfjHXJA5Iz7Us0ktxeapq1pqCRTrBJBbRNHhYyCMli3Rvl6dOc1sJJHdTxRXKXDGW2OWYfu8nnaPU89vSgDP0rUre9nurSwi3GzCiN5MAODkbfYjb+WKr3cRjbUNUkh2xW6IXVyfmRB8524IBAJGRz+lNtUe28yJ7NLaTarPIwCDAwGYgZHUDp61pANKsrahcMn72WPyCwH7phwOO+OQevSgDntG0fbqBN1cs1xGfNtWQswgySVJB9VOMduazNVk1O6uZ7ERQwX4KPNKRukmiDciMg8KDzj3q7Z38Isnhu9TO8tFDNczSGMHA/d/OB145HGc1PqF1Y6jfiVIZEukm8q3lXG24ZTnaGztGSO59KAJNf0m3tL62vYo5XKuZJ7lny/QAbfT144GKyNYijfWJ/IRLpb2SBomjJVsgnnf9cZHpxUdjqt6waORmvEEpB+YMyFSeo9txHvx6Vc06CLUtNnt7BpIjZjaIBkG3fkgZ6nHXI7mgDy/4veC73XI4L2wjhGp27G3mtvlV5cAEsh7genvXzzr1rLaSNDcxtHMjYdWHIOK+pfEN1NBEllfGYanIRcTTSsD9lUEfIWxghgQRjpzXz38VYFg10hJlmjlUToVGMBi2B74AHNAHD0UUUAd58CwD8WPDoPTz2/9AavuWEAE4Hevhr4GcfFjw7/13b/0Bq+5Ij8xOe9AF2LrVhcYGTiqyMBjJqwrDgDqaAJBTlHPNNFLgHgjIoAmUD0qT6VGKUYAoAZK3X2rKddzlvWrt0x+6O9RIvrQBVaMlTXM+IdFW+i2kEHrkV2ojHFQSwKW6UAeZaZ4bihvmBiHUde1Q+JvC8Jd3RAD7DrXp62as4JUcd6q39oshwR0oA8SXwtkcovPXI7VsaF4Vt0uGDLtVh/Dxg130umjP3AKfBpuHUgYxQBi2Xhk2TFh86HpimT6YBKTjmu+s4P3e1uTVe90tWyyDBoA4iXSkljbK8461QGhKkqtt4Hau3NoUBBHNVmgx/DQBzaafFAxHlBgRzxXE+K/Dkcqu2zk84A4r1cwhkIYVlalBDsAcZ/CgD55uPD6pMfk+70U9KW/0Z8R3AQgYwPevZW02yNzxGp3cAkdKwtb0+a2uNkQDwOpByOAaAOV8JWxnuo1IYEHmvUncRRjBzgYrnfDunrDL5iptJ+8BWvekcgHkdqAM3xBIToeqZ/59Zv/AEBq+PT1r651xv8AiR6kDn/j1m/9ANfIx60AJRRRQAUUUUAFe4/DL4d6h4qngvEYQackvMpHLlT/AADocHGa8Or7q+ATvN8LtJMknmGKWeMdPlUSHA4/rzQBqWPh2Oz024ubqB7mVHMrQ7s+aV4AJ/z2rQ1DTbHTtFmKWhc3EipGinBDuQBhu3rn2rQ8NabPYaS1rqEizytK7swJIIJyOtak9tFcIiSrkKwcD0I6UAYN54Ut5rEwW7m2d23SOqhmbrlcntzWHN4f1Gz0xo7S4u0toJvLEOQ7GDdklffBxXoSjAA/OqVzdx2cskl1KkMG5FV3bC7jxj88UAcVrWgWsV1DcwRi0s2mjH735SxxwvPqR3rD8QWWqS3+m3M08QhZ0CSlNq8tkAFenGMe9epX6Ranpt9ax+XK21oyrrkBsd8/WqetaPJqGn2qwyRQTQqfkZdyt8uNv0zjkUAcPbaxfrrGoZWG48xnaIJw8e35cKfUYwR3JNdDpaSoY/lnEnyz5QKrMzctu4wDwcj8M1ieGJZ7TUpdLt7VPsUly0bvIrP5UhGSoYnpkZ59a2rXxPG9/d6e1jdy3UFurvIpVUkYkDaDngkkn8KAHpaxQ+JXSSURtPCvlluMkEnav55496vavMINOmeViNgIYd/rTr+wt724itriORQ8O7cO2MdD6ivKfGGvXen6vc6feTNMqQlFH8T5IK/XjNAGdqcU3iTU59Nsg7tAGllbH3EGCWPPSvdPC1pFa6YiQqVQkuATnGecV5V4bZL2eS50uFmsliishNIdsxZWG4MAOQe/1Fey6em23UAYAoAZqj+Xase+K8Z8Z3X7+SQk7du4CvWvEjqllLn77KVBA5r578e6qCsix53kbEx19KAPH/Hd7588cSkgFy34dv61yiKpkB5x71f1uUTanNtGAh2fXHXP61WhXLDjmgD6Y/Z2sHTwZEzxo0dxcSysQpJABCj8cIT+NevXFxcXSlYJPsJCv5qhwSUABBJxwSD255rhv2ftGa08DWs97uxLH5sf8ICP831zXpFjbRm7me6kw4nLQRg4IXpnjkg+9AGQY5tV0qKKK3hjt52CPskJZQMY3tjnPRu/arWs+fbmO0j4SLEkUs2W3YzkDHOeo9hW/wDZxaxILa3P76fdL82Suc5Y+varaouVRvnZV6kdaAPO9bglliuJoJme+it0i8xf+WG/AUsCepGfXtmtmKCdbANeYubhUR5ZYwBvbBBCjsQOp79eK2YdO043d9FBCUn3LJK2T8xI47+nbtUV5ZXELstjKFM2SxkG4k+3pQBx2rHT2L2ohWKytnB8+QfK8rIQqgYycEsc8g1jrDiO2tbQNb/ZNrv5TFN4Qne2CPoxyO3FaetWWtG6nutSt7iS1SExERRqQn911A5OCM89MmpbqKfVZo7qD7NLdBEk2b9n2pej5xyvoR+dAFm1TTrZ7nVEu4/slwu1jL8mQSBvB67cciuN1bxJ/wAIje6rPaxGVp8GBpvnSbBJBGOgwW69eK3NeewuEXcjmSCVBJbuuAkTDHynHQHPA64rhvGBGu6jBp1usVvHBIqLIikBgRt5z2yOKAMXwlqia34uf+0II5ra4eSe4kdiUUeUflweAARnNeOfEEKdK0uVVI8ySYhiPvKCAMH0Fd7GsVrNryKfniDxRsjEfPv2gDHXI3cVx3xSDxaVoVrJH5bWvnxle/LA8jseaAPOqKKKAO6+B/8AyVXw9/13b/0Bq+3oH5Psa+HvgocfFHw+f+m5/wDQGr7XtpMMfrQBsRtkc1YVvSs6KTirKvnigC8je9SqapRtjvU6uAOtAFoH3pGbiog/HWhjQAxxk/1oUY96QtSjJoAlXpTSMninDpRigAUYBqOSMN2qSlAzQBRaDnipY4AO1WgvNOVRQAyKPaeKewzTunagmgCrNAHUj9azLi2eM5xlfWto4qNwCMGgDmrjCoSRiue1KRnbaOc9DXaX1qkiEY4Nc3e2BT7gJGevpQBk2sI3AOByalurKI7t4+vpVt4girx0qrezLGCcjHegCg1qtrHIU6EcVkyvuOTW1dTho+SPu1zt2+wHnFAGfrr/APEm1IZ/5dZf/QGr5LPWvqrVnzo2ps3a1l/9ANfKp60AJRRRQAUUUUAFfeXwRltB8M9G+xIo/dv5uxcZl3ncT6nPevg2vuz4W2v9nfCfS3hkkJktXnyAMqXYtxQB6RCwkRXB4NLNEs0LxPna42nBwcfWoNOO+yhfAGVDccjmrlACZCJycAAdTWfqNgbrUtNuBKFjt5GaSMjPmAoQPbIJBqj43vJLHQ1mjbaonjEhx/Bn5vzAxW5pjpLYW0se8xvGrKX64I4zQBkeFtOexmvTJO9w8z+Y8rcbjlu3bjAPrW60KmcTY+cLsHsM5puVilVVUDfknA71OzqgBZguSBz6ntQB534ptbqLxcILSEyW1/EJZFDlACPlbGOM5C9evSrsVhbyNp/2jTykZCqTn5S+QQrAd/l/pWL8U7+5bxLp2k6bI0dzPbu8jeZtBTkgD0Pyn610fh6e8udGhju4lguT87I+MmM9HGOh/rQBrQSTT2he+jCbjuVFUgqOwPv9K8W+J9tFqPiexhhQxXDKV+0ckqOxAHWvabb7emlzLqBjklWPIZON3y9D+Oea8ZuJ4L7x3FNeStFaWlrJPNsPzYVeB7Zz17UAdD8P9PlfU0Mr+YIFxuUEK56bsZ6+9etQkKrL0wcdetcJ8MbVYdNhWNX8sRja0nLNkk5J/Gu2nhiFylw2fMiQqPTnH+FAHHfES/ktbN9jbfXNfO1xM99rkSSP+7UtL8o6YFekfFnxLHLvtoJMt1yBwR9fzrzfQbZWstU1CUktbqgXnqSTxQB5fr1p9i1q9tjNHMY5D+8jPynIDcfTOD7g1q+A/DF/4u8SWujaTsW6nDt5kn3I0UZLN3wOBx61neI5I5tfvpIUCRtJwo6DgA/rk/jXrn7NXg+61zWbjXbLVZtPm0e4gASNf9crcyIxP8JQEY9aAPpXwj4fOgeHdJ06ZxJPb2ywyOpO1nVQCQD24recxxyqWQByu1W7njOKg1Wx+2PbyCaVPs7GQIhwGYjAJ+nPtzRNH5l/CWw4U5VTj93xgkfy/GgB0L3KaP5jxiS7ETNsz95ucDPvxT9Md5dNtJZiGlaJWYj+8QM/rWdqmpReatpbThZtxVmAH7rGMk5/l71f0uOG3tVt7ZdkUXyheeM89/rQA60hdbm7ll481xsGc/KBgH69akMW67RyeAuB7Gsy11gz+JrvTcxeVDGCrAncX/iX8Bj862T0460AZ+lTT3dkJLyHyZizAx+g3ED9MVQfQrSK9aazItLh02fIByN2Tx+HWtSxmiYywxgZgOxgDnFOkhja6SVkUuqkBiOR9KAPKvGt8+g+ZcMJxLPKbcBgrblCEh13ZwuT+deZ6PeXLSQs8QNtH5cs07rvCRISenUs33Qe2c816B8ewRf6f5aje1tIM+nzrzXmDrPPeaFFp+6FjCFZdxwWXduP5CgDU0Tw7Fe3enXW6VINQ1FbhYyQsiIHIwSOBjb1rzn9o5dvi25HH/H1If8Ax1K9Q8T69ceGrnQJhZWkg2LNKSrBpPmPHXrxn614Z8Wdbl13WpbuUofNmaYEDB+bjBHbAAoA4KiiigDZ8Ia5J4a8SWOrwwpPJauXEbnAbgjr+NevL+0XqQP/ACALP/v83+FeEUUAe/R/tKammP8AinrI/wDbZv8ACpl/aa1Mf8y5Y/8Af9v8K+e6lt5RFLuaNZBgjawoA+gh+09qg/5lux/7/t/hTh+1Dqg/5lqw/wC/7f4V7ppnwv8ABMVta27eFtIkaKJUZpLdWZmAGSSepzmr5+GXgbt4R0T/AMBFoA+fh+1Hqo/5lqw/7/t/hTj+1Lqv/QtWH/f9v8K9+/4Vn4Gx/wAijon/AICLS/8ACs/Au0/8Ujomf+vRaAPn4ftRaoP+ZZsP+/7f4U4ftS6oP+ZZsP8Av+3+FfQH/CsvA3/Qo6H/AOAi03/hWfgb/oUdD/8AARaAPA/+Gp9V/wChZsP+/wC3+FH/AA1Pqn/Qs2H/AH/b/Cvek+G/gUkj/hENEyP+nRauJ8MPAhjUjwhofI/59FoA+ev+GqNV/wChYsP+/wC3+FL/AMNU6r/0LFh/3/b/AAr3+7+GPgVVQL4R0MEntaLUI+GngbIP/CI6GR/16LQB4N/w1Tqv/Qs2H/f9v8KP+GqdV/6Fiw/7/t/hXvo+GngVuR4Q0P8A8BFrnviH8OvBtp4B8S3Nn4X0aC5h06eSKVLZVZGCnDA9iKAPI/8AhqnVf+hYsP8Av+3+FIf2qdVP/Ms2H/f9v8K8ams7aKZGFvEQCDjHB9q9/wDg5N4A8U6lHo174Q0xdQeJpI3e2RlfYoLDPY9aAMT/AIan1X/oWbD/AL/t/hSH9qbVSP8AkWbD/v8At/hXvJ+GngfB/wCKS0Tt/wAui0y5+HPgOCJTL4V0JAxC5Nqo5oA8FP7UWqEf8i1Yf9/2/wAKhf8AaZ1J+vhux/7/ALf4V70ngD4fPBJMvhnQTGmSzC3TAA61xzyfCCO9Nu2g6GSCfmFou3AHrQB5Rc/tE38wIHh6yT6TN/hWXcfHLUJz82j2wHp5p/wr6L8M6P8ACXxDPLaaZofhya8iG8xfZkDFc43D1FdIPhf4Ew3/ABSOid/+XVaAPlCb4538iKv9i2oA/wCmp/wqvN8aL2VcHR7Uf9tD/hX1avwz8DFMnwlouf8Ar1Wg/DPwPg/8Ulon/gKtAHyHd/Fe7uLO6tzpduonjaMsJDxkEZ6e9eaV+gR+G3ggED/hEdFyTj/j1WprP4aeB3lKN4R0Q8nraLQB+e9Ffoe/wx8ClWC+EdEBHOfsi1CPhp4H/wChR0T/AMBFoA/Paiv0JPwz8D/9Clon/gIteL/tS+DvD3h/wRp93oeiadp80morG0lvCEYr5T/LkdsjNAHy9X6E/CtQfhz4aGMj7DH1/Gvz2r9DvhguPh54bA6Cwix+VAHUgBVwoAx09qx/FWrjR9NaYbmmKt5SD+NwOF/GtgEE8HNVNT02DUhbfaVYi2nS4j2tj51zjPqOelAGF4pxrOnWWjTXC2s+oBGUgZO5QGZCPQjIzXVKhiEKRALGoC7QOAAK5qbTHfxtaag+0rHG8aLtzt+XO7P4kV1MUe13bP3jnHoaAHlMup3YA6j1plzbxTmJpEDtE/mRk/wtgjP5E1neJJNQXSpf7K+Wcsg8wMAUXPzFc8Zx61daZIrWBbh8GXEYPqxFAHjvxGmmufH9jqGnciyRYZWOQN6MSU49Qa9Fsbi4utHiSBGDSK6724x6Hj68fSuS13S7XUfG8+kaUbeL7NbJJcJyp3E5JPHJII5rvrNDb21vBGwKomM+tAGcxvI9FtrW7m827mHk7y2N56559gfyrxOGyfW/F/iAQX8VgtpavuJUMJU+60Y+uD+leuePdRXT9Iku3AaaMfuFH948fh9a8X06wme/khmtop5dSlhSPzCVCsDvJOOQcZwfWgD3nwNNBeaat3Y28lvZyACGOQbWVQMYI7dKt+I7w21m4jRpJX4VV5LfSmeDvMGiRLMMSjIbnvmn6iVF7Zl4XkcTYVhwF4PzH/PegDlh4I0sq09xbvJdygGRpDvVTjkKOgHJrxfxuv8AYw1a3hh8stKuVwMcAnB/AD86+pRytfLv7RUMltqypFLthuZX81ugzgEA45xyfrQC1PCZWaSV3bqxya98/Zb8YaboF5qejal5iXGrXEH2V0QtubaylTjoBgHPTmvKtK8LwXzgtqls2eqQnc364/lXtnwOsNO0XxHcvHpdzeyW8AljaFBJIjkld3OMfLuHH948Vh9Yhzcq3PTWU4j2LrtJRXmtfu/U+hRL9nmDzsxjnm2R49W6D9KiWwDX8U7NLvhkYglyAQw9B1H1rH0fVI3vXtprDWSZrozxm5h+WHgYA54UenvXW4AOR19fWtlJS2PPqU5U3aSOW1fRYJvEDXCR7LueAbZSMr8rANx67SK6OCERrgEnJySe5qC+sPtV7ZTmWRVt2LFFbAfpjP0xV2mQYFvoRh8Wz6usiiGSIoIguDvONzE++K36MjODjNB56CgClY20cD3LRbv38plbJz8x4OPyqVpcXHlgD7uc0lpaJa+eI2c+bK0rbmzhm6geg9qNjm4ZiBtHAOe2KAPN/ivYJf3tqsrAL5aREDqQ0oyB74rxG/uE0PxLdrFmSOwkmiiDMTzkhTn2zXrPxVubjT/EAdmi8lx9oTB+YbRjB993SvF9aWW/ke9jRhLOZJZvTOSc0AbfxCn8/wAH+EbkoBLLDJI/8XVwRz+deB+Ks/bpywIJkzgjHavap5PJ8J+H7u/Y3EH+lQxxO/yoVYY7ds5ryDx1Ikt9vQvlmJIJ+UA5wB+tAHL0UUUAFb2gQxLpWsag0Uc09qkYiSRQygu2CxU8HHvxzWDVqxvbixkZ7WTaWUowKhlZT2KnII9jUzTkrI3w1SNKopTWmvyumk/k9fkLf3n2x0dre3hdV2sYI9gc+pUcA/QCqlW7+/ub90a6kDeWuxFVQqoPQKAAPwFQQxmWVUBVSxxlug/z7c04qyIqyUptp3/D/M/STT5XltLOV1KySQxu49GKgkfnmtLisvS7r7XYWN8yFBcQRz7D/DuUHH61qjkfhmmZjXztwvWmgkkHtTz19qQ/KuQDx2oARmC59uaYzu4OAaazCM/Pgse1TW8xGQU6d6AGwxMWyR0FSyF4YxzgZwKn5IxkDPpTLgDymLc7RkfWgCJyZGBfPA4Api5ywJ96IzhRnr1oI+dSO9ACoeSMfSuc+KIB+GfixWwAdLuASf8AcNdH3GOorg/jpqIsPhPr/c3caWQ57yuFP6ZoA+Nrzls/56V6J+zqhf4saPtONkdw5+nlMP6151dcyHFeu/suWaz/ABEvbl+tnpUjLj1d0X+WaAPqUn5lUdO9eJftB+KYd2n6BZXSLeIxuLhQCSmB8oJ7E8n8K9omkEMEszDiKNpDk46KT/Svh3UtSn8QaxcajeOPtV+7Tk9QCRkKPYAACgC63i3WbbT57ZbyRbbUIXDrngqWxx+K1zlzdZSMBQMR7Dx2P/1qrXFw0kcQb/lmmwD05J/rUDMS3PagDQguzbXYntWeF1xtZThh+New+APjdqmli2s9dJvLILs8z/lovoc968XvREhtPIJINtG0n/XQg7h/Kmn92sTZ5IyRQB91+F/E2meJbbztJu45wuC6qfmQn1FbqngHHNfDPgnxRqXhjWft+ky7Zdu2RD92RfQ19neAvFWneMfDNpqemOCTGFnhP34ZB1Vh+f1FAGq6hhz1qS3wswY8dv0p86BWBHQ9KixzQBcCBgxXuMVV27Rg8EdakicoeuR6VNIglQFTz60AVK8I/bDX/i3OknnA1Rf/AEU9fQCwDOWPHpXhP7ZQA+GulALgf2onOf8AplJQB8a1+h/wzP8Axb7w3j/nwh/9Br88K++vgnqo1X4b6S7KBJbK1m4UEDMZwOvtigDu0CRA9EBOTz3NBkYThVA29zUVzEtxEUJ4BB+hHSnqr+fuPKkD8/WgB6Q7Lp7hpW2lQoTAwDnk1ZdtsZIAJAzVSxvIb6OUxciOVomBH8SnBqwjKWxnn+VAEMf7+ySGRiJXQE5GSKsOqRwZk2hY1yTjgADrT1A44qCFpd9wbgDy/MxGP9nA6/U5oA4OZtMv/iC81peRT3BgYSIqfKnljGS+fvZPSteyvIYYZ2kuNzI5X7wwBjP+NcJoulx6h4p1rWXaSO0e4kRkIxuyx3BW9sYOPWtdtatNC8HXwNvvYM5QRrhmznAP0HGfSgDG8Y6+2rStb6PbtNauqNNLJGzKVU7sgDqAQD2q5oWjQ3Ooz6rex+ZHbRDCo+dzMpYjI9MDgd/pWX4Lvp7uPUL2K8+xW6DzbjbxuwoBGfRRgj1ziu30mOSONpYooYY775kiCjK7UA57ZYDOPegDT8AzNd6FBO24NICzKf4TnpWpr1l9tsJIBJJEzDh42KsD7EVi/D65Etg4DOcOR8+AR7EDpgYFdTcRKQzhQGPU+uKAOdsvEtvG8ltrDpa3cQByxwkoJwCpz145HbNeLftHT2+paZbXGmyJKokBlKDJ4BA5/GvV/FGnLPA5dFZsHBI6V4f8SoCdMeLBTGc+3FAHiMYImyMhgeMHvX1L+y3b3P8AYmp6vqJuCslwtpau3O9doLe+AwGD/Ovm3QdJu9Z1i00zTIlkvruQRQozhQzkdyenevvzw3pceieHdM0uBmaOzto7dWfkkKoGTjvxScU9WXGpOKcYuye/mVr2SK31qJo8mVwZHUsR0Ujjtk8cHHSr+kX8epadBdRjb5i5Kk52nuM9/rVS/ihtNSjvPsslzPKBbkhvuR5JJ5479Opp9kWtXtLXyy5cMDIeNqL90fXkCmQXYGdppiRiIHC5GCSOv4dKsDp9aR2VFZmOFUZJ9BUN5P8AZ7OSf5fkXdhzgfjQBl3GqwrqV3bsNk1t5ZXzDgSAjkr9BxWvnfGCjY3DIPWvKdR1C3l8S3Ut1aysEuQ6yOeSuMAKB2B59816Roc/2nTLeQZI2cEjBoA0ccUh5pGOBxUErsHTHQ5yKAPHPj7KE1TSVY/IIJHI992KxIItKHw98SRKlq2sRMQcnMiR/IQQOwznkVufHuBpb7S2AJ/dFP8Ax6vPPDWpx6HrOtyzp9ola0ktlZj/AHh96gDkreaa+hg0y5wLa2WZ4xju2WOfxFcP8UdFm0a9sxMUPnwqw2t/EMhuCPcV6Hq1rutLbVEwltMyIq9D90g5rzv4m6zd6xcWTX255IEKee/WXP4dsYoA4eiiigAooooAKkt0eSeNIwS7MFUDuSajr0b4AeHR4j+KmhwzRh7W3m+1TA9NsY3/AMwB+NAH3HaQ+Ta2tuRzFDHER7qoH9K0jwMVXgG+ZnPrmpzwTQAH36daUAk4ptcX8VPiBZeBfDzSBo5dZuMraWxPU/32/wBkfr0oAu+MPF2i+E4PM1m6WOdgdkS8u30HpXkl58fHt5z/AGVo6GEk5M7kE+h4rxDxD4g1DxBqk+pazdG4vpWyWxgAZ6KOw9qzTMwGBz2xQB7hc/tBeIZP+PbT9OgwOSSzZNYl18ZPFd7NEftkcaRtu8uNAA/se9eSrKenr0qxDKQ+cnBGMjpnigD7P+F/je38aaLNMoEV/asFuYP7uRwwPoefyrssdTXyd8CPFY8O+MoY7qZo9O1IC2mAUt+8/wCWR46fMcfjX1lIfLViw+6DnigBoP0r57/af8Rb7jSfDMLcQr/aF0AerNlYlP0G5vyr3i0nS+jjlg5V+Aa+QfjVqserfEvxDcQMWhjuBaIfXykVD/48GoA4RsGTJxX0F+ypp7Jb+KNVK4SRreyQ+6hnbH/fa/lXz6SFBdiAqjJPoBX2N8FvD8/h74ZaVa3iCK8uWe+mUHODKcqD7hNooA6rWb620/RNRvdQKrZQW0jzbum0Kcj8en418M3u2OUG3GyMHMa5+6Ow/AYFfW3x0W7b4X6qlipYPJCLgDqId4L/AMhXynewnKsw6NyMdcYoAyNQWFLiMW7F0aGNiT2cj5h+BojgeK3hupEP2eV3hVz0LBckfhkGku0U3Emz5VaQ7R6DPFMNxKbIWhdjAspmCdg5XaT+VACzTCW2s41QL5ERRmHVyXJyfzAqAEk4z+NDgAYB5qRGUSlio2nPFAEikxSOg5ycZHpXdfD3xre+A9SsNRtCZbK6TN5b5/1i72HH+0AM15+p5GfSnxyElFYnAzj260AfoDpOq2utaRaajp0yz2dwnmRSKeCKtHpmvmL9nbx+dH1UeGtWm26Zetm1dukMxP3fo386+oGRguT0oAZUsEhQjPQ1EKO1AF8nkA+uK+ff2yJfM+HOlBQQo1UZyev7qSve55M2pPdxtrwD9sMD/hXWk8dNUXB/7ZPQB8f19+fBbRpND+HemQzyB5rndesF6L5h3BQe+BivgOv0X8C5/wCEP0LP/PhB/wCgCgC7ql89nqWkwJGrJeztFIx/gAUnI984rXHQVQvYBdPbjn9zKJRjHUAj+tXQwyR3FAEGn2EFj9p+zBgLiZp3UnOGbrj24rmp/EU8Xio6dLEqRJsKuD8zlu3612APFchrMM114nhsbd0hkUR3gkKDMiB8OgPsAD+NAHZkk42kVn213cPcagl3CkVrCwMM27AdMc59MY6+9Lo9obG0aEvI5MjuWkbcSWYnj0HPSuU+Ivig6HpM0TxI7XEcsZDHou3GR6/eH60Acw1yjWeoxwSYWS4eVDFgAAsT+IrndXuZYLMCSZ2WTKBiPVM5/XFaF8gmsoVtRHCiWsYKRjg7lGT655rZ1Cxs9XF0rCMQw4kMeRgKAQc+1AHDaBfx6XodobsifMUwS0D/ACurNsfJH8StgnPoMV2Hhm5vJvCnh6Pf5EpdkZ248tUZlyQf9kZri9XsI7bw3pM800YSDfCkawnAjZ9w3EEcH1616DYRPLqNrJGxjhubVp4YM/KoOzkj1BPHtQB03hGP7KLh5pEbdITuUYH4V04u43ZlDIV4wQ2c+vFVrKziW2CuoI6njqasLawRuG2KCvANAFTULRZ4j6V5B8RdAJt5ty7lIJHr0r3L5XTAxiuQ8YaO93EzQ4LEdDQB87/s/WMX/C49OjkjDrBHPKnmJyCEOGHoef1r7DBGQO9fOHwz0CPRvi/ZXVxcpCXimiSNlJaWRlwFGOnAJ59K+inwsqsWAB+Ue5oAldA64P1pNp3g+mafn9a5H4h6nc2FhbQ2zmL7TJseUHBUYzwfegDrJFDhlYAqRgj1FJLGssTxyDcjDBHtXH/De9ebTJVuLpppXbzEjeTeyL0x7dM4966wysIA6rknkg8YoAzYvD9gnMsRll2Km9jyMdx6E9607aCO3iEcQIUZPJzyTmi2jWNMR5Ck5AJz1qWgBCMjmmbBnJGTUneoo5UlBMbA4ODg96APKvix5Z8Q2EUpY5s5XUDn5gTivJviHpA0i3sJ7eUSC4hDO4XGM/w++PX3r1z4lQ/avHvh+1yF82B0yRxkk8fpXmvjy+a88LaTb3CAXNhLPbTDtxgAj1GBQBzmobF0NLG7YKBbLdW+XAJLdQB3wM8V5j8RbeaDStAeVdqTxzSx/wC0u/GfzBrurqSXxA+nW8UUha1AgXYu47Mnnj0riviiQlvo1sCx+zLNEdx/6aGgDgKKKKACiiigAr6X/Y40F2m17xDIo8uNPsEB7l22u/5AL/31XzRX3T+zfpf9kfCDQTJbJDPdiW6fCgF90jBGYjqSgTr2AHagD06BdsfPU0/oTSn9aRuKAK2pX1tpenXN/fyiK0to2llc9lAya+HPHnii48W+KtQ1m5LhZ5CII2P+qhB+Rfy5Pua9o/aW8bwyabH4YsJSXklEl0VPBVein8cH8K+dJN2AxBAY8GgBWYfLj8frQW5zTAuAP9qrNk8KT/6Qu6PBBx1HvQBEsbOsjqCVjALY7AnA/WpxMXt4IdoHl72BHfcR/hVq5gksLCGSORXh1SFxtB5UJLjn8QD+NVJJ/MgtIwir9nR0yP4tzlsn88UAWY5JIkDRMwkA3oQeVYcgj3yK+gPHvxUiuvCUFlZXLtqtxaRGaSFyAjlRu59a+eIScgjJ7itaCOSTiNHduDhUJPSgD6T/AGe9Xb/hAdSur+6DxadcyNl2yURYw5z+dfLtzK91K88pYyTu0zFupZ2LHP5mvpuw0ifwj+zzr6SAPd3FjcXEigYwZQFAP0Uj8q8w+CHgmx8YeItS/tU77LTYY3MIJBlZ2YDp2Gw/mKAOa+GPhd/FfjXS9KMQktfNW4u8/dFuhBcH/e4X/gVfa20ZwoCqAAoHQAdBXKaNpvhbwQkpgGn6dLLGEY7grOB6AnOM1R1b4laVbuIdLR76diFU/wCrjB92P+FZzqwh8TOqhgcRiP4UG/y+/Y7DUtPt9S067sbtN9vcxtFIucZBGK8D8ffCOXSoGu9Gke5tI423REZdff3r3O11mwa3j+0alp3n7R5nlzrtz3xz0rQhmguoS0MkU8R4JVgwPtkVaknsYTpTh8SPgrUYIlsbfywftW+RpSfTI2/1q78NrDS9Q8eaRBr8qw6UGeW5Zm2gqiMwXPuQK6b41aBF4e8earaWgH2R9lxGo/g8xclfqDk/QivNpPlzhSMUyBJ5EnuJZYl2RPIzRj0Xccfpio85wPSlzhT9QaQA9R0zzQA4KTsIHBzj3p7LGIU2sfMLHI7AcY/rVrUb77XHp8EMSxR2duIFwOXOSzOfck1Qbg4FAFiKQ7l2EoykFWXqGHcfjX278IfFy+MPAWn38z5v4EFper3EqDBb6MMMPrXw2nB565r2j9mPxGdN8cXGjzSYttYgwi54+0R/Mv4ldw/CgD6o/lSYORg4wfzp20hQ1J70AOk/1EQ9ya8G/bDP/FudKH/UUX/0U9e8Sfci9Oa8H/bD/wCScaVn/oKL/wCinoA+Pq/RnwWQvhHRM9BYw/8AosV+c1fox4Q+fwlowYcNYwgj6oOKANe0gjieaRCxM7mRsnvgDj8qbfPLFp15JHIPOEbtGxGADjj8qzoNQdbm9iPS2jDe3U/4VHa+I/OvrWL7FOkFwP3cxIxnryB0B7GgDcsGH2SBfMMpManeed3HXNSPCryLJtUyoCEYjJXPX86hkvLaCWGKWaNJZiRGhPLY5OBWZ4q1e1tND1FBdxpdtay+Uiv85bYcYA75oAsXurJFYX7288UlxbxMQARjcB6VyE81p4i1TS4tYMpjFy/lpLH+7nKxghUx2zzzkfLXBeB3aHxPpsMcU1x5sW66UKSUG0khs/hyfWu78a2d1BFazRJJGYIpHHk5xHuIGAfUAfrQBW1q30681O4ZXe2mWYZKNgMmOhHQc+mKboFhLFfXFvsuZNPvwYZWJCqByS3TIPYYPeua1i+ttL03QLjULRpEluSJWV8yXW0gEE9sA5x7Y4re0rW54Y7rQbq2uvs9pbmSe+nA+YuxIA5OSqkZFAEll4XsdZv3e8eaaKxuwkKEkfcOMMc/N24x0+tdgtvDfXlosW14rIko+c5bGD+Vcdphhub+8WylRre4fydkSlVVc5aQepbj8q9K0+CGCFUiUAAUAWSh2YVyuBXL+INcttInRby/ZfMZVVQm48+w/nW/qdzFDCS7heOua+dviXqYk1iJ7aWR9uWZs/d/yKAPorTJopoQY5Q4PcHrVi4jV0YEZyK4v4RyNP4RsXljZGAKqT/GvZ/xru3wFNAHkniLZ4V8WafrewXECygMrZ3KGO1iMdxnIr16d1WSDOSrH5SBx0yP0ry34oWIudLk352kkEdulaXwl8Xr4msX0q5hmF/pMEQlmONkoOVBAHOcLzkUAehR3ETzvCrhpY/vL6cA/wBRWL4piTENzJb+eLeN3HHQ5Xn61qQWUUV9cXce4S3AUSDPB28A/lxUsipMXilQMpHIPIIoA5jwH9juLV7u0jhVld4n2YLBickt74NdSzRyI43KQpIbB6Edc+lUtK0vTdDtpI9NtYLK3LtM4QbQSeSxrgPBV6+oavrRkuC+nXN2xCkkiQk5GD2G0D65oA9JleT5BCBgMN2Rxt74ommKXNvGACsm7J+gzWVaXlxPrOr2k4QWkHlCEgYJLAk5PfpWhcR75YGUDMbd/pQBbctsbbgMQcE9jjisrw3a3Nlo8EWoMr3h3PMy9CxJP49q0yeAaPegDyb4sX4sPFmiThAzxBXGTgZ3EDmvJ/FtussqPCSS6STXAOflk3nI/L1r0X46NI2t2iIvyi0Lk+mGavOtYmWLwrZuZN11LFIsih8lef4h+IIzQBlfD+5Sx8Yxu+7yjDKpI6Dg8n0Fec/FOdbq5tbiM7o5nmdGxjI8w4NeqeGvDm42GoXEgW0nhlLDJw5A+7+Rryj4lReTBoqeW0eIpDtbqPnNAHDUUUUAFFFFAF3RLFtU1mwsEO1rq4jgB9CzBf61+j2iWMWn6TY2UC7YbSCO3jX/AGUUAfyr4X+AWgSeIfitoMKoxgtpvtk7L/Ckfzc+xIVfxr7ygyZGYnIoAmBw2T+dcl8SPFkHhPwxd6jM3zgeXCvd5DwABXVn0HU18ffHzxt/wlvjGS3s+NL0otbQbWyJXz88n5jA9h70AeeazfXGp6hLe3b7pZWJYk9+tVN7FfLJyucj60jYaLOehyR60kQLvgfUfzoAeOgzU8EQkjuZC4UQx7wD1Y5AwPzqsG5JFPZdrdaAJSTJGiHOEBAHbk5q3pFrHc3YhnkEUb/x4+6fp9cVTXkDHGBz71ZhUiZR06E/TrQA+zQNGuclgK+t/hF4Nj0rwlay3qwyT3S+aTGwcAHoM/Svnr4SaHLr/jK1tYPsZaNTOyXZYJIisAyjAPODX2Xbww20CQ28axwxgKqKOFHoKAMTxnpCaz4L1zSt7RrcWUsasvUELkfqBXxt4Q8Van4X1OLV9GlEU0sQWVHGVkQ87WH1r7mUAyhXwUb5WHqDwa+C9ftBYatqNmmSlrdTW65GDhJGUfoBQB9DfDz4r2fjHX7XQvEGkWsb3SssczsrIXAztww6nt713Gs/DzSbuQTafnT7pCCrRjcmR0yh/pivjjS76XT9Ss723Cme0njuI1YkAsjhgD7HGPxr7j8Ma5D4k8Nabr1ojJBqEKzCNusZPBU/QgionTjP4kdNDGV8O70pNfl92xYt9Isjbx/adPsGmCjeUgXaT3xkdKtxx2thbOyJFb28YLvsUKoAHJwKRGYZ6kV418ffHUllbpoGi3YSeUEX+zBKxkcJnsTnn2qlFLYxlUlLdnj/AMV9eXxN4x1XU4ZVktZJRHblVKhokGFOD6iuYuPDt/H4VXxBPE8djJOsEJZceaSM5Ht1qG9dZPIiDBFbajMP4QTgn8BmvTvj/wCKdMu20Twn4YlifRtGiDM0RyrSgbUXPfC5P1amQeNuu1yD2H6V0tp4Q1q60jTpYbCQx6hcskLEYyFXk/TJ/Sul+HHgi01C0l8TeKZfsvhu0US7WODdEfwj/ZyPxqn4t+IWparqCm0aTT7C3/48rWMbfLQ9CfcjFAGRruhWWgaUjy6is2tLJhreMfKgOQcn24/OuVZSzdCWboPc0sjM5ZnZmdiSS3JJ9SaQSMrI4+8jZH4UAXL6IR3sqqc7WwoxjgDr+hqTRNTl0XWLDVrf/W2FxHdAf7jAkfiMj8aoGVvNMhOXOcn1zT4huBU/dI5HqKAP0OtnS6tY54HDRTxiaMjupGR+lN61xfwN1kax8KvDk7kma2gNnIT3aIlD+gB/GuzOO1AD3/1ceegzXg37YRX/AIVzpXBBOprjLf8ATJ+1e7nJjBJG3JAFeB/tfsD8PtNzjeNTT8vJc/1oA+Q6/RnwpkeGdHHpZw/+ixX5zV+jfhfjw7pI/wCnSH/0BaAKHim0e3s57i1lSE3MqLcPK52hOgxxwM4z+NZ15NDb2FnHZtGbdDvkkB3FVPBKZ+vB7V1WpRQXls9hcMM3aNEEzgtxzj6V55YafLtYCKRoty26SzfKFcMQeO5wTx0oAx7q8m1PxBEsbPIlpaGYgcyBVcAAMeOhJqjruqyyXlzd2cyQxQTQQwAJu3BlJz79T1rTt5L3StbvbOK2WV44ngkhBA3xnowPqAc5qnp2gS2lpbx296qyNIqRyQSCRrcMdoBX+I/MaANLwNpN9L4qhnsdZtjaQWsqtbiMN9pV3GAW64BGcj/ZHTNbviqfUtKvLjTovNuLAxQ3CSPJ88Q3FXVe+OM85xXXaToFpo9m0VrmLO3dIgwxx2+me3vXLzatZz+NdY+1Sb4YglrGQMpgDLe3DEg+9AC2MXhy906TLBwsbq4uC3yh23MQCPvEjkiplNtJZhLC1leQOTFI4x1GOSeSME8fStm207TpIlmhjjcHlfTNaMFso/eYGewHagDN8OaImnwLJcFWl68DgVr3N4kaZDBRUMjyrGVkXjsVNcl4knZYSqvtXPZuaAIPGuqyRQyKXUR46+1eRWmmXV/pt/qlxFIsplVbdZBsDr/EwB56Yrv9Asm8Rao8U77tMtCJbiSQcOw6R88H1PtXT+PrZJdNkc7VKRkxkccjoPpQBz/wR8TW76YdJldFvLbJKHhmUHGR6+mB0xXrkU6yjg18NatqM9hq9rc2sxiureRpI5V4IOfX0PSvqX4a+PdN8T6VHJA+28jUC4tz9+I9OfYkHBoA6fxNpw1CwkhIxu714/4f1d/AfxLtRLGW03VttlcYySjFv3bgDOcEkEejH0r2++1C0gtTJczRxIRwXYDNeV+PNFudqa3pUzW1zG3mQSAZ2v1B/wDrUAe3AYOD2o46isrwve3Oo+GdKvb4RreXFrHLMIxhd5UE49s1btrnzrq5g2OPI2gsRw24Z4Pf/wCvQBl+Nrz7L4Q1WdCd32dgp44J4B59zXF6BHP/AGXb6kbaZEudrIluA43nC73x1BOTnsK2vixcKvh17VWjM1xgeWzYZlDDJH4+tVdF1p5IrVF8n7NFGsMwhZcwycYBH0zQB0ulxq+pXd1ICs8qpG67vlymeQPfd1ra28c+tY2hWkkYa4uLgyuwAwF2qWHVgPfj8quTTiPVbeNpDueJ/kB44I+Yj9KALLCXz1wyeTtOQRzu9c+lSnpUN8kktpKkTbZGXCk09QcAnrjn60AeXfE3T21HxLsRkVk02RgG/i5OcV4Frryw3MtocKmArfgMf0r37x3fwaZ4+s57xmELWDx4HOSScD26da8I8Xwu91eX4AEU1x5aMDwWHUUAbmn311qnhrR7K3gUNHdiBmUnCjj5j9dpNeX/ABoUpeaXGekcciD3w5r0fwharY6q9jrlvNCmpacz2xB6dWDHB4zgj1FeTfEppDJYh5vNjXzFjJHIXeep70AcRRRRQAUUU5F3OF9TQB9T/sf+Hfs+ka34imUh5mWxgY+nDuR/44K+j4xiPJ781xnwn8ODwx8O9B0plKz+SLm4Gc/vZPmI/DIH4V3KJu47CgDzz43+K28JfD69uLVwmoXrCxtT3DODuYf7q5NfFmQigL0XgA17D+0z4pOseNhodu6NYaIChx/FO4Bcn6DC/nXjixtMJNi7iiF29gOpoAaxIIOOOmfxpclCGHbNCysIvLYApnP0zQGABGPvDH60APH3TjqB0p6jINPsXiWRmnGUKkYr0iH4YXviDTpNT8IyxXtsEDmEvhlyBxQB50Ym8p1U4ZlIB9Divbfiv4XtLr4eeFfG+jIkSSafa290ipywKgK5I7g5U/WvIRZ3NtK6XEDq8RcSZH3SBzzX0f8ABi3m8S/AnxBoTsJWVrqzt1fkLuiDoPwZsigDA/Zj0eY69qWqy2xe2SH7PHMGXEb5yRjrnAFfR1eZfs9aZ/Z3w+jaawnsr6adzciZyfNdTt3AH7owAMD0r02gBj8++K+dvjV8NvEGr+L9T1zRdOFxZzRxu2JkVtyoFOFJHoK+hmcBic9aikPmfLgMvegD4CnjeGZ0dSrxuUZTwQQcEfXIr3D9mDxNLFrl/wCGrmSaS3u7cz2aFvkidCS4A7bgwPH901w3xrsxZ/FTxNEsENun2lXVIgApDRqwb6nJJ965/wAE683hXxZpGuDcUsbgSyqvVoiCrj/vljQB9xyNIlnO8CBphG5jQ9CwUkD86+Ibq5u9QvJri9LtqE7GSfcCG8w8sCO2PT2r7ijaOeGOW3ffDIFljYH7ysMg/ka5Dx34I0vWNN1O6h02E6w1pKkM0aAOXK8c9zQB8XTjcWB9OKWwtRdXltbuxjS4kWPcoyRuOMgVua1oN3pmoGx1C2ltrjbkLKu3I9R6ivY/hp8OY/C/hvU/GniZEeaztZLiztyOIwqEhz7k4x6UAeW/FfxH/btzaaZp7Kmi6XB9ltUjyFcrwXI7nPStbx7430TWfAGhaTpunqNUjggS7uGQAp5agEA9ySPyriNW027srGwu7tVC6lC1zCR0IDlW/wDHqXwxpdvrOr6faT3SWyTSOk0jH7oCkg8/SgDGlxtT15P1qM4x0qe6AE8qqQ0cbFFPqAcZqKSNo2AcYJUMPoaAEAOeBn6U9CQeeDSwSSJIpiGXycd6buLuxbkk54oA+o/2VL5pvBGsWTHP2TUiy464kjUn9Qa9s9a+ff2RJx5Xi62zlwbWYL7YkUn+VfQ0wBKMO4oAaihlfOflXI5rwT9sFMfDzTWB+9qi/pE4/pXvkXV/dTXgn7YPHw50rn/mJj/0U9AHyBX6K6JMYdA0ZUAbfBChP90eWOf0r86q/RjQo1bQ9OH922ix/wB8CgCpqgubqLUJNmFhiKW5DYJcj5jxz6D8K0IrSKawtbWV2f7MsUgcnkso6n9c1djiCpg8561z/iW7uYZrW3t0EP2qVFa4BzsIcYGO+RQA3XYdJvhPe21vBcagf9FLlTlVPX/6xrVs7DTfD2m+ZHBtt4sMAq7ygOOnfGefzri/DGYfE09rfzJNd3DlH2nOzGWx+ld/qzxRWZM8wjjOFyeOTwBQA24uofmkiuFMaqCybsEEjcMjtxz+Nc7Nq1lFFqF/bRpNGG5JG0PgZxz2z3rqo4YLmHzDGpEqgPwPm4xz61574j/eXjrpbWcmnNcRtLIT5gQ4x90cY4HHY5oAf4K1Se9+2texmB1nUxx7s5D5zkeuR29a9CRspg9hXDeF7Nlvb5jjaZY1TjrtySR7c12sziOLPtQBX1C9htY907gA+teYeMfEEBbZaxrJI7iOPH8bHgD86ueNNSneXy1bAHGPesz4c6Ml9qU2r6jDIzplLNwPkQ5wzDP8Q6A/WgDqfCennR2Mc0cjsyKj5wpaVmy3GcYwB/3zR49uIoLWR2LAr8pyex610VlHJJMPMBKpkhmwTnOPzrz/AOIJe7tL0RowSWZgc8ZwOfw4oA+Y/E7hb/CcAFgPzrR8AeMb3wdrY1GxVJg8ZhlhkJCyIee3Qgjg/X1rK8XspvY3HBYEkfjWIknSgD1nxJ8W9b1nUBcQhLO3CCP7JkyRkcZ3dN2cV7T8K/E0vj3wbfi8hEU1rKsTbeVY4yCK+QhNg4zX0b+y9rNlbaNqlkJQLx7kSyRsw5XaArAenb60Ae6+Cle2017KUsPJkPlhuyHoB7VvqoUsV781l27LLc28kJBAJDAemD/WtXPGaAMHWdDs9UuriS/RnVoPKHzH5B1O0evvXFalp1trGsQrpUm2GwIMybCokKEMFI9+Bk969GvUSWSMDO4H72O3cfpU4gRfuqoJHzEAc/X1oA4xNUnvI4Y724WxtmkkYlXAlX5/ljY9FO3PP5Vz+hWr22qQ30+qSTWMl1Kbdw5C+T6sT06/mM103i7Q0vYr+bygZDDt443YH9BXF/DsS61oI1W6Z7S2028ls1jjHyzQoQCDnueBx6UAemaXqkUOnl76fZEjBFmlbIkDH5Tn3BFa32iIyiMSL5hydueeK4lrVIDBDFJeXjPJtjcAGNONqo2PQc5PcV10EeCrNhnAxn39aAPH/jHbvqviuytYFZWaLylfPDdScfTpXnHjefb4M8LWwRS6wyTFhwSdxXBx1PvXrfxBuktviJ4flndFhjR9zHHGUYYP415jqwsl8MeGrkwR3Kosscysx3CQk/IfQdOlAEXxXa5h8T2DaahLrpMJURjJVSvJx+NeOfEuFreXT4XIJRZBkf75rr7zUro3MpEmdlsbdWkyWWPPQH1FcP47k8yPTD22SY/77NAHI0UUUAFdn8IPDh8VfETRtKK5ilnDTegjX5nz/wABDVxlfSX7H2hqNT1jXJkG9LcW0DHqC7fMfyXH40AfUkeHnLKMKPuj0HasP4k+K4fBfgfUNZcr9oRPLtUP/LSduEH58/QGtmHo3avmP9qfxC974usNCikb7NplsJpYwePPl55HqEx/31QB4pdzy3NxJNdStLcTSNLLIeruxJZvxJNV0kaNm2sQGUqSPSlc9fpTJFChB3ZQ350ANAyoA4ODS55wM803r165qdyhigCIQxyHJ7nP+FAEigEAKCCOa9K+HnxBn8BeHtWh0+HztR1JkaNpD+7iVQRnHrya8wTOM59qtHIVy3IRc8/nQB6J8Ob3TtU+IvhyTxFKotpfMtrtXHySyMHCk/Usv4ivorwnd+GdB8SXvg7w6IYi0TXvloxIMv3XXPqFCnFfLnjDwXqvgwaJNqhiMWpwfard4mztI2kqT/eG5T+NXPh5rFzpnjXRtSib96bxFldgWLrIwV8+vBNAH2jZxmG1jibaCq42qOB7Cpj064pzbS7c55NJQBGI17igxr1AwafRQB498e/h+fEWmnW9HtpJtdtUVHjQgefACSc56soOR37V8tbR8pHKtyPevv6dd7lezKVPP5ivO/EHw+8KaF4P8RXFj4ctbiUWk0yRsNx3bDgLnpzzxQByX7PvxGjmsIPC2u3IS6twsenSvwJYh/yzJ7svbPUV7uM7ua+ALdniWB0lfeu1lkU4IYchgexzzX0F8E/ixdXeqR6D4tvmuWuSsdjdSL8xf/nm5HHOOCe9AHtGv+HdL11ANTs4p2UEK7L8y54ODXBftC6l/ZPw1TSoEwNSmSy9ljUb2/MJj8a9U9iCK5X4meFR4x8IXWlo4julZbi2kI6Sp0H0IJU/WgD4u1i8mnhtLe4cvHZxtFCp/gUsWIH4kmsViQ5wSCPStnV7eSC4miuEMc0TmORG6qynBH4EVjNy31HWgBJMFS3HLc0yRzIyliTwAM0px0puQBxjr3oAlSQxujRnDKKURv5Qm2nYzFN3v1xUK4yAO/epFdggTJKg7se9AHtH7K189v8AEPULNThbzTHJ9zG6kf8AoTV9Us+/b7Cvj39nEMfjFowi6G3ug3Pbyj/XFfYUkewI2eDkUAPh6yf7hrwX9sP/AJJzpPp/aa/+inr3q35L8fw4rwP9sPP/AArzScHj+0xkf9s3oA+QK/RnQSBo9gD2tov/AEAV+c1fevgTXmvfAGh6g4knleGKGUrjO8HYzHsAMZoA7bzAFYt/CMnj2rzfWpBreuXhe5K29vAGhKj5QCN3TuTjiu+u3b7LKIz8+w7frivGrzeoja1AeeNXjlGexBXH5mgDofhLZ/abh9RkVvtJd5ZXZRkZJVVz3GBu+teieIrBtSsUgTYD50cmX6AKwJ/TNc38MkntPBtrZypGJYXZcI+4AFi3584xXYWkwmiB46kcUAWYxgcHAJz0xXmNxaW9y2qz21vdWtsbp1eLdy7BuSB2Gegr0xmAGa4Ca9juYL1rWVT9ov32AMCflYKw/Q0Abnh60W1s4IshmTLM2OpNL4p1NdP0+SUkZwQo9TQsiWNmHdjuI6V5Z8RPEL3EJjQEtnbGo6sx4oArWLT+LvEbWULsLeM7ruWMgFE6ce5PA/E9q9PntRZPaixu5LcIABb8MHHA79Metc74MsLjw9oVlZCGOR3f7RPcIcKXbr154GB+FdHp3nXl7JeOHEGdkcRxjAP3vxoA3IFlt7QCeQSyE8lVx1PQD2rzvxtcmFZI3GCZHKj8D0rvbi8EK/vPlAwK8g8ZavvN7NMqKY0lVS3OM/KpHvgk0AfOviyQSX6uRgEHj05rBLH1ArT8UPjVGUFioUbc9fr+NY2/5aAJ1fketa2i6pd6VeR3en3L21wo4kQ4OPQ+o9qxA30qSN8HtQB9LfDX4r+fJFDqd20F6CM7sFJcAZI7A9eK+l4JBLDHIpyHUMPxr847WXdgHBB619qfBbX7U/DzQ4b7UPMvPsqOyuSzYI7YznFAHpJYMzoOCBT14qtDdwTJ5kEgdMfeXofep9wIyMc9KAKjq7RhJUEhYlWI6Y5/+tXG6lqU8via+8O2lottpdhYrc+esR+aYtnaB0IwcnA5Nd3kfl1rl7m4nh8STBZII1l2jlSWKqvGew5JoAXRDbwzTxWEMkNsWV8hScsw+YjPIGefxrpNpSIqhy2Op6msrTnsbUvN9qQtI+0s8nVvQZ/lWmsqyAFDuXGQw6GgD58+MTywyWlvNC8bpu2ljksASSc9+TXl15JMImWOTKqRJgdAQK9s+MkAudX1SQ7S1pp0Uig98yEHH4V49o84h1qAKxVzPEFbGeGYA9fY0AYMpkkjZ1yCTsY449a4jxRctM8ELKAtuu1T3OSTzXr/AI10u30OyNvaFTcveujZbJC8FeO3BNeW+O7VbSSxUIqyMjeYR/EQxH8qAOUooooAK+5P2eNFTSfhToszRgXF/G1y5BOSCx2/oBXw3XtHhn9oXxJ4f8P6bpNvpWizQWECW8bypLuZVGBuxIBn8KAPs+LCBd/C9z6DvXwL4t1iTXvFGr6vMSXvbuWYZ7Luwo/BQorvLj9p3xbNbyxDSdCTzEZNyxzZGRjP+srxRdSmVVXbGcDHQ0Aa77WVBt5BOf8AGmMS4y+cAEZ7+1ZZ1KY9o+PalfU5nABWPhQvC0AaA4PfPtVrTfKGpWguTtg89N59F3DJ/KsH7fL/AHU/KnNqMxYttjBJzwKAN6dI47uaOFi0SSMqk/xKCQD+Ir2b4UfCaw8a+Dm1a9vpYS0k0JVcAALxzXz6upzL/BGfwrdsviB4hsfD8uiWV6bfTZXLvFHkbieoznODQB6l8bPFFzrS+HNNnFsYtNjlVZIW3B/up/JQa6f4D+A11eOz126lt5YbecOkKud4ZezDp15xXzWNWnChQse1egwcD9a7X4d/FzXfAkl0dLtdPniucGSO5RyMgYBGGBBoA+92+8QDwecCmZxnJAFfIP8Aw1B4qzkaLoAP/XOb/wCOUyX9p3xa4H/Eo0EEf9Mpv/jlAH2EGBzyKCSa+PU/ad8WL10jQD/2ym/+OVL/AMNReK8f8gXQP+/c3/xygD65MfzZGc0pUMCGAK9wRxXyL/w1F4r/AOgLoH/fub/45R/w1F4s/wCgLoH/AH7m/wDjlAHpPxU+DUeoStqXhFEhupGzNZk7Y3J/iX+6fbpXiGqeF/EOgXyR3unXNrcRsskTjDYZTkMCPQgV0g/af8VkDfo2gMR38uYf+1Kw5/j/AOKbnU3u7qy0eaNhj7O8L7APT7+f1oA+vfBOt3Ot+F9NvtSSKLUJIh9ojjfcA3c/j1xXRQ4MqemRXwRqHxh8Szaj9q0z7NpKYH7i0D+Xkd8Mx612sP7UPi1Fj3aRoTsoGWMc2SfX/WUAch4om+061qs5ff5l9cPu9cytzXNMclj+VVL7xLc3VxNL9nt4xJI8mxQ2F3MTgZPTmqP9qTZ+5H+R/wAaANTHzZpv06H0rM/tOXn5I8nvg/40n9oyZ/1cfTHf/GgDU9cd+Me9Kh245+lZX9oyc5SPn6/40f2jLj7kf6/40Aet/AC/XTvi94ckc8TSSWp5/wCekbAfqBX2pOAIivX5+P1r839D8S3ej6zp+p2sUJnsriO5jDBtpZGBAPPTjH0Neun9pzxUc/8AEn0Prn7k3/xygD7AtT+7cj2/nXg/7ZC7fAGmDnB1JSP+/b15wn7T/ixQQNI0I565jm/+OVyXxQ+MmufEXRrbTNXsdNt4IJhOrWqOGLAEYO5jxzQB5jX0Z8P/AIraf4Z8NQaO+lzNHEWZpvNB8wk5JI21851L9omxjzpMf7xoA+sbv40W1zE6WO232YYyM+4sMfdUYGCT60zw14r0qCJbiZxPdSJ5k+xycsSfve5z0r5RM8x6yyf99GpEvbqMkpczqfaQigD7N0/4gWFisqWtvHmUmRRHKPmPQ5GODxUlh8Qp4J4bK30acgZMm+T5kByQTxgZPY18aw6zqkClYNSvYwTuISdxz68Gpo/EmuRySyR6zqSvKNsjLdOC49Cc8igD7TvfiFLaaU13LbW5kXLGJZDkDgc985NUfCer2Bt5tUuJbaC3Z3mUAhVBc5bbnrk+lfGk2tarMSZtTvpCeu+dz/WoGvrttu66nOzhcyE4+lAH2P4q8RXNxIxsEY2vlCRG6bgRxx1H41ymg2wgsZPFfiKWMtbqzWVlI4G5h1Zh6+g/GvmZtSvm4a9ujznmVuv50+fV9SuIwlxqF5KikkK8zMAT16mgD7XtPE+lX1vZreX9rG7IGlVXypbAOM+lX5PG3h2CMmPV7VCiMQpJHT2xXwvHquoxgCO/u0AXaNszDA9OvSiTVNQkOZL66c+rTMf60AfZ2qeNNMn0mN1v7fz5EDFA49a8u8W6tFOt1EVeU7ARHyu4Hqc14ANSvghUXtyFJzgStj+dK+qag5Be+umI7mZj/WgDS8STLLqchTIAAUj0IHSssEmq5dj1Zj+NJk+poAsE+9PRj69KqZPqaNx9TQBtWBha5hW5kaO2ZwJHTllXPOPfFfTuhfEbw3bWtrb6IbGxaHEVtHtB+TAHPTBPNfJIdx0Zh+NPE8o6SuP+BGgD7LtfG9/FdOh1u1FonLpF5W6LJ4Ve351t6V8QdLumj8nxT5sxJTyJ41jLOPTjp+NfDQuJx0mk/wC+jS/a7jGPtE2P980AfY2ofFKe2lniGqAvEzLiOFX3tngZ7cd+ag8c+L5G8Orq2l3lvLcMPMlSZE4iXr8uck/zr5A+13IGPtE2P980n2mfqZpf++zQB9aXfjnRNT0C2+3apB9klBdLZQqSK/TLIOQR78VVh+JbTqFt9VuokJIy1wNwUd//AKwr5U+0Tc/vZMn/AGjR9omPWaT/AL6NAH0zrPiHTNbjl3a5593Kn35W270H8AJxj1wa4d77T9MvIJvtqSTRSRs0YOQNjg/e98V48Z5W6yufqxpvmP8A32/OgD1LxBrcepXE10Jl86SZpvvgleeB+AxXJ+OLoXZ06QyrLIYmLkEHB3muY3N6n86TJI60AJRRRQB9q/8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAB/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zRRQAf8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M0UUAH/AAyp4H/6CviT/wACIP8A4zR/wyp4H/6CviT/AMCIP/jNFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple images obtained from a patient with a tracheal hamartoma. This lesion, visible on the lateral radiograph (A), is further characterized using axial (B) and coronal (C) computed tomographic images and a computer generated shaded surface reconstruction (D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence Goodman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8118=[""].join("\n");
var outline_f7_59_8118=null;
var title_f7_59_8119="Doxazosin: Drug information";
var content_f7_59_8119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxazosin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/2/44?source=see_link\">",
"    see \"Doxazosin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/63/27638?source=see_link\">",
"    see \"Doxazosin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardura&reg;;",
"     </li>",
"     <li>",
"      Cardura&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Doxazosin;",
"     </li>",
"     <li>",
"      Apo-Doxazosin&reg;;",
"     </li>",
"     <li>",
"      Cardura-1&trade;;",
"     </li>",
"     <li>",
"      Cardura-2&trade;;",
"     </li>",
"     <li>",
"      Cardura-4&trade;;",
"     </li>",
"     <li>",
"      Gen-Doxazosin;",
"     </li>",
"     <li>",
"      Mylan-Doxazosin;",
"     </li>",
"     <li>",
"      Novo-Doxazosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F162909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      BPH:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     1 mg once daily in morning or evening; may be increased to 2 mg once daily. Thereafter titrate upwards, if needed, every 1-2 weeks, balancing therapeutic benefit with doxazosin-induced postural hypotension. Goal: 4-8 mg daily; maximum dose: 8 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Reinitiation of therapy: If therapy is discontinued for several days, restart at 1 mg dose and titrate as before",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     4 mg once daily with breakfast; titrate based on response and tolerability every 3-4 weeks to maximum recommended dose of 8 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Reinitiation of therapy: If therapy is discontinued for several days, restart at 4 mg dose and titrate as before",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Conversion to extended release from immediate release: Omit final evening dose of immediate release prior to starting morning dosing with extended release product; initiate extended release product using 4 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release:",
"     </i>",
"     1 mg once daily in morning or evening; may be increased to 2 mg once daily. Thereafter titrate upwards, if needed, every 1-2 weeks, balancing therapeutic benefit with doxazosin-induced postural hypotension. Maximum dose: 16 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reinitiation of therapy: If therapy is discontinued for several days, restart at 1 mg dose and titrate as before",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Distal ureteral stone expulsion (unlabeled use):",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release:",
"     </i>",
"     4 mg once daily in evening (Gurbuz, 2011; Resorlu, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     Patients with stones &gt;10 mm were excluded from studies.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4473154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/63/27638?source=see_link\">",
"      see \"Doxazosin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypertension (unlabeled use): Children and Adolescents 1-17 years: Oral: Immediate release: Initial: 1 mg once daily; maximum: 4 mg daily (NHBPEP, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F162910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, immediate release: 0.5 mg once daily) and titrate to response (Aronow, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15788950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (however, limited data suggest renal impairment does not significantly alter pharmacokinetic parameters).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2932031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in mild-to-moderate hepatic dysfunction. Do not use with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg, 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardura&reg;: 1 mg, 2 mg, 4 mg, 8 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardura&reg; XL: 4 mg, 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F162887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardura&reg; XL: Tablets should be swallowed whole; do not crush, chew, or divide. Administer with morning meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F162886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release formulation: Treatment of hypertension as monotherapy or in conjunction with diuretics, ACE inhibitors, beta-blockers, or calcium antagonists; treatment of urinary outflow obstruction and/or obstructive and irritative symptoms associated with benign prostatic hyperplasia (BPH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release formulation: Treatment of urinary outflow obstruction and/or obstructive and irritative symptoms associated with BPH",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4589529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric hypertension; facilitation of distal ureteral stone expulsion; erectile dysfunction in patients with concomitant BPH",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxazosin may be confused with doxapram, doxepin, DOXOrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardura&reg; may be confused with Cardene&reg;, Cordarone&reg;, Cordran&reg;, Coumadin&reg;, K-Dur&reg;, Ridaura&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F162943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Type and frequency of adverse reactions reflect combined data from BPH and hypertension trials and immediate release and extended release products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Dizziness (5% to 19%), malaise (12%), fatigue (8% to 12%), headache (6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (3% to 4%), hypotension (1% to 2%), orthostatic hypotension (dose related; 0.3% up to 2%), arrhythmia (1%), facial edema (1%), flushing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Vertigo (2% to 4%), somnolence (1% to 5%),  pain (2%), anxiety (1%), ataxia (1%), hypertonia (1%), insomnia (1%), movement disorder (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Sexual dysfunction (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (2%), nausea (1% to 2%), dyspepsia (1%), xerostomia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria (2%), impotence (1%), incontinence (1%), urinary tract infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4% to 7%), arthritis (1%), muscle cramps (1%), muscle weakness (1%), myalgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection (5%), rhinitis (3%), dyspnea (1% to 3%), epistaxis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal lacrimation, abnormal thinking, agitation, allergic reaction, alopecia, amnesia, angina, anorexia, appetite increased, arthralgia, back pain, blurred vision, bradycardia, breast pain, bronchospasm, cerebrovascular accident, chest pain, cholestasis, confusion, cough, depersonalization, diaphoresis increased, diarrhea, dry skin, dysuria, earache, eczema, emotional lability, fecal incontinence, fever, gastroenteritis, gout, gynecomastia, hematuria, hepatitis, hot flashes, hypoesthesia, hypokalemia, impaired concentration, impotence, infection, influenza-like syndrome, intraoperative floppy iris syndrome (cataract surgery), jaundice, leukopenia, liver function tests increased, libido decreased, lymphadenopathy, micturition abnormality, migraine, MI, neutropenia, nocturia, pallor, palpitation, paranoia, paresis, parosmia, peripheral ischemia, pharyngitis, photophobia, priapism, pruritus, purpura, renal calculus, rigors, sinusitis, skin rash, syncope, taste perversion, thirst, thrombocytopenia, tremor, twitching, urticaria, vomiting, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F162890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinazolines (prazosin, terazosin), doxazosin, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F162873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina: Discontinue if symptoms of angina occur or worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: Can cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor is introduced. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Priapism has been associated with use (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; not recommended in severe dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: Rule out prostatic carcinoma before beginning therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use as an antihypertensive due to high risk of orthostatic hypotension; alternative agents preferred due to a more favorable risk/benefit profile (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release formulation: Consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction. Use caution in patients with increased GI retention (eg, chronic constipation) as doxazosin exposure may be increased. Not indicated for use in women or for the treatment of hypertension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F162900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid saw palmetto when used for BPH (due to limited experience with this combination). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2931842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Delayed postnatal development was also noted. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F162914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8097533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The extended release formulation is not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2932026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Cardura&reg; XL: Take with morning meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F162893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Cardura XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $77.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $81.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cardura Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $225.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $225.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $236.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $248.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Doxazosin Mesylate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $92.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $92.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $97.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $102.47",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F162882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, standing and sitting/supine; syncope may occur usually within 90 minutes of the initial dose or dose increase",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F162894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfadil (SE);",
"     </li>",
"     <li>",
"      Alfadil XL (PH);",
"     </li>",
"     <li>",
"      Alfamedin (DE);",
"     </li>",
"     <li>",
"      Cadex (IL);",
"     </li>",
"     <li>",
"      Cadil (KP);",
"     </li>",
"     <li>",
"      Cadlin (KP);",
"     </li>",
"     <li>",
"      Cardenalin (JP);",
"     </li>",
"     <li>",
"      Cardoral (IL);",
"     </li>",
"     <li>",
"      Cardular (DE);",
"     </li>",
"     <li>",
"      Cardular PP (DE);",
"     </li>",
"     <li>",
"      Cardular Uro (DE);",
"     </li>",
"     <li>",
"      Cardura (AE, AR, BG, BH, CN, CO, CR, CY, CZ, DO, EC, EG, GB, GR, GT, HK, HN, HU, ID, IE, IQ, IR, JO, KW, LB, LY, MX, MY, NI, NL, OM, PA, PK, PT, QA, RU, SA, SG, SV, SY, TH, TR, UY, VE, YE, ZA, ZM);",
"     </li>",
"     <li>",
"      Cardura CR (CH);",
"     </li>",
"     <li>",
"      Cardura XL (CL, CN, CO, CR, DO, EE, GT, HK, HN, MY, NI, PA, PE, PL, SV, TH);",
"     </li>",
"     <li>",
"      Cardura-XL S.R. (KP);",
"     </li>",
"     <li>",
"      Carduran (AU, BR, ES, NO);",
"     </li>",
"     <li>",
"      Carduran Neo (ES);",
"     </li>",
"     <li>",
"      Carduran Retard (DK);",
"     </li>",
"     <li>",
"      Cazosin (TH);",
"     </li>",
"     <li>",
"      Dalgen (CO);",
"     </li>",
"     <li>",
"      Dedralen (IT);",
"     </li>",
"     <li>",
"      Diblocin (DE);",
"     </li>",
"     <li>",
"      Diblocin PP (DE);",
"     </li>",
"     <li>",
"      Diblocin Uro (DE);",
"     </li>",
"     <li>",
"      Dophilin (TW);",
"     </li>",
"     <li>",
"      Dosabin (TW);",
"     </li>",
"     <li>",
"      Dosan (NZ);",
"     </li>",
"     <li>",
"      Doxaben (TW);",
"     </li>",
"     <li>",
"      Doxaben XL (TW);",
"     </li>",
"     <li>",
"      Doxacard (IN);",
"     </li>",
"     <li>",
"      Doxacor (PE);",
"     </li>",
"     <li>",
"      Doxagamma (DE);",
"     </li>",
"     <li>",
"      Doxaloc (IL);",
"     </li>",
"     <li>",
"      Doxan (TW);",
"     </li>",
"     <li>",
"      Doxatensa (ES);",
"     </li>",
"     <li>",
"      Doxazone XL SR (KP);",
"     </li>",
"     <li>",
"      Doxazosina Alter (ES);",
"     </li>",
"     <li>",
"      Doxazosina Cinfa (ES);",
"     </li>",
"     <li>",
"      Doxazosina Combino Pharm (ES);",
"     </li>",
"     <li>",
"      Doxazosina Geminis (ES);",
"     </li>",
"     <li>",
"      Doxazosina Normon (ES);",
"     </li>",
"     <li>",
"      Doxazosina Pharmagenus (ES);",
"     </li>",
"     <li>",
"      Doxazosina Ratiopharm (ES);",
"     </li>",
"     <li>",
"      Doxazosina Ur (ES);",
"     </li>",
"     <li>",
"      Doxolbran (AR);",
"     </li>",
"     <li>",
"      Dozozin (TH);",
"     </li>",
"     <li>",
"      Genzosin (TW);",
"     </li>",
"     <li>",
"      Jutalar (DE);",
"     </li>",
"     <li>",
"      Kinxaben (TW);",
"     </li>",
"     <li>",
"      Magurol (MY);",
"     </li>",
"     <li>",
"      Pencor (HK, MY, SG, TH);",
"     </li>",
"     <li>",
"      Progandol (ES);",
"     </li>",
"     <li>",
"      Progandol Neo (ES);",
"     </li>",
"     <li>",
"      Pzocin XL (KP);",
"     </li>",
"     <li>",
"      Saxobin (TW);",
"     </li>",
"     <li>",
"      Supressin (AT);",
"     </li>",
"     <li>",
"      Tensiobas (ES);",
"     </li>",
"     <li>",
"      Tonocardin (HR);",
"     </li>",
"     <li>",
"      Tonokardin (HR);",
"     </li>",
"     <li>",
"      Uriduct (DE);",
"     </li>",
"     <li>",
"      Xadosin (TW);",
"     </li>",
"     <li>",
"      Xadosin XL (TW);",
"     </li>",
"     <li>",
"      Zoxan LP (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F162872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Hypertension: Competitively inhibits postsynaptic alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure; ~50% as potent on a weight by weight basis as prazosin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     BPH: Competitively inhibits postsynaptic alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors in prostatic stromal and bladder neck tissues. This reduces the sympathetic tone-induced urethral stricture causing BPH symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F162889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not significantly affected by increased age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to active metabolites; primarily via CYP3A4; secondary pathways involve CYP2D6 and 2C19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: ~65%; Extended release relative to immediate release: 54% to 59%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: ~22 hours; Extended release: 15-19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: 2-3 hours; Extended release: 8-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (63%, primarily as metabolites); urine (9%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis BR, Cutler JA, Gordon DJ, et al, &ldquo;Rationale and Design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1996, 9(4 Pt 1):342-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/8722437/pubmed\" id=\"8722437\" target=\"_blank\">",
"        8722437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurbuz MC, Polat H, Canat L, et al, &ldquo;Efficacy of Three Different Alpha 1-Adrenergic Blockers and Hyoscine N-butylbromide for Distal Ureteral Stones,&rdquo;",
"      <i>",
"       Int Braz J Urol",
"      </i>",
"      , 2011, 37(2):195-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/21557836/pubmed\" id=\"21557836\" target=\"_blank\">",
"        21557836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 283(15):1967-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/10789664/pubmed\" id=\"10789664\" target=\"_blank\">",
"        10789664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McConnell JD, Roehrborn CG, Bautista OM, et al, &ldquo;The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(25):2387-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/14681504/pubmed\" id=\"14681504\" target=\"_blank\">",
"        14681504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Resorlu B, Boskurt OF, Senocak C, et al, &ldquo;Effectiveness of Doxazosin in the Management of Lower Ureteral Stones in Male and Female Patients,&rdquo;",
"      <i>",
"       Int Urol Nephrol",
"      </i>",
"      , 2011, 43(3):645-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/59/8119/abstract-text/21072591/pubmed\" id=\"21072591\" target=\"_blank\">",
"        21072591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9389 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8119=[""].join("\n");
var outline_f7_59_8119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162904\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162905\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162945\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162909\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4473154\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162910\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15788950\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2932031\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162884\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162869\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162887\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162886\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589529\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162953\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162943\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162890\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162873\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299231\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162878\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162900\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162880\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2931842\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162914\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097533\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2932026\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162893\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162882\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162894\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162872\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162889\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/2/44?source=related_link\">",
"      Doxazosin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/63/27638?source=related_link\">",
"      Doxazosin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_59_8120="Mechanical ventilation in acute respiratory failure complicating COPD";
var content_f7_59_8120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanical ventilation in acute respiratory failure complicating COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/59/8120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8120/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/59/8120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8120/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/59/8120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8120/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/59/8120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of invasive mechanical ventilation in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD) varies among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The variable estimates reflect the different patient populations and definitions of exacerbation included in the studies. Invasive mechanical ventilation is associated with increased ICU mortality and hospital mortality, although the cause of mortality appears to be related to the severity of the underlying disease and not mechanical ventilation per se.",
"   </p>",
"   <p>",
"    Invasive mechanical ventilation for patients with an acute exacerbation of COPD is discussed in this topic review. Noninvasive positive pressure ventilation (NPPV) is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe the decision to institute mechanical ventilation should be based on clinical judgment that integrates many clinical variables. As an example, the precipitating illness and its rate of progression should be considered, as well as the patient's symptoms, signs, cardiopulmonary reserve, and comorbidities. Some clinicians advocate specific physiologic measures as indications for mechanical ventilation, but these have never undergone rigorous or systematic evaluation.",
"   </p>",
"   <p>",
"    Deteriorating gas exchange unresponsive to conservative measures and respiratory distress are the most common reasons for mechanical ventilation in patients with acute respiratory failure due to COPD exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Specifically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxemia that has not corrected with supplemental oxygen delivered by either a nasal cannula or a face mask.",
"     </li>",
"     <li>",
"      Severe respiratory acidosis, usually due to the precipitating illness or the injudicious administration of oxygen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"       \"Use of oxygen in patients with hypercapnia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical manifestations of distress including severe dyspnea, tachypnea, nasal flaring, accessory muscle recruitment, tracheal tugging, recession of the suprasternal and intercostal spaces, pulsus paradoxus, diaphoresis, and paradoxic motion of the rib cage and abdomen .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A goal of mechanical ventilation is to prevent excessive work of breathing, while maintaining a work of breathing that is sufficient to prevent respiratory muscle atrophy. This can be achieved by using assisted modes of ventilation (ie, modes in which ventilator assisted breaths are triggered by the patient), including assist-control ventilation (ACV), intermittent mandatory ventilation (IMV), and pressure support ventilation (PSV). In addition, IMV is frequently combined with PSV",
"    <span class=\"nowrap\">",
"     (IMV/PSV).",
"    </span>",
"    The assisted modes of ventilation are reviewed in this section.",
"   </p>",
"   <p>",
"    We suggest that patients with acute respiratory failure due to COPD exacerbation be ventilated with ACV or",
"    <span class=\"nowrap\">",
"     IMV/PSV",
"    </span>",
"    until the underlying process that precipitated the acute respiratory failure has improved and the patient is ready to begin weaning. This suggestion is based on our clinical experience during which we have found that the goals of mechanical ventilation are most easily achieved using these modes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=see_link\">",
"     \"Weaning from mechanical ventilation: Readiness testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Assist-control ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During ACV, breaths can be triggered by the patient's inspiratory effort or the ventilator. Each breath is delivered with the set tidal volume and flow. The work of breathing can be excessive when the peak flow or trigger sensitivity is insufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9176?source=see_link&amp;anchor=H6001897#H6001897\">",
"     \"Management of the difficult-to-wean patient\", section on 'Ventilator settings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intermittent mandatory ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During IMV, breaths are delivered at a set rate, tidal volume, and flow (ie, mandatory breaths). In addition, the patient can breathe spontaneously through the ventilator circuit (ie, non-mandatory breaths). Many ventilators synchronize the mandatory breaths with inspiratory effort by the patient, which is called synchronized IMV (SIMV). Similar to ACV, the work of breathing can be excessive if the peak flow or trigger sensitivity of the mandatory breaths is insufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient effort was previously believed to increase in proportion to the reduction of mandatory breaths only. More recent data suggest that this is not true. Instead, patient effort (measured as inspiratory work and the pressure-time product) increases in proportion to both mandatory and non-mandatory breaths [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/8\">",
"     8",
"    </a>",
"    ]. This is largely due to the inability of the respiratory center to rapidly adapt its output to intermittent support [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pressure support ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During PSV, each breath is augmented by inspiratory pressure. The amount of inspiratory pressure (ie, the pressure support level) is set by the clinician. The patient triggers each inspiration, which continues until the inspiratory flow decreases to a system-specific minimal level. Exhalation follows. The tidal volume is determined by the pressure support level, effort, and mechanics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective cohort study of 12 patients with COPD, the inspiratory effort decreased as the pressure support level increased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the response was quite variable (coefficient of variation was 60 to 96 percent). At higher pressure support levels, many patients displayed expiratory muscle activation during the late inflation phase, indicating that the patient was \"fighting the ventilator\" (",
"    <a class=\"graphic graphic_waveform graphicRef77977 \" href=\"UTD.htm?23/63/24565\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/14\">",
"     14",
"    </a>",
"    ]. This was more common in patients who had elevated time constants (ie, the product of resistance and elastance) and who required more time for the inspiratory flow to fall to the threshold value required for termination of inspiratory assistance (in this instance, 25 percent of peak inspiratory flow).",
"   </p>",
"   <p>",
"    In the subset of patients who require full or nearly full ventilatory support, PSV alone should be avoided because it has several disadvantages. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H11#H11\">",
"     \"Modes of mechanical ventilation\", section on 'Pressure support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative effectiveness of IMV and PSV were compared in a prospective cohort study of 11 mechanically ventilated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/15\">",
"     15",
"    </a>",
"    ]. The amount of ventilatory assistance provided by IMV was increased by elevating the frequency of mandatory breaths, while the amount of ventilatory assistance provided by PSV was elevated by increasing the pressure support level. The rate of change in effort per minute decreased similarly with the two modes (",
"    <a class=\"graphic graphic_figure graphicRef71301 \" href=\"UTD.htm?28/50/29487\">",
"     figure 1",
"    </a>",
"    ). The efficacy of unloading was greater with PSV than IMV up to a medium level of assistance (defined as 60 percent of maximum), but greater with IMV than PSV from a medium level of assistance to a maximum level. From a practical standpoint, PSV is more useful than IMV because these two modes are primarily used to provide partial assistance (eg, 20 to 60 percent of maximum) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Combination",
"    </span>",
"    &nbsp;&mdash;&nbsp;IMV and PSV are frequently combined",
"    <span class=\"nowrap\">",
"     (IMV/PSV).",
"    </span>",
"    In an international survey of mechanical ventilation, the most commonly used modes were ACV and",
"    <span class=\"nowrap\">",
"     IMV/PSV",
"    </span>",
"    (34 percent each) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/17\">",
"     17",
"    </a>",
"    ]. Presumably, clinicians use the inspiratory pressure provided by PSV to overcome the work imposed by the endotracheal tube and demand valve during the non-mandatory breaths of IMV. In the study discussed above, the respiratory effort associated with both the mandatory and non-mandatory IMV breaths decreased after a pressure support level of 10 cm H2O was added to the non-mandatory breaths [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     IMV/PSV",
"    </span>",
"    may be beneficial when it is difficult to achieve a high inspiratory flow with ACV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal ventilator settings can minimize the work of breathing, but not eliminate it. Conversely, inappropriate settings can create work that is greater than that required for spontaneous breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/8,9,18\">",
"     8,9,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician must specify numerous settings when mechanical ventilation is initiated, including the inspired oxygen fraction, trigger sensitivity, inspiratory flow rate, tidal volume, ventilatory rate, pressure level, and positive end-expiratory pressure (PEEP). These settings are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inspired oxygen fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fraction of inspired oxygen (FiO2) should be adjusted to achieve an arterial oxygen tension (PaO2) at least 60 mmHg; higher levels increase the risk of oxygen toxicity without substantially increasing tissue oxygenation. Arterial oxyhemoglobin saturation measured with a pulse oximeter (SpO2) is often monitored instead of PaO2 because it is a noninvasive measure that can be followed continuously.",
"   </p>",
"   <p>",
"    The target SpO2 should be considered in the context of the patient's skin pigmentation because SpO2 can be erroneously elevated in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. As an example, an SpO2 of 92 percent predicts satisfactory oxygenation in white patients, but may be associated with hypoxemia in black patients. A higher target SpO2 will prevent hypoxemia in black patients, but some patients may develop oxygen toxicity. It is prudent to correlate the SpO2 and PaO2 before determining the target SpO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link&amp;anchor=H13#H13\">",
"     \"Pulse oximetry\", section on 'Skin pigmentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our clinical practice, we titrate the FiO2 of ventilator-dependent patients to an SpO2 of 92 percent for white patients and 95 percent for black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Triggering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilators can be triggered by a change in alveolar pressure (ie, pressure triggered) or flow (ie, flow triggered):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The trigger sensitivity is usually set at -1 to -2 cmH2O when pressure triggering is used. This means that ventilator-assisted breaths will be triggered when the alveolar pressure decreases to 1 to 2 cmH2O below atmospheric pressure. The pressure decrease that a patient must generate to trigger a ventilator-assisted breath may be greater than the settings indicate if the demand valve is poorly responsive [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/21\">",
"       21",
"      </a>",
"      ]. Inappropriate breaths may be initiated if the trigger setting is too sensitive, which can cause respiratory alkalosis. Conversely, the work of breathing may be increased if the trigger setting is not sensitive enough.",
"     </li>",
"     <li>",
"      The trigger sensitivity is usually set at 2",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      when flow triggering is used. This means that ventilator-assisted breaths will be triggered once the patient's inspiratory effort generates a flow of 2",
"      <span class=\"nowrap\">",
"       L/min.",
"      </span>",
"      Total inspiratory effort is 30 to 40 percent less with flow triggering than pressure triggering in patients receiving IMV [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. In contrast, inspiratory effort during triggering is only 10 percent less with flow triggering than pressure triggering in patients receiving PSV [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/24\">",
"       24",
"      </a>",
"      ]. This is of minimal clinical importance because the difference occurs during triggering only, which is a small part of the total inspiratory effort [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/16,24\">",
"       16,24",
"      </a>",
"      ]. Inspiratory work does not appear to be impacted by the triggering method during ACV [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we use flow triggering in patients receiving IMV and in a subset of patients receiving PSV &mdash; those who have increased inspiratory effort during triggering. We do not have a preference for pressure or flow triggering in patients receiving ACV. We initially set the trigger sensitivity to -2 cm H2O when we use pressure triggering. We initially set the trigger sensitivity to 2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    when we use flow triggering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Auto-PEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrinsic positive end-expiratory pressure (ie, intrinsic PEEP or auto-PEEP) can be measured in a relaxed patient by occluding the expiratory port of the ventilator circuit. The pressure recorded on the manometer at end-expiration is the auto-PEEP (",
"    <a class=\"graphic graphic_waveform graphicRef57873 \" href=\"UTD.htm?14/34/14880\">",
"     waveform 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/25\">",
"     25",
"    </a>",
"    ]. It is common in patients with COPD. In a prospective cohort study of 13 patients with COPD who were being mechanically ventilated, all of the patients had measurable auto-PEEP (mean 9.4 cmH2O), and seven had an auto-PEEP greater than 10 cmH2O [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Auto-PEEP is an impediment to triggering ventilator-assisted breaths because it increases the amount of respiratory effort that is required to lower the alveolar pressure to the trigger value. As an example, consider a patient whose trigger value is set to -2 cmH2O. When the auto-PEEP is 10 cmH2O, the patient must lower the alveolar pressure 12 cmH2O to reach the trigger value. In contrast, when there is no auto-PEEP, the patient must lower the alveolar pressure only 2 cmH2O to reach the trigger value. Patients who cannot generate sufficient negative pressure will fail to trigger ventilator-assisted breaths despite obvious respiratory efforts (",
"    <a class=\"graphic graphic_figure graphicRef59751 \" href=\"UTD.htm?11/57/12178\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of auto-PEEP on triggering breaths was confirmed by a study that compared the breaths that preceded failed attempts to trigger ventilator-assisted breaths (ie, non-triggered efforts) versus the breaths that preceded successfully triggered ventilator-assisted breaths (ie, triggered breaths) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/15\">",
"     15",
"    </a>",
"    ]. Those breaths that preceded non-triggered efforts had a shorter expiratory time and a higher tidal volume than triggered breaths, both of which can cause auto-PEEP. When measured directly, auto-PEEP was higher at the onset of the non-triggered efforts than the triggered breaths. Auto-PEEP can be responsible for up to one-third of the total work of breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Applied PEEP decreases the amount by which the patient must reduce the alveolar pressure to trigger ventilator-assisted breaths, which reduces the work of breathing (",
"    <a class=\"graphic graphic_figure graphicRef52671 \" href=\"UTD.htm?32/41/33437\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. When the trigger sensitivity is set at -1 to -2 cmH2O, a ventilator-assisted breath will be triggered once the alveolar pressure decreases to 1 to 2 cmH2O below atmospheric pressure without applied PEEP, or 1 to 2 cmH2O below end-expiratory pressure with applied PEEP. As an example, consider a patient whose trigger value is set to -2 cmH2O and whose auto-PEEP is 10 cmH2O. A breath will be triggered at an alveolar pressure of 3 cmH2O if there is applied PEEP of 5 cmH2O, which requires the patient to decrease the alveolar pressure 7 cmH2O. In contrast, a breath will be triggered at an alveolar pressure of -2 cmH2O if there is no applied PEEP, which requires the patient to decrease the alveolar pressure 12 cmH2O.",
"   </p>",
"   <p>",
"    Applied PEEP decreases the work of breathing without aggravating hyperinflation in patients who have an expiratory flow limitation. This can be illustrated using the analogy of a waterfall (",
"    <a class=\"graphic graphic_figure graphicRef72568 \" href=\"UTD.htm?11/51/12094\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/31\">",
"     31",
"    </a>",
"    ]. In this analogy, the water level upstream from the waterfall represents auto-PEEP, the height of the waterfall represents the closing pressure of the airways, and the water level downstream from the waterfall represents applied PEEP. Elevating the water level downstream has no influence on the height of the waterfall or the level of the water upstream, as long as the downstream water level remains lower than the height of the waterfall. When the downstream water level rises above the height of the waterfall, however, the upstream water level will rise. In other words, neither expiratory flow nor auto-PEEP will be altered by applied PEEP, as long as applied PEEP remains equal to or lower than the critical closing pressure. When applied PEEP surpasses the critical closing pressure, auto-PEEP will immediately increase and hyperinflation will be exacerbated. This usually occurs when applied PEEP is &gt;80 percent of the auto-PEEP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inspiratory flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high inspiratory flow rate has several advantages in mechanically ventilated patients with COPD, including decreasing the work of breathing and decreasing the likelihood of hyperinflation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanically ventilated patients with COPD generally have an increased respiratory drive, which requires a high inspiratory flow rate. The default inspiratory flow rate (usually 60",
"      <span class=\"nowrap\">",
"       L/minute)",
"      </span>",
"      is often inadequate. The inspiratory work necessary to overcome pulmonary and ventilator impedance is markedly increased if the inspiratory flow is insufficient [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/9,18,33\">",
"       9,18,33",
"      </a>",
"      ]. Increasing the inspiratory flow rate will often satisfy this demand and decrease the work of breathing.",
"     </li>",
"     <li>",
"      A high inspiratory flow rate decreases the inspiratory time and increases the expiratory time. As a result, the likelihood of hyperinflation and auto-PEEP decreases [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. In one prospective cohort study of 13 mechanically ventilated patients (seven with COPD), increasing the inspiratory flow rate from 40 to 100",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      improved gas exchange, probably due to less gas trapping (",
"      <a class=\"graphic graphic_figure graphicRef50636 \" href=\"UTD.htm?1/23/1406\">",
"       figure 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/34\">",
"       34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A high inspiratory flow rate is occasionally associated with an increase in the respiratory rate [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. In one study of patients with COPD, increasing the inspiratory flow rate from 30 to 90",
"      <span class=\"nowrap\">",
"       L/minute",
"      </span>",
"      increased the respiratory rate from 16 to 20 breaths per minute (",
"      <a class=\"graphic graphic_figure graphicRef56446 \" href=\"UTD.htm?43/38/44641\">",
"       figure 6",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/35\">",
"       35",
"      </a>",
"      ]. The tendency of the high inspiratory flow rate to increase expiratory time outweighed the tendency of the high respiratory rate to decrease expiratory time. The net effect was an increase of the expiratory time (2.1 to 2.3 seconds) and a decrease of the auto-PEEP (7 to 6.4 cmH2O).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, we suggest that the initial inspiratory flow rate be set at 60",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    The inspiratory flow rate can then be increased to a level that satisfies the patient's demand if the patient appears to be struggling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tidal volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing recognition that large tidal volumes (eg, 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    can cause alveolar overdistension and lung injury, as well as increase the risk of hyperinflation and barotrauma. As a result, lower tidal volumes (eg, 5 to 7",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    are increasingly being used during volume-assisted modes of ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ventilator rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the discussion that follows, the respiratory rate (RR) refers to the total number of breaths that the patient receives in one minute. The ventilator rate (VR) refers to the number of breaths per minute that is set by the clinician on the ventilator. In other words, it is the number of mandatory breaths that a patient will receive per minute of mechanical ventilation. The spontaneous rate (SR) refers to the number of breaths per minute that a patient receives beyond the ventilator rate (RR = VR + SR). The spontaneous rate reflects non-mandatory, patient-initiated breaths.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ventilator rate should be set approximately four breaths per minute less than the respiratory rate during ACV. As an example, the ventilator rate should be set at approximately 14 breaths per minute if the patient's respiratory rate is 18 breaths per minute. This ensures that the ventilator will continue to supply an adequate minute ventilation even if there is a sudden decrease in respiratory center output. The patient should be monitored closely because a significant increase in the respiratory rate will decrease the expiratory time. This can cause hyperinflation, auto-PEEP,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inverse ratio ventilation. Inverse ration ventilation exists when the inspiratory time is longer than the expiratory time.",
"     </li>",
"     <li>",
"      During IMV, the initial ventilator rate should be based upon the clinician's estimate of the required minute ventilation. There is an inappropriate tendency to adjust the ventilator rate according to the patient's acid-base status only. The problem with this approach is that arterial blood gases give no information regarding the work of breathing, which may be excessive even when the ventilator rate is as high as 14 breaths per minute and the arterial blood gases are acceptable [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/8\">",
"       8",
"      </a>",
"      ]. We believe the ventilator rate should be adjusted according to the patient's acid-base status, respiratory effort, and comfort.",
"     </li>",
"     <li>",
"      A ventilator rate is not set during PSV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pressure level",
"    </span>",
"    &nbsp;&mdash;&nbsp;During PSV, the pressure support level should be increased until the patient's respiratory rate is below 30 breaths per min because this respiratory rate indicates that the inspiratory effort has been reduced to a reasonable level. However, the expiratory effort of patients with COPD may increase when the pressure support is increased, which makes selection of the optimal pressure support level difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Applied PEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, applied PEEP was avoided in patients with COPD because of concern that applied PEEP could worsen hyperinflation. It is now recognized that applied PEEP is beneficial in patients with an expiratory flow limitation due to dynamic airway collapse. This was discussed above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Auto-PEEP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Inhaled medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of inhaled medications to mechanically ventilated patients is problematic because the medications accumulate in the ventilator tubing and the endotracheal tube. This can be overcome by delivering large amounts of bronchodilators via an in-line nebulizer.",
"   </p>",
"   <p>",
"    A metered dose inhaler (MDI) can also be used. As an example, one study demonstrated that the administration of four puffs of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    to mechanically ventilated patients produced similar bronchodilation as in-line nebulizers, but with greater efficiency and lower cost [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8120/abstract/37\">",
"     37",
"    </a>",
"    ]. Four puffs produced the maximal bronchodilating effect, but precise technique was required.",
"   </p>",
"   <p>",
"    The following has been proposed for using MDIs in mechanically ventilated patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shake the MDI vigorously.",
"     </li>",
"     <li>",
"      Place the canister in the actuator of a cylindrical spacer, situated in the inspiratory limb of the ventilator circuit.",
"     </li>",
"     <li>",
"      Actuate the MDI once with the onset of inspiration by the ventilator.",
"     </li>",
"     <li>",
"      Repeat actuations every 20 to 30 seconds until the total dose is delivered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to institute mechanical ventilation in patients with acute respiratory failure due to COPD exacerbation should be based on clinical judgment that integrates many clinical variables. Deteriorating gas exchange unresponsive to conservative measures and respiratory distress are the most common reasons for mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A goal of mechanical ventilation is to prevent excessive work of breathing, while maintaining a work of breathing that is sufficient to prevent respiratory muscle atrophy. This can be achieved by using assisted modes of ventilation including assist-control ventilation (ACV), intermittent mandatory ventilation (IMV), and pressure support ventilation (PSV). In addition, IMV can be combined with PSV",
"      <span class=\"nowrap\">",
"       (IMV/PSV).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Modes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with acute respiratory failure due to COPD exacerbation be ventilated with ACV or",
"      <span class=\"nowrap\">",
"       IMV/PSV,",
"      </span>",
"      rather than IMV alone or PSV alone, until the underlying process that precipitated the acute respiratory failure has improved and the patient is ready to begin weaning. This is based upon our clinical experience during which we have found that the goals of mechanical ventilation are most easily achieved using these modes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Modes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal ventilator settings can minimize the work of breathing, but not eliminate it. Conversely, inappropriate settings can create work that is greater than that required for spontaneous breathing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Settings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend titrating the fraction of inspired oxygen (FiO2) to achieve an arterial oxygen tension (PaO2) &ge;60 mmHg. The arterial oxyhemoglobin saturation (SaO2) should be correlated with the PaO2 in order to determine the appropriate target SaO2 if pulse oximetry is used in lieu of arterial blood gases. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inspired oxygen fraction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients receiving intermittent mandatory ventilation (IMV) and patients who have increased inspiratory effort while triggering pressure support ventilation (PSV), we suggest flow triggering, rather than pressure triggering. In all other patients, we do not have a preference for pressure or flow triggering. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Triggering'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reasonable initial settings include a trigger sensitivity of -2 cm H2O when using pressure triggering or 2",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      when using flow triggering. Regardless of the trigger method chosen, we use an initial flow rate of 1",
"      <span class=\"nowrap\">",
"       L/second",
"      </span>",
"      (ie, 60",
"      <span class=\"nowrap\">",
"       L/min)",
"      </span>",
"      in most patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Triggering'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Inspiratory flow rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have intrinsic positive end-expiratory pressure (ie, intrinsic PEEP or auto-PEEP), we suggest adding applied PEEP (ie, extrinsic PEEP). An appropriate amount of applied PEEP is &le;80 percent of the measured auto-PEEP. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Auto-PEEP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients receiving volume-targeted modes of mechanical ventilation (eg, ACV, IMV,",
"      <span class=\"nowrap\">",
"       IMV/PSV),",
"      </span>",
"      tidal volumes of 5 to 7",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      may decrease the risk of ventilator-induced lung injury, hyperinflation, and barotrauma. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Tidal volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients receiving ACV, we use an initial ventilator rate that is approximately four breaths per minute less than the respiratory rate. In patients receiving IMV or",
"      <span class=\"nowrap\">",
"       IMV/PSV,",
"      </span>",
"      we base the initial ventilator rate upon our estimate of the required minute ventilation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ventilator rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients receiving PSV, the pressure support level should be increased until the patient's respiratory rate is below 30 breaths per min because this respiratory rate suggests that the inspiratory effort has been reduced to a reasonable level. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pressure level'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18078349\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Amal Jubran and Dr. Martin Tobin, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/1\">",
"      Jeffrey AA, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management. Thorax 1992; 47:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/2\">",
"      Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/3\">",
"      Slutsky AS. Mechanical ventilation. American College of Chest Physicians' Consensus Conference. Chest 1993; 104:1833.",
"     </a>",
"    </li>",
"    <li>",
"     Laghi, F, Tobin, MJ. Indications for mechanical ventilation. In: Principles and Practice of Mechanical Ventilation. Tobin, MJ (Ed), McGraw Hill, New York, 2006.p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/5\">",
"      Tobin MJ, Perez W, Guenther SM, et al. The pattern of breathing during successful and unsuccessful trials of weaning from mechanical ventilation. Am Rev Respir Dis 1986; 134:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/6\">",
"      Tobin MJ, Guenther SM, Perez W, et al. Konno-Mead analysis of ribcage-abdominal motion during successful and unsuccessful trials of weaning from mechanical ventilation. Am Rev Respir Dis 1987; 135:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/7\">",
"      Tobin MJ, Perez W, Guenther SM, et al. Does rib cage-abdominal paradox signify respiratory muscle fatigue? J Appl Physiol 1987; 63:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/8\">",
"      Marini JJ, Smith TC, Lamb VJ. External work output and force generation during synchronized intermittent mechanical ventilation. Effect of machine assistance on breathing effort. Am Rev Respir Dis 1988; 138:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/9\">",
"      Ward ME, Corbeil C, Gibbons W, et al. Optimization of respiratory muscle relaxation during mechanical ventilation. Anesthesiology 1988; 69:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/10\">",
"      Imsand C, Feihl F, Perret C, Fitting JW. Regulation of inspiratory neuromuscular output during synchronized intermittent mechanical ventilation. Anesthesiology 1994; 80:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/11\">",
"      MacIntyre NR. Respiratory function during pressure support ventilation. Chest 1986; 89:677.",
"     </a>",
"    </li>",
"    <li>",
"     Brochard, L, Lellouche, F. Pressure support ventilation. In: Principles and Practice of Mechanical Ventilation, Tobin, MJ (Ed), McGraw Hill, New York, 2006.p.221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/13\">",
"      Jubran A, Van de Graaff WB, Tobin MJ. Variability of patient-ventilator interaction with pressure support ventilation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/14\">",
"      Parthasarathy S, Jubran A, Tobin MJ. Cycling of inspiratory and expiratory muscle groups with the ventilator in airflow limitation. Am J Respir Crit Care Med 1998; 158:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/15\">",
"      Leung P, Jubran A, Tobin MJ. Comparison of assisted ventilator modes on triggering, patient effort, and dyspnea. Am J Respir Crit Care Med 1997; 155:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/16\">",
"      Tobin MJ, Jubran A, Laghi F. Patient-ventilator interaction. Am J Respir Crit Care Med 2001; 163:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/17\">",
"      Esteban A, Anzueto A, Al&iacute;a I, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med 2000; 161:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/18\">",
"      Marini JJ, Rodriguez RM, Lamb V. The inspiratory workload of patient-initiated mechanical ventilation. Am Rev Respir Dis 1986; 134:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/19\">",
"      Jubran A, Tobin MJ. Reliability of pulse oximetry in titrating supplemental oxygen therapy in ventilator-dependent patients. Chest 1990; 97:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/20\">",
"      Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology 2005; 102:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/21\">",
"      Gibney RT, Wilson RS, Pontoppidan H. Comparison of work of breathing on high gas flow and demand valve continuous positive airway pressure systems. Chest 1982; 82:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/22\">",
"      Sassoon CS, Del Rosario N, Fei R, et al. Influence of pressure- and flow-triggered synchronous intermittent mandatory ventilation on inspiratory muscle work. Crit Care Med 1994; 22:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/23\">",
"      Giuliani R, Mascia L, Recchia F, et al. Patient-ventilator interaction during synchronized intermittent mandatory ventilation. Effects of flow triggering. Am J Respir Crit Care Med 1995; 151:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/24\">",
"      Aslanian P, El Atrous S, Isabey D, et al. Effects of flow triggering on breathing effort during partial ventilatory support. Am J Respir Crit Care Med 1998; 157:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/25\">",
"      Pepe PE, Marini JJ. Occult positive end-expiratory pressure in mechanically ventilated patients with airflow obstruction: the auto-PEEP effect. Am Rev Respir Dis 1982; 126:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/26\">",
"      MacIntyre NR, Cheng KC, McConnell R. Applied PEEP during pressure support reduces the inspiratory threshold load of intrinsic PEEP. Chest 1997; 111:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/27\">",
"      Tobin MJ, Jubran A, Hines E Jr. Pathophysiology of failure to wean from mechanical ventilation. Schweiz Med Wochenschr 1994; 124:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/28\">",
"      Coussa ML, Gu&eacute;rin C, Eissa NT, et al. Partitioning of work of breathing in mechanically ventilated COPD patients. J Appl Physiol 1993; 75:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/29\">",
"      Smith TC, Marini JJ. Impact of PEEP on lung mechanics and work of breathing in severe airflow obstruction. J Appl Physiol 1988; 65:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/30\">",
"      Petrof BJ, Legar&eacute; M, Goldberg P, et al. Continuous positive airway pressure reduces work of breathing and dyspnea during weaning from mechanical ventilation in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 141:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/31\">",
"      Tobin MJ, Lodato RF. PEEP, auto-PEEP, and waterfalls. Chest 1989; 96:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/32\">",
"      Ranieri VM, Giuliani R, Cinnella G, et al. Physiologic effects of positive end-expiratory pressure in patients with chronic obstructive pulmonary disease during acute ventilatory failure and controlled mechanical ventilation. Am Rev Respir Dis 1993; 147:5.",
"     </a>",
"    </li>",
"    <li>",
"     Tobin, MJ, Alex, CA, Fahey, PJ. Fighting the ventilator. In: Principles and Practice of Mechanical Ventilation. Tobin, MJ (Ed), McGraw Hill, New York, 2006.p.1121.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/34\">",
"      Connors AF Jr, McCaffree DR, Gray BA. Effect of inspiratory flow rate on gas exchange during mechanical ventilation. Am Rev Respir Dis 1981; 124:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/35\">",
"      Laghi F, Segal J, Choe WK, Tobin MJ. Effect of imposed inflation time on respiratory frequency and hyperinflation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/36\">",
"      Puddy A, Younes M. Effect of inspiratory flow rate on respiratory output in normal subjects. Am Rev Respir Dis 1992; 146:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8120/abstract/37\">",
"      Dhand R, Duarte AG, Jubran A, et al. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1996; 154:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1632 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-504D3CBC15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8120=[""].join("\n");
var outline_f7_59_8120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Assist-control ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intermittent mandatory ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pressure support ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Combination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inspired oxygen fraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Triggering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Auto-PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inspiratory flow rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tidal volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ventilator rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pressure level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Applied PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Inhaled medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18078349\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1632|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/50/29487\" title=\"figure 1\">",
"      IMV versus PV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/57/12178\" title=\"figure 2\">",
"      Ventilator trigger with COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/41/33437\" title=\"figure 3\">",
"      PEEP ventilation in COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/51/12094\" title=\"figure 4\">",
"      External PEEP with auto PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/23/1406\" title=\"figure 5\">",
"      Increased inspiratory flow rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/38/44641\" title=\"figure 6\">",
"      COPD flow rate frequency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1632|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/63/24565\" title=\"waveform 1\">",
"      COPD pressure flow muscle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/34/14880\" title=\"waveform 2\">",
"      Occluding expiratory port COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9176?source=related_link\">",
"      Management of the difficult-to-wean patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=related_link\">",
"      Weaning from mechanical ventilation: Readiness testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_59_8121="Cutaneous lichen planus interface dermatitis";
var content_f7_59_8121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked interface dermatitis resulting in vacuolization of the basal layer is present in this pathologic specimen from a lesion of lichen planus. Hypergranulosis is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8121=[""].join("\n");
var outline_f7_59_8121=null;
var title_f7_59_8122="Ocular melanoma";
var content_f7_59_8122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ocular melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Evangelos S Gragoudas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Anne Marie Lane, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Helen A Shih, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/59/8122/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/59/8122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 95 percent of ocular melanomas arise in the uvea, while the remainder arise in the conjunctiva. Uveal and conjunctival melanomas will be reviewed here.",
"   </p>",
"   <p>",
"    There are significant differences between uveal melanomas (including iris, ciliary body, and choroid) and primary melanomas arising in the conjunctiva, and each of these groups are discussed in this topic, as is the treatment of metastatic ocular melanoma.",
"   </p>",
"   <p>",
"    Issues related to cutaneous and mucosal melanomas are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UVEAL MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveal melanomas arise from melanocytes in the uvea. These melanomas have significant differences from cutaneous melanomas that guide their management [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uveal melanomas can develop in any part of the uveal tract, including the iris, ciliary body, and choroid. Iris melanomas are less common than choroidal melanomas (approximately 5 versus more than 80 percent of cases). Iris melanomas are also associated with a better prognosis than ciliochoroidal tumors (10 year-survival approximately 95 versus 77 percent). Because of the less aggressive nature of iris melanomas, these tumors are usually managed conservatively (ie, close monitoring of the tumor). Fast-growing tumors may be excised. This topic will emphasize the management of uveal melanoma as it pertains to choroidal and ciliary body melanoma, the more common and life-threatening forms of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular pathogenesis of uveal melanoma is incompletely understood, but recent advances may provide important opportunities for targeted therapy in patients with metastatic disease. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1576?source=see_link&amp;anchor=H5643585#H5643585\">",
"     \"The molecular biology of melanoma\", section on 'MAPK pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous epidemiologic studies have analyzed various factors that may increase the risk of uveal melanoma. These risk factors have been analyzed in a series of meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Factors that have been extensively studied include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Host pigmentation factors &mdash; Host pigmentation factors associated with a statistically significant increase in risk for uveal melanoma include light eye color, fair skin color, and propensity to sunburn (odds ratio [OR] 1.75, 1.80, and 1.64, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cutaneous and iris nevi &mdash; Atypical cutaneous nevi, common cutaneous nevi, cutaneous freckles, and iris nevi are all significantly associated with an increased risk of uveal melanoma (OR 2.82, 1.74, 1.22, and 1.53, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultraviolet light exposure &mdash; For intermittent occupational exposure, welding was associated with a significant increase in risk of uveal melanoma (OR 2.05) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/4\">",
"       4",
"      </a>",
"      ]. Other occupational exposures to ultraviolet light were associated with a statistically insignificant increase in risk of uveal melanoma (OR 1.37, 95% CI 0.96-1.96) and latitude of birth and outdoor leisure exposure were not associated with a significant risk of uveal melanoma (OR 1.08 and 0.86, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choroidal melanoma generally arises in pigmented nevi. Research has focused on identifying the factors that can identify those nevi that are most likely to progress.",
"   </p>",
"   <p>",
"    In the largest series, 2514 consecutive eyes containing pigmented nevi were examined and followed longitudinally for the risk of progressing to melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/5\">",
"     5",
"    </a>",
"    ]. Transformation was observed in 180 cases (7 percent). The actuarial risks of progression to melanoma at 5, 10, and 15 years were 9, 13, and 17 percent, respectively.",
"   </p>",
"   <p>",
"    Multivariate analysis showed that the following factors were associated with a significant increase in the risk of transformation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thickness greater than 2 mm",
"     </li>",
"     <li>",
"      Subretinal fluid accumulation",
"     </li>",
"     <li>",
"      Symptoms (decreased vision, presence of flashes or floaters)",
"     </li>",
"     <li>",
"      Presence of orange pigment",
"     </li>",
"     <li>",
"      Distance from the optic nerve less than 3 mm",
"     </li>",
"     <li>",
"      Hollow rather than solid on ultrasound",
"     </li>",
"     <li>",
"      Absence of a halo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there continues to be debate regarding observation versus early treatment for small choroidal lesions, the data generally support an observational approach for lesions less than 3 mm in height and 10 mm in diameter. When observation is chosen, follow-up at six-month intervals is necessary, using fundus photography, ultrasound, and ascertainment of patient symptoms to identify any evidence of malignant transformation. Some ophthalmologists have chosen to utilize a risk factor score in addition to documentation of tumor growth to aid in the decision-making process of when to treat lesions that may not be definitively diagnosed as melanomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the efficacy of many available therapies in achieving local tumor control, death due to metastases eventually occurs in up to 23 percent of patients who require active treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/6\">",
"     6",
"    </a>",
"    ]. The factors most strongly associated with a poor prognosis include large tumor size (as measured by largest tumor diameter), tumor involvement of the ciliary body, increased age, and extrascleral extension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Tumor pigmentation and iris color and the presence of symptoms are additional factors that negatively affect survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, a retrospective analysis of 510 patients with nonmetastatic uveal melanoma treated with proton radiation identified tumor diameter &lt;15.0 mm, lack of ciliary body involvement, and age less than 60 years as favorable prognostic factors for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A TNM staging classification of uveal melanoma was originally developed by the American Joint Committee on Cancer (AJCC), but this was not widely used by ocular oncologists, due in part to the lack of lymph node metastasis and infrequency of histopathologic confirmation with uveal melanoma. The TNM system was revised in 2010, and this may partially address the concerns that have been raised (",
"    <a class=\"graphic graphic_figure graphicRef77041 \" href=\"UTD.htm?4/25/4510\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58476 \" href=\"UTD.htm?41/22/42350\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor size has consistently been demonstrated to be of prognostic significance, in terms of the subsequent risk of metastasis and death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. This is illustrated by two large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The COMS Group reported that rates of metastasis after iodine-125 brachytherapy or enucleation were directly related to tumor size [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/14\">",
"       14",
"      </a>",
"      ]. Ten year rates of metastasis were 21 percent for patients with tumors &lt;16 mm in diameter and &lt;8 mm in height, 35 percent with tumors &lt;16 mm in diameter and &gt;8 mm in height, and 55 percent with tumors &gt;16 mm in diameter. Among patients who developed metastases, the death rate was 92 percent by two years.",
"     </li>",
"     <li>",
"      In a retrospective series of 8033 uveal melanomas treated at a single institution over a 38-year period, multivariate analysis found that increases in both tumor diameter and tumor thickness were associated with an increasing risk of subsequent metastasis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/15\">",
"       15",
"      </a>",
"      ]. The 10-year risks of metastasis for thin (0 to 3 mm), intermediate (3.1 to 8.0 mm), and thick (&gt;8.0 mm) melanomas were 12, 26, and 49 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk associated with ciliary body location was evaluated in a review of 1848 consecutive patients who were treated with proton beam RT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/16\">",
"     16",
"    </a>",
"    ]. Melanoma-associated death rates increased with the proportion of the tumor base lying within the ciliary body. The relative risk of death was 2.3 when &gt;75 percent of the ciliary body was involved, and the adjusted five-year death rates for patients with tumors of ciliary body origin was significantly higher than for patients with a choroidal origin (16 versus 10 percent).",
"   </p>",
"   <p>",
"    The prognosis is poor when local control is not achieved with the initial treatment. In one study, 10-year rates of melanoma-related mortality for patients with tumor recurrence were nearly twice that of those with local control (53 and 27 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/17\">",
"     17",
"    </a>",
"    ]. Consistent with this finding, in a study that compared survival in patients who had their eyes enucleated for tumor recurrence or complications, an elevated risk of metastatic death was found in patients who had eyes enucleated secondary to tumor recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of circulating tumor cells at the time of diagnosis may be an independent risk factor for relapse and shortened survival in patients at high-risk based upon clinical parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Additional studies are required to confirm these observations.",
"   </p>",
"   <p>",
"    The use of chromosomal markers in the tumor (ie, monosomy of chromosome 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/21-25\">",
"     21-25",
"    </a>",
"    ] and gene expression profiling [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/26\">",
"     26",
"    </a>",
"    ] are also under evaluation to define groups at high risk for subsequent development of metastatic disease.",
"   </p>",
"   <p>",
"    Prognostic factors for patients with metastatic disease are discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Posttreatment follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ocular oncologists treat medium and large uveal melanomas conservatively with one of two forms of RT: brachytherapy using radioactive plaques (",
"    <a class=\"graphic graphic_figure graphicRef68943 \" href=\"UTD.htm?21/38/22115\">",
"     figure 2",
"    </a>",
"    ) or external beam radiation therapy (EBRT). The majority of EBRT experience has been with charged particle irradiation, while results from the use of photon-based stereotactic radiotherapy (SRT) are more limited. Although these tumors have historically been considered radioresistant, all types of RT achieve local tumor control in the vast majority of cases with similar survival outcomes to those achieved by enucleation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Enucleation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Immediate treatment after diagnosis is routine, and a comparison of patients who underwent immediate versus delayed treatment for choroidal melanomas in the Collaborative Ocular Melanoma Study (COMS) supports this standard of care. In this small subgroup analysis, the five-year all-cause mortality was lower in 20 patients who underwent immediate treatment than in 22 patients who delayed treatment (18 versus 30 percent, respectively). Death was due to histopathologically-confirmed melanoma metastases in 32 and 44 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT is hypothesized to affect the viability of the tumor through two mechanisms: a direct toxic effect on the tumor cells via lethal chromosomal injury and damage to the tumor vasculature that is necessary for tumor growth and systemic tumor cell dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Radioactive plaques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of radioactive plaques have been used to treat uveal melanoma including cobalt-60 (60Co), iodine-125 (125I), iridium 192 (192Ir), palladium-103 (103Pd), and ruthenium 106-rhodium 106",
"    <span class=\"nowrap\">",
"     (106Ru/106Rh).",
"    </span>",
"    125I may be the most popular plaque because it can be easily shielded, resulting in fewer untoward radiation effects than 60Co, and because it has greater tissue penetrance than",
"    <span class=\"nowrap\">",
"     106Ru/106Rh",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher local recurrence rates have been reported after brachytherapy (five year rate: 8 to 13 percent regardless of the type of plaque used) than after particle irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/12,17,34-40\">",
"     12,17,34-40",
"    </a>",
"    ]. However, with careful patient selection, it may be possible to achieve local control rates that are similar to those achieved with charged particles; one study in patients with smaller tumors located away from the optic disc reported a 2 percent recurrence rate at five years after ruthenium plaque therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since local recurrence is associated with an increased risk of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], it is critical that the most reliable treatment be chosen based upon patient and tumor characteristics. Guidelines for the use of radioactive plaque therapy have been published by the American Brachytherapy Society [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all types of radiotherapy, radiation retinopathy, a slowly progressive occlusive vasculopathy, and optic neuropathy can develop after brachytherapy. The incidence of this complication was illustrated by a series of 1300 patients treated with plaque therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/42\">",
"     42",
"    </a>",
"    ]. At one year after treatment, nonproliferative and proliferative radiation retinopathy occurred in 5 and 1 percent of patients, respectively, and at five years, in 42 and 8 percent, respectively. Not unexpectedly, tumor location near the optic disc or fovea and high RT dose rate to the tumor base are risk factors for radiation vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The risk of proliferative radiation retinopathy was significantly increased in patients treated with 192Ir compared to 125I, among diabetics, and in patients with tumor base diameter &gt;10 mm. These factors should be taken into consideration when deciding upon treatment strategy.",
"   </p>",
"   <p>",
"    Other RT-induced complications include cataracts, neovascular glaucoma, and vitreous hemorrhage with a risk of vision loss as a secondary complication. In one series evaluating the long-term visual outcome in 1106 consecutive patients treated with plaque radiotherapy, 68 percent had poor visual acuity at 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/44\">",
"     44",
"    </a>",
"    ]. Visual acuity was better preserved in eyes with small tumors outside a radius of 5 mm from the optic disc and foveola.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Charged particle irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Charged particle irradiation (protons, carbon ions, helium ions) have been used to treat patients with medium to large choroidal tumors, including tumors located near the optic disc and fovea [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/18,35,45,46\">",
"     18,35,45,46",
"    </a>",
"    ]. It is possible to treat such tumors with minimal collateral damage due to the physical properties of charged particles: increased dose at the end of the beam range (called the Bragg peak) and a sharp decrease in dose of the radiation beam beyond the targeted area. These properties permit highly localized and homogeneous dose distributions and sparing of normal ocular structures (",
"    <a class=\"graphic graphic_figure graphicRef50758 \" href=\"UTD.htm?19/52/20289\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, charged particle irradiation offers the capacity to treat larger tumors compared to radioactive plaque therapy. Plaque therapies typically are limited to tumors approximately 5 mm thick whereas there is no limit with the use of charged particles. Charged particle therapy is also not hampered by the dosimetric challenge of tumors located over the optic disc where plaques cannot be directly overlaid and is thus often the preferred method over plaques for tumors involving or the optic disc.",
"   </p>",
"   <p>",
"    Using this technique, improved outcomes are achieved. The rate of local tumor control is high (95 to 100 percent), with a reduced rate of ocular complications. A systematic review of the literature analyzed the outcomes in 27 studies that included 8809 patients with uveal melanoma; 7457 were treated with charged particle therapy either as initial or subsequent therapy, and 1352 received either brachytherapy or enucleation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/47\">",
"     47",
"    </a>",
"    ]. The rate of local recurrence was significantly lower compared with iodine-125 brachytherapy (odds ratio 0.22, 95% CI 0.21-0.23), but the differences in risk of enucleation or death were not statistically significant.",
"   </p>",
"   <p>",
"    Results with this approach are illustrated by the experience in 2069 patients who were treated with proton therapy at the Harvard Cyclotron Laboratory and Northeast Proton Therapy Center at Massachusetts General Hospital between 1975 and 1997, and followed at the Massachusetts Eye and Ear Infirmary (MEEI) between 1975 and 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/12\">",
"     12",
"    </a>",
"    ]. Key observations included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Actuarial results 15 years after treatment included a local control rate of 95 percent (",
"      <a class=\"graphic graphic_picture graphicRef59406 \" href=\"UTD.htm?17/21/17758\">",
"       picture 1",
"      </a>",
"      ) and eye preservation of 84 percent. Enucleation was performed in 179 eyes because of neovascular glaucoma, discomfort in a blind eye, or local recurrence in 46, 31, and 23 percent of cases, respectively.",
"     </li>",
"     <li>",
"      The 15-year cumulative probability of developing metastasis, calculated using risk scores derived from logistic regression models of prognostic factors, varied from less than 10 percent in patients in the low risk group to over 50 percent in the high risk group.",
"     </li>",
"     <li>",
"      Increased risk of vision loss (to worse than",
"      <span class=\"nowrap\">",
"       20/200)",
"      </span>",
"      was associated with location of the tumor near the optic disc",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      macula, larger tumor diameter and thickness (height), poorer baseline visual acuity, retinal detachment involving at least one quadrant, and a history of diabetes. Cumulative rates of vision loss reached 100 percent by 10 years after treatment in patients with the highest risk scores. In contrast, 10 year rates in patients with the lowest risk scores were less than 25 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of radiation vasculopathy was studied in 558 patients who had undergone proton therapy for small to moderate sized tumors located near the optic disc or macula [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients were selected because tumor location, rather than size, placed them at high risk of radiation complications. The five-year rates of maculopathy, papillopathy, and vision loss were 64, 35, and 68 percent, respectively. These complications were related to the total RT dose to critical structures. In another retrospective analysis of 21 cases in which eyes were enucleated after proton radiation because of failure to control disease or for radiation complications, neovascularization of the iris was documented in 11 cases but occurred in areas outside of the primary irradiated field, which was often atrophic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective randomized trial of lower dose (50 Gy(RBE)) versus standard dose (70 Gy(RBE)) proton RT for uveal melanoma patients with small to moderate sized tumors located near the optic disc or macula, showed no differences between the two groups in rates of visual acuity loss or radiation maculopathy at five years after proton therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/50\">",
"     50",
"    </a>",
"    ]. Approximately 45 percent of patients treated at either dose had visual acuity worse than",
"    <span class=\"nowrap\">",
"     20/200.",
"    </span>",
"    Approximately 75 percent of patients with tumors within 1 disc diameter of the macula and 40 percent of patients with tumors greater than 1 disc diameter from the macula developed maculopathy by five years after RT, regardless of the total radiation dose they received.",
"   </p>",
"   <p>",
"    Lower rates of visual field loss and radiation papillopathy were observed in the lower dose group; radiation papillopathy was lower in a subgroup of patients with tumors within one disc diameter of the optic disc. At five years, local and systemic recurrences were equivalent in the 50 and 70 Gy (RBE) groups, 2 and 3 percent and 7 and 8 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Photon-based radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear accelerators generate the high energy X-rays used to deliver most therapeutic EBRT. The use of linear accelerator-adapted stereotactic radiotherapy (SRT) has recently been implemented as a new means of treatment for uveal melanomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical experience with SRT comes from several single institution series, generally using total doses of 50 to 70 Gy delivered in five daily fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The largest experience consists of a series of 212 patients with choroidal melanoma treated between 1997 and 2007 with 50 to 70 Gy in five fractions over one week [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/52\">",
"     52",
"    </a>",
"    ]. Rates of local control at five and ten years were 96 and 93 percent, respectively, while distant metastatic disease developed in 32 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Enucleation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of enucleation of the eye has been a controversial issue since survival outcomes do not appear to differ from those achieved with radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery was compared to radiation in the Collaborative Ocular Melanoma Study (COMS), which randomly assigned 1317 patients with medium-sized choroidal melanomas to enucleation versus 125I brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/30,54\">",
"     30,54",
"    </a>",
"    ]. At least 12 years follow-up was available for a subset of 515 patients in the latest report [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/54\">",
"     54",
"    </a>",
"    ]. The 10- and 12-year mortality rates were 18 and 21 percent for patients treated with enucleation and 17 percent at both time points for those managed with brachytherapy. These differences were not statistically significant and provide evidence supporting the use of brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since RT is not associated with an increased risk for metastasis, enucleation should be considered only in selected patients, such as those with large tumors, tumors with large extrascleral extensions or neovascular glaucoma in a painful eye. At least in the setting of large choroidal melanomas, there appears to be no benefit for preenucleation radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Local resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of uveal melanoma typically involves tumor excision using scleral lamellar dissection or similar techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/56\">",
"     56",
"    </a>",
"    ]. The main disadvantages of this and other surgical techniques are the serious and immediate postoperative complications, such as retinal detachment and vitreous hemorrhage. Tumor recurrences are more frequent than with other types of treatment, and there is a concern that tumor cells may be disseminated into the blood stream during surgery. For these reasons and because advances in radiotherapy offer a viable alternative to surgery, local resection has limited use.",
"   </p>",
"   <p>",
"    In select cases (eg, patients who are poor candidates for plaque therapy), resection continues to be used by some surgeons who are experienced with this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Adjuvant plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] or charged particle radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/61\">",
"     61",
"    </a>",
"    ] is often applied after surgery in an effort to reduce the number of recurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Photocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With photocoagulation, thermal energy is used to damage the vasculature and destroy tumor cells. It has been used in the past to treat selected cases of small choroidal lesions. However, photocoagulation is associated with a number of adverse effects, many of which are associated with vision loss, including retinal vascular occlusions, vitreous hemorrhage, and traction retinal detachment. Furthermore, it is not clear that the heat effects of photocoagulation are sufficiently powerful to destroy tumor cells beyond the surface layer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/62\">",
"     62",
"    </a>",
"    ]. Because of these limitations, we employ photocoagulation only for marginal recurrences after proton therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Transpupillary thermotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transpupillary thermotherapy (TTT) also utilizes the effects of heat, delivered with a modified infrared diode laser (typically at a wavelength of 810 nm), to achieve tumor necrosis. It is similar to photocoagulation in that it can only be used to treat small choroidal tumors. Rapid tumor regression can be achieved but complications including vision loss and treatment failure may occur and TTT has not provided an advantage in terms of retention of visual acuity after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, TTT is not recommended as a primary treatment for uveal melanoma. Although it may be valuable as an adjunct to radiation by reducing rates of tumor recurrence following brachytherapy, there is accumulating evidence that complications continue to be a problem [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. Five-year rates of maculopathy or retinopathy were 51 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/69\">",
"     69",
"    </a>",
"    ] and 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/70\">",
"     70",
"    </a>",
"    ] in patients who received transpupillary thermotherapy in combination with ruthenium-106 and iodine 125, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT) combines injection of a photosensitive compound followed by light application at a wavelength that activates the photosensitizer. Singlet oxygen and free radicals are formed which damage endothelial cells and lead to vascular occlusion and tumor necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/72\">",
"     72",
"    </a>",
"    ]. In preclinical studies of benzoporphyrin derivative, we have demonstrated histopathologically that tumor regression can be achieved in tumors up to 4.6 mm via vascular damage and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Vascular occlusion and thrombosis after PDT with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33060?source=see_link\">",
"     verteporfin",
"    </a>",
"    has also been observed in histopathological studies of human eyes with uveal melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies of photosensitizers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39157?source=see_link\">",
"     porfimer",
"    </a>",
"    sodium and hematoporphyrin have yielded disappointing results due to high rates of failure and recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. In a study of 36 patients with posterior uveal melanomas treated by PDT with hematoporphyrin derivative, tumor recurrence occurred in 62 percent of patients at five years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, as new photosensitizers like benzoporphyrin derivative become available, PDT may play a role in the treatment of uveal melanomas, either alone or in combination with other forms of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant systemic therapy has now been evaluated in patients with primary uveal melanoma as it has in patients with intermediate and high risk melanomas of the skin. Possible efficacy of such an approach was suggested in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/79\">",
"     79",
"    </a>",
"    ]. However, human studies did not demonstrate a survival benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of adjuvant therapy involving a two-year maintenance dose of interferon alfa-2a (3 MU three times weekly) after primary treatment with proton radiation or enucleation was conducted in 121 patients at higher than average risk of metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/80\">",
"     80",
"    </a>",
"    ]. Patients were compared with a historical series of 242 matched controls. There was no significant difference in melanoma-related or overall mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Posttreatment follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveal melanomas are remarkable for their purely hematogenous pattern of dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/62\">",
"     62",
"    </a>",
"    ]. In one series of patients with metastatic primary uveal melanoma, the most common initial sites of involvement were the liver and lungs (60 and 25 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/81\">",
"     81",
"    </a>",
"    ]. Most North American centers monitor patients after local treatment with clinical examination, liver function tests, and chest radiographs in order to detect metastases early. Many European centers also recommend liver imaging because of the high frequency of hepatic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/82-85\">",
"     82-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appearance of metastases may be delayed, suggesting that long-term surveillance is needed to detect late recurrences. As an example, the Collaborative Ocular Melanoma Study (COMS) of 2320 patients with primary choroidal melanoma documented five- and ten-year rates of distant metastasis of 25 and 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although regular monitoring can detect metastatic disease when a relatively limited disease burden is present, this may have only a limited effect on survival because of the lack of effective treatment for metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/82\">",
"     82",
"    </a>",
"    ]. In an analysis of 91 patients who died of metastatic uveal melanoma, the median dimension of the largest metastasis was significantly smaller in the 77 patients who underwent regular review (44 versus 88 mm), as was the total and hepatic burden of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/86\">",
"     86",
"    </a>",
"    ]. Although patients who underwent regular evaluation survived longer than those who did not (8.9 versus 4.3 months), the survival from the original diagnosis of the primary tumor was comparable suggesting that earlier detection results in lead time bias without true survival benefit.",
"   </p>",
"   <p>",
"    Using multivariate analysis, performance status (as measured by the Karnofsky score, (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    )), size of the largest metastasis, and serum alkaline phosphatase significantly correlated with survival. Using these three factors, patients could be stratified into three groups, with median survivals of 15, 9, and 2 months, respectively.",
"   </p>",
"   <p>",
"    Although there is no curative therapy for metastatic disease and there is no evidence that earlier diagnosis of metastases prolongs overall survival, affected patients may benefit from palliative or experimental therapies. We generally follow patients every six months to annually, depending upon each patient's medical and ophthalmological characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H681876064\">",
"    <span class=\"h1\">",
"     CONJUNCTIVAL MELANOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H681876092\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of ocular melanomas arise within the conjunctiva [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/87\">",
"     87",
"    </a>",
"    ]. They usually develop within the bulbar rather than the forniceal or palpebral conjunctiva, and can arise in areas of primary acquired melanosis, from a preexisting nevus, or de novo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/88\">",
"     88",
"    </a>",
"    ]. Regional lymph node metastases are present in up to 40 percent of patients; preauricular (parotid) nodes are the most commonly involved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/89\">",
"     89",
"    </a>",
"    ]. Conjunctival melanoma is staged according to the tumor node metastasis (TNM) system (",
"    <a class=\"graphic graphic_table graphicRef67661 \" href=\"UTD.htm?10/7/10365\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73188 \" href=\"UTD.htm?32/3/32828\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These tumors have a propensity for local recurrence. This was illustrated in a series of 150 patients all of whom were treated with at least excision (with or without cryotherapy and or alcohol) or alternatively enucleation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/90\">",
"     90",
"    </a>",
"    ]. The local recurrence rates at 5, 10, and 15 years were 26, 51, and 65 percent, while metastatic spread occurred in 16, 26, and 32 percent, respectively. Cause-specific survival rates were 93 and 87 percent at five and eight years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H681876099\">",
"    <span class=\"h2\">",
"     Treatment and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred management is wide surgical resection, with alcohol application, and supplemental cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/91\">",
"     91",
"    </a>",
"    ]. Combined therapy results in a significantly lower rate of local recurrence than simple superficial excision [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/92\">",
"     92",
"    </a>",
"    ]. Incisional biopsy and direct manipulation of the tumor should be avoided to prevent tumor cell seeding. RT using radioactive plaques or proton beam therapy has been used successfully to treat large conjunctival melanomas, and promising results have been reported with local application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orbital exenteration may occasionally be necessary for either advanced tumors or for persistent local recurrences. In one series of 151 patients, 20 (13 percent) required exenteration, and the clinical features that predicted the need for ultimate exenteration included initial visual acuity",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    or worse, lack of tumor pigmentation, and extralimbal tumor location [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/95\">",
"     95",
"    </a>",
"    ]. Patients with these characteristics may benefit from wide local excision and RT to enhance local control and avoid exenteration.",
"   </p>",
"   <p>",
"    There are no definitive data on the optimal follow-up after initial treatment. In our institution, patients are seen every four to six months. Any recurrent lesions are promptly excised and treated with additional cryotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H681876106\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis is mainly dependent on tumor thickness, size, and location [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. In one series of 256 consecutive cases of conjunctival melanoma, the five- and ten-year survival rates were 83 and 69 percent. Tumors in non-bulbar locations had a 2.2-fold higher mortality rate, and the death rate was also significantly higher among tumors having a thickness of &ge;4 mm, particularly among those in unfavorable locations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/96\">",
"     96",
"    </a>",
"    ]. In another report, a high mitotic rate, presence of many epithelioid cells, and size &gt;10 mm in diameter were adverse prognostic features [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no effective long-term treatments for the majority of patients with metastatic ocular melanoma, perhaps because metastases are found in the liver and other visceral organs in the vast majority of cases. In unselected series, the prognosis is poor, with reported median survivals ranging from 2 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/81,100\">",
"     81,100",
"    </a>",
"    ]. The Collaborative Ocular Melanoma Study Group reported a one-year survival in patients that develop hepatic metastasis of only 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/14\">",
"     14",
"    </a>",
"    ]. Treatment for metastatic disease continues to be largely investigational but there is some evidence for selective role of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected patients, surgical resection of metastatic uveal melanoma may provide long-term survival, as with metastatic cutaneous melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/101-104\">",
"     101-104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"     \"Surgical management of metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the largest series, 24 of 78 patients with metastatic disease underwent attempted complete resection of metastatic lesions; 22 of these patients had only one metastatic site, 19 had no evidence of liver involvement (the major sites were soft tissue, lymph node, and lung), only two had &ge;5 metastatic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/102\">",
"     102",
"    </a>",
"    ]. The patients who underwent surgery were significantly more likely to have a disease-free interval from diagnosis of the primary tumor to detection of metastases &ge;45 months (79 versus 42 percent in those treated without surgery).",
"   </p>",
"   <p>",
"    Complete resection was achieved in all but three patients, each of whom had hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/102\">",
"     102",
"    </a>",
"    ]. Outcomes were substantially better in patients undergoing surgical resection (median survival 38 versus 9 months, and five-year survival 39 versus 0 percent compared to patients treated without surgery).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy in patients with advanced ocular melanoma has been patterned after therapy in patients with nonocular melanoma, but data are limited and no approach has established efficacy in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3405185\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy regimens used in nonocular metastatic melanoma have also been studied in patients with ocular melanoma. Response rates do not appear to be different from metastatic disease due to nonocular melanoma, and there is no evidence to suggest an impact on survival.",
"   </p>",
"   <p>",
"    In an analysis of 64 patients treated for metastatic ocular melanoma with a variety of regimens that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , only one complete response and five partial responses were observed (nine percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/105\">",
"     105",
"    </a>",
"    ]. Only two responses were seen in the 56 patients with hepatic metastases. Other studies have not resulted in consistently higher responses rates [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"     \"Cytotoxic chemotherapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3405192\">",
"    <span class=\"h3\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that immunotherapy has a significant anti-tumor effect or impact on survival in patients with metastatic ocular melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ocular melanoma were excluded from the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    phase III trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/108\">",
"     108",
"    </a>",
"    ]. In a subsequent series, 13 patients with ocular melanoma were treated with ipilimumab. Although no objective responses were observed, three patients did have stable disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H262059990#H262059990\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3405200\">",
"    <span class=\"h3\">",
"     Molecularly targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular melanoma appear to have a different molecular pathogenesis compared with cutaneous melanoma. BRAF mutations are typically not seen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/109\">",
"     109",
"    </a>",
"    ], and thus BRAF inhibitors are not indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1576?source=see_link&amp;anchor=H5643585#H5643585\">",
"     \"The molecular biology of melanoma\", section on 'MAPK pathway'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H615776956#H615776956\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'Molecular pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Regional nonsurgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with hepatic metastases, somewhat better responses have been described with therapy directed specifically toward the liver metastases. With all regional approaches, the development of extrahepatic disease limits survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Chemoembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoembolization with a range of chemotherapy agents may result in regression or stabilization of hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. As an example, in a retrospective review of 201 patients treated for hepatic metastases from ocular melanoma at the M. D. Anderson Cancer Center, chemoembolization using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens gave a response rate of 36 percent, compared to less than 1 percent with systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/110\">",
"     110",
"    </a>",
"    ]. However, the higher response rate may have reflected patient selection, and multivariate analysis identified serum alkaline phosphatase and metastasis-free interval as the main independent prognostic factors for survival, not the approach to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hepatic artery infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another regional approach is the intrahepatic artery administration of chemotherapy. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and fotemustine, a nitrosourea, are being evaluated by this route.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97418913\">",
"    <span class=\"h4\">",
"     Melphalan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated hepatic artery infusion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , with or without tumor necrosis factor, has been studied in patients with isolated liver metastases from primary ocular melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. Based upon evidence of activity in these studies, a phase III trial (EORTC 18021, NCT00110123) was conducted in 93 patients with metastatic melanoma and predominantly or exclusively hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/115\">",
"     115",
"    </a>",
"    ]. Patients were randomly assigned to either hepatic artery infusion using the Delcath balloon catheter system or to best alternative care. The hepatic artery infusion consisted of melphalan (3",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    given every four to five weeks for four to six cycles. Patients treated with best alternative care were allowed to cross over to hepatic artery infusion following hepatic progression.",
"   </p>",
"   <p>",
"    Preliminary results were presented at the American Society of Clinical Oncology (ASCO) meeting in 2010. There was a statistically significant improvement in hepatic progression-free survival, the primary study endpoint, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    hepatic artery infusion compared to best alternative care (median 245 versus 49 days). However, there was no difference in overall survival between the two groups (median survival 301 and 298 days, respectively), leaving the impact of this technique upon survival unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97418918\">",
"    <span class=\"h4\">",
"     Fotemustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a pilot study, 12 of 30 assessable patients had an objective response to a hepatic artery infusion of fotemustine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/84\">",
"     84",
"    </a>",
"    ]. Based upon these results the European Organization for the Research and Treatment of Cancer has initiated a phase III trial (EORTC 18021, NCT00110123) that is comparing intrahepatic fotemustine with intravenous fotemustine in patients with hepatic metastases from ocular melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/59/8122/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Choroidal and ciliary body melanoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic patients with small tumors (&lt;10 mm in diameter and &lt;2 mm in height), we recommend observation, rather than active intervention, until evidence of growth is documented (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with larger tumors and those with symptoms, we recommend active treatment with either radiation therapy (RT) or enucleation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For symptomatic patients and those with medium or large tumors, we recommend treatment with radiation therapy rather than enucleation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Radiation therapy (RT) can be administered either using brachytherapy (with radioactive plaques), the most widely available form of RT, or with charged particle irradiation where available. Similar rates of local control have been observed with photon based, stereotactic radiotherapy, although experience is more limited. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Enucleation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Radioactive plaques'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Charged particle irradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enucleation is generally restricted to patients in whom RT is unlikely to achieve adequate local control of the tumor or its symptoms. This includes patients with large tumors that have an extrascleral extension and those with a painful eye due to neovascular glaucoma. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Enucleation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who present with metastatic disease or who develop metastatic disease after treatment of their primary tumor, the prognosis is poor. Therapy is generally palliative and experimental. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Conjunctival melanoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with melanoma arising in the conjunctiva, initial management focuses upon local control of disease. For most patients this includes wide local excision, supplemented by cryotherapy and alcohol application. (See",
"      <a class=\"local\" href=\"#H681876064\">",
"       'Conjunctival melanoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/1\">",
"      Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/2\">",
"      Weis E, Shah CP, Lajous M, et al. The association between host susceptibility factors and uveal melanoma: a meta-analysis. Arch Ophthalmol 2006; 124:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/3\">",
"      Weis E, Shah CP, Lajous M, et al. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology 2009; 116:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/4\">",
"      Shah CP, Weis E, Lajous M, et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology 2005; 112:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/5\">",
"      Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 2009; 127:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/6\">",
"      Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol 1998; 125:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/7\">",
"      Gragoudas ES, Seddon JM, Egan KM, et al. Prognostic factors for metastasis following proton beam irradiation of uveal melanomas. Ophthalmology 1986; 93:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/8\">",
"      Schmittel A, Bechrakis NE, Martus P, et al. Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. Eur J Cancer 2004; 40:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/9\">",
"      Kleineidam M, Guthoff R, Bentzen SM. Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. Radiother Oncol 1993; 28:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/10\">",
"      Affeldt JC, Minckler DS, Azen SP, Yeh L. Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol 1980; 98:1975.",
"     </a>",
"    </li>",
"    <li>",
"     Schmittel A, Bechrakis NE, Scheilbenbogen C, et al. Prognostic factors for development of metastatic disease in ocular melanoma: 5 years follow-up of 271 patients (abstract). Proc Am Soc Clin Oncol 2003; 22:711a. (Abstract available online: www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed on January 7, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/12\">",
"      Gragoudas E, Li W, Goitein M, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002; 120:1665.",
"     </a>",
"    </li>",
"    <li>",
"     Malignant melanoma of the uvea. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.541.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/14\">",
"      Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/15\">",
"      Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009; 127:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/16\">",
"      Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol 2000; 118:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/17\">",
"      Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 2003; 55:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/18\">",
"      Egan KM, Ryan LM, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: an example of regression on time-dependent covariates. Arch Ophthalmol 1998; 116:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/19\">",
"      Schuster R, Bechrakis NE, Stroux A, et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007; 13:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/20\">",
"      Boldin I, Langmann G, Richtig E, et al. Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res 2005; 15:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/21\">",
"      Sandinha MT, Farquharson MA, McKay IC, Roberts F. Monosomy 3 predicts death but not time until death in choroidal melanoma. Invest Ophthalmol Vis Sci 2005; 46:3497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/22\">",
"      Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci 2006; 47:3703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/23\">",
"      Onken MD, Worley LA, Person E, et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res 2007; 13:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/24\">",
"      Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 2007; 114:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/25\">",
"      Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 2009; 127:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/26\">",
"      Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 2007; 13:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/27\">",
"      Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990; 97:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/28\">",
"      Adams KS, Abramson DH, Ellsworth RM, et al. Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates. Br J Ophthalmol 1988; 72:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/29\">",
"      Augsburger JJ, Corr&ecirc;a ZM, Freire J, Brady LW. Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 1998; 105:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/30\">",
"      Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/31\">",
"      Straatsma BR, Diener-West M, Caldwell R, et al. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol 2003; 136:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/32\">",
"      Macfaul PA, Bedford MA. Ocular complications after therapeutic irradiation. Br J Ophthalmol 1970; 54:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/33\">",
"      Packer S, Rotman M, Salanitro P. Iodine-125 irradiation of choroidal melanoma. Clinical experience. Ophthalmology 1984; 91:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/34\">",
"      Damato B, Kacperek A, Chopra M, et al. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys 2005; 62:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/35\">",
"      Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993; 100:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/36\">",
"      Jensen AW, Petersen IA, Kline RW, et al. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 2005; 63:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/37\">",
"      Char DH, Kroll S, Phillips TL, Quivey JM. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 2002; 109:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/38\">",
"      Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002; 109:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/39\">",
"      G&uuml;nd&uuml;z K, Shields CL, Shields JA, et al. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999; 127:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/40\">",
"      Damato B, Patel I, Campbell IR, et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005; 63:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/41\">",
"      Nag S, Quivey JM, Earle JD, et al. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003; 56:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/42\">",
"      G&uuml;nd&uuml;z K, Shields CL, Shields JA, et al. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999; 117:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/43\">",
"      Finger PT, Chin KJ, Yu GP, Palladium-103 for Choroidal Melanoma Study Group. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol 2010; 149:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/44\">",
"      Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000; 118:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/45\">",
"      Tsuji H, Ishikawa H, Yanagi T, et al. Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: a Phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 2007; 67:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/46\">",
"      Caujolle JP, Mammar H, Chamorey E, et al. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience. Int J Radiat Oncol Biol Phys 2010; 78:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/47\">",
"      Wang Z, Nabhan M, Schild SE, et al. Charged Particle Radiation Therapy for Uveal Melanoma: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/48\">",
"      Gragoudas ES, Li W, Lane AM, et al. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999; 106:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/49\">",
"      Boyd SR, Gittos A, Richter M, et al. Proton beam therapy and iris neovascularisation in uveal melanoma. Eye (Lond) 2006; 20:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/50\">",
"      Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000; 118:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/51\">",
"      Modorati G, Miserocchi E, Galli L, et al. Gamma knife radiosurgery for uveal melanoma: 12 years of experience. Br J Ophthalmol 2009; 93:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/52\">",
"      Dunavoelgyi R, Dieckmann K, Gleiss A, et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 2011; 81:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/53\">",
"      Muller K, Naus N, Nowak PJ, et al. Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results. Radiother Oncol 2012; 102:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/54\">",
"      Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/55\">",
"      Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 2004; 138:936.",
"     </a>",
"    </li>",
"    <li>",
"     Foulds WS. Results of local excision of uveal tumors. In: Intraocular tumors, Lommatzsch PK, Blodi FC (Eds), Lommatzsch, PK, Blodi, FC, Berlin 1983. p.374.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/57\">",
"      Damato B. The role of eyewall resection in uveal melanoma management. Int Ophthalmol Clin 2006; 46:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/58\">",
"      Bechrakis NE, Petousis V, Willerding G, et al. Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol 2010; 94:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/59\">",
"      Bechrakis NE, Bornfeld N, Z&ouml;ller I, Foerster MH. Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 2002; 109:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/60\">",
"      Kivel&auml; T, Puusaari I, Damato B. Transscleral resection versus iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case-control study. Ophthalmology 2003; 110:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/61\">",
"      Char DH, Miller T, Crawford JB. Uveal tumour resection. Br J Ophthalmol 2001; 85:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/62\">",
"      Gragoudas ES. Current approaches in the management of uveal melanomas. Int Ophthalmol Clin 1992; 32:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/63\">",
"      Shields CL, Shields JA, Cater J, et al. Transpupillary thermotherapy for choroidal melanoma: tumor control and visual results in 100 consecutive cases. Ophthalmology 1998; 105:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/64\">",
"      Shields CL, Shields JA, Perez N, et al. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002; 109:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/65\">",
"      Win PH, Robertson DM, Buettner H, et al. Extended follow-up of small melanocytic choroidal tumors treated with transpupillary thermotherapy. Arch Ophthalmol 2006; 124:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/66\">",
"      Harbour JW, Meredith TA, Thompson PA, Gordon ME. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. Ophthalmology 2003; 110:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/67\">",
"      Oosterhuis JA, Journ&eacute;e-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 1995; 113:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/68\">",
"      Oosterhuis JA, Journ&eacute;e-de Korver HG, Keunen JE. Transpupillary thermotherapy: results in 50 patients with choroidal melanoma. Arch Ophthalmol 1998; 116:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/69\">",
"      Bartlema YM, Oosterhuis JA, Journ&eacute;e-De Korver JG, et al. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience. Br J Ophthalmol 2003; 87:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/70\">",
"      Shields CL, Cater J, Shields JA, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002; 120:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/71\">",
"      Kreusel KM, Bechrakis N, Riese J, et al. Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications. Graefes Arch Clin Exp Ophthalmol 2006; 244:1575.",
"     </a>",
"    </li>",
"    <li>",
"     Zografos L, Gragoudas ES. Photocoagulation treatment of pigmented intraocular tumors. In: Current techniques in ophthalmic laser surgery, Singerman LJ, Coscas G (Eds), Current Medicine, Philadelphia 1999. p.146.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/73\">",
"      Kim RY, Hu LK, Foster BS, et al. Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness. Ophthalmology 1996; 103:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/74\">",
"      Young LH, Howard MA, Hu LK, et al. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol 1996; 114:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/75\">",
"      Wachtlin J, Bechrakis NE, Foerster MH. [Photodynamic therapy with verteporfin for uveal melanoma]. Ophthalmologe 2005; 102:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/76\">",
"      Favilla I, Barry WR, Gosbell A, et al. Phototherapy of posterior uveal melanomas. Br J Ophthalmol 1991; 75:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/77\">",
"      Bruce RA Jr. Evaluation of hematoporphyrin photoradiation therapy to treat choroidal melanomas. Lasers Surg Med 1984; 4:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/78\">",
"      Favilla I, Favilla ML, Gosbell AD, et al. Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res 1995; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/79\">",
"      Dithmar S, Rusciano D, Lynn MJ, et al. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol 2000; 118:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/80\">",
"      Lane AM, Egan KM, Harmon D, et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 2009; 116:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/81\">",
"      Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23:8076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/82\">",
"      Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/83\">",
"      Sato T, Babazono A, Shields JA, et al. Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest 1997; 15:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/84\">",
"      Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/85\">",
"      Summanen P, Immonen I, Heikkonen J, et al. Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surg 1993; 24:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/86\">",
"      Eskelin S, Pyrh&ouml;nen S, Hahka-Kemppinen M, et al. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003; 97:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/87\">",
"      Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/88\">",
"      Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011; 118:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/89\">",
"      Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology 2001; 108:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/90\">",
"      Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc 2000; 98:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/91\">",
"      Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas. Ophthal Plast Reconstr Surg 1998; 14:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/92\">",
"      De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol 1993; 77:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/93\">",
"      Kemp EG, Harnett AN, Chatterjee S. Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol 2002; 86:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/94\">",
"      Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol 2000; 118:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/95\">",
"      Shields JA, Shields CL, G&uuml;nd&uuml;z K, Cater J. Clinical features predictive of orbital exenteration for conjunctival melanoma. Ophthal Plast Reconstr Surg 2000; 16:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/96\">",
"      Paridaens AD, Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 1994; 78:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/97\">",
"      Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-91. Acta Ophthalmol (Copenh) 1992; 70:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/98\">",
"      Fuchs U, Kivel&auml; T, Liesto K, Tarkkanen A. Prognosis of conjunctival melanomas in relation to histopathological features. Br J Cancer 1989; 59:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/99\">",
"      Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol 2002; 25:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/100\">",
"      Augsburger JJ, Corr&ecirc;a ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/101\">",
"      Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 2000; 89:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/102\">",
"      Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 2004; 100:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/103\">",
"      Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006; 13:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/104\">",
"      Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/105\">",
"      Flaherty LE, Unger JM, Liu PY, et al. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/106\">",
"      Nathan FE, Berd D, Sato T, et al. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 1997; 16:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/107\">",
"      Kivel&auml; T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/108\">",
"      Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/109\">",
"      P&oacute;pulo H, Soares P, Rocha AS, et al. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 2010; 20:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/110\">",
"      Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/111\">",
"      Gupta S, Bedikian AY, Ahrar J, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol 2010; 33:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/112\">",
"      Alexander HR Jr, Bartlett DL, Libutti SK. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am 1998; 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/113\">",
"      Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6:3062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/59/8122/abstract/114\">",
"      Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9:6343.",
"     </a>",
"    </li>",
"    <li>",
"     Pingpank JF, Husghes MS, Alexander HR, et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma (abstract #8512). J Clin Oncol 2010; 28:955s.",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7617 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-D3C9B8B2AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8122=[""].join("\n");
var outline_f7_59_8122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UVEAL MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Radioactive plaques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Charged particle irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Photon-based radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Enucleation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Local resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Photocoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Transpupillary thermotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Posttreatment follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H681876064\">",
"      CONJUNCTIVAL MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H681876092\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H681876099\">",
"      Treatment and follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H681876106\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3405185\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3405192\">",
"      - Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3405200\">",
"      - Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Regional nonsurgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Chemoembolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hepatic artery infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H97418913\">",
"      Melphalan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H97418918\">",
"      Fotemustine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Choroidal and ciliary body melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Conjunctival melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7617|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/25/4510\" title=\"figure 1\">",
"      Ciliary choroid thickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/38/22115\" title=\"figure 2\">",
"      Radioactive plaque ther",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/52/20289\" title=\"figure 3\">",
"      Uveal melanoma threeD XRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7617|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/21/17758\" title=\"picture 1\">",
"      Ocular melanoma Fundus photo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/22/42350\" title=\"table 1\">",
"      TNM stage uveal melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/7/10365\" title=\"table 3\">",
"      TNM clin staging mel conj",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/3/32828\" title=\"table 4\">",
"      TNM path staging mel conj",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=related_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=related_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1576?source=related_link\">",
"      The molecular biology of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_59_8123="Dose mod neurotox Velcade";
var content_f7_59_8123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended dose modification for neuropathic pain and/or peripheral sensory neuropathy during treatment with bortezomib (Velcade)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Severity of symptoms",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose modification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 1 (asymptomatic, loss of deep tendon reflexes or paresthesia without pain or loss of function)",
"      </td>",
"      <td>",
"       No action needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 2 (interfering with function but not activities of daily living) or Grade 1 with pain",
"      </td>",
"      <td>",
"       Reduce dose to 1 mg/m2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 3 (interfering with activities of daily living) or Grade 2 with pain",
"      </td>",
"      <td>",
"       Withhold until toxicity resolved, may reinitiate at 0.7 mg/m2 once weekly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 4 (life-threatening, disabling, eg, paralysis)",
"      </td>",
"      <td>",
"       Discontinue therapy",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8123=[""].join("\n");
var outline_f7_59_8123=null;
var title_f7_59_8124="Antibiotics AOM children";
var content_f7_59_8124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial agents available for treatment of acute otitis media: United States 2006",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Most used drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        Cephalexin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin-clavulanate*",
"       </td>",
"       <td>",
"        Cefaclor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefuroxime axetil*",
"       </td>",
"       <td>",
"        Loracarbef",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone IM or IV*",
"       </td>",
"       <td>",
"        Cefixime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin + sulfisoxazole",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Ceftibuten",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Cefprozil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Cefpodoxime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Cefdinir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ofloxacin otic",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Trimethoprim",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin-dexamethasone otic",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscular; IV: intravenous.",
"     <br>",
"      * Usually used when amoxicillin fails.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Choices for penicillin-allergic patients.",
"       <br>",
"        &Delta; Should be avoided if penicillin-resistant pneumococcus prevalent in the area.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         With tympanostomy tubes.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Bluestone CD, Klein JO. Epidemiology. In: Otitis media in infants and children, 4th ed, BC Decker, Hamilton, ON 2007. p.73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8124=[""].join("\n");
var outline_f7_59_8124=null;
var title_f7_59_8125="Treatment of paraneoplastic syndromes";
var content_f7_59_8125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paraneoplastic neurologic syndromes: response to treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndromes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Syndromes that often respond to treatment*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lambert-Eaton myasthenic syndrome",
"       </td>",
"       <td>",
"        IV immunoglobulin; plasma exchange, 2,3 diaminopyridine, immunosuppression&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myasthenia gravis",
"       </td>",
"       <td>",
"        IV immunoglobulin, plasma exchange, immunosuppression, anticholinesterases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dermatomyositis",
"       </td>",
"       <td>",
"        IV immunoglobulin, immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Opsoclonus-myoclonus (pediatric)",
"       </td>",
"       <td>",
"        IV immunoglobulin, steroids, ACTH, rituximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuropathy associated with osteosclerotic myeloma",
"       </td>",
"       <td>",
"        Radiation, chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-NMDAR",
"       </td>",
"       <td>",
"        <p>",
"         First line: Corticosteroids, IV immunoglobin, plasma exchange",
"        </p>",
"        <p>",
"         Second line: Cyclophosphamide, rituximab",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-LGI1",
"       </td>",
"       <td>",
"        Corticosteroids, IV immunoglobin, plasma exchange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-cell surface antigens other than NMDAR and LGI1 (AMPA receptor, GABA(B) receptor, CASPR2)",
"       </td>",
"       <td>",
"        Corticosteroids, IVIg, plasma exchange, cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Syndromes that may respond to treatment*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stiff-man syndrome",
"       </td>",
"       <td>",
"        IV immunoglobulin, steroids, diazepam, baclofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuromyotonia",
"       </td>",
"       <td>",
"        IV immunoglobulin, plasma exchange, phenytoin, carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Guillain-Barre (Hodgkin's lymphoma)",
"       </td>",
"       <td>",
"        IV immunoglobulin, plasma exchange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasculitis of nerve and muscle",
"       </td>",
"       <td>",
"        Steroids, cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limbic encephalitis",
"       </td>",
"       <td>",
"        IV immunoglobulin, steroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Opsoclonus-myoclonus (adults)",
"       </td>",
"       <td>",
"        Steroids, cyclophosphamide, protein A column, clonazepam, thiamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-MAG-associated peripheral neuropathy (Waldenstroms macroglbulinemia)",
"       </td>",
"       <td>",
"        IV immunoglobulin, plasma exchange, chlorambucil, cyclophosphamide, fludarabine, rituximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute necrotizing myopathy",
"       </td>",
"       <td>",
"        Immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Syndromes that usually do not respond to treatment*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Encephalomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Sensory neuronopathy&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Autonomic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Cerebellar degeneration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Cancer and melanoma-associated retinopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In all cases, initial treatment should focus on identifying and treating the tumor.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Immunsuppression includes corticosteroids or azothioprine.",
"      <br>",
"       &Delta; Rare partial response to steroids.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: Approaches to diagnosis and treatment. Semin Neurol 2003; 23:215. Copyright &copy; 2003 Thieme.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8125=[""].join("\n");
var outline_f7_59_8125=null;
var title_f7_59_8126="Respiratory burst pathway";
var content_f7_59_8126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reactions of the respiratory burst pathway in neutrophils",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The enzymes responsible for reactions 1 to 9 are as follows: (1) The respiratory burst oxidase (NADPH oxidase); (2) superoxide dismutase or spontaneous; (3) nonenzymatic Fe2+- catalyzed; (4) myeloperoxidase; (5) spontaneous; (6) glutathione peroxidase; (7) glutathione reductase; (8) glucose-6-phosphate dehydrogenase; (9) glutathione synthetase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Curnutte JT, Orkin SH, Dinauer MC. Genetic disorders of phagocyte function. In: Stamatoyannopoulous G, ed. The molecular basis of blood diseases. In Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8126=[""].join("\n");
var outline_f7_59_8126=null;
var title_f7_59_8127="Band slippage and gastric prolapse after gastric banding";
var content_f7_59_8127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Band slippage and gastric prolapse after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This x-ray shows a slipped gastric band creating esophageal dilatation. The band was removed. The arrow points to the band.",
"    <div class=\"footnotes\">",
"     AS: anterior slippage of the pouch; P: pouch; S: stomach.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Raul J Rosenthal, MD, FACS, FASMBS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_59_8127=[""].join("\n");
var outline_f7_59_8127=null;
